Frontiers in Medicinal Chemistry Bentham Science Publishers Ltd. http://www.bentham.org/fmc
Volume 5, 2009 Contents Preface
i
Contributors
vi Central Nervous System
Always Around, Never the Same: Pathways of Amyloid Beta 1 Induced Neurodegeneration Throughout the Pathogenic Cascade of Alzheimer’s Disease Jeroen J.M. Hoozemans, Sidhartha M. Chafekar, Frank Baas, Piet Eikelenboom and Wiep Scheper Novel Neuroprotective Therapies for Alzheimer’s and 15 Parkinsons’s Disease Kirubakaran Shanmugam, Annette E. Maczurek, Megan L. Steele, Obdulio Benavente-García, Julián Castillo and Gerald Münch 58
Improving Memory: A Role for Phosphodiesterases Arjan Blokland, Rudy Schreiber and Jos Prickaerts Biologics Progress in Current Non-Viral Carriers for Gene Delivery
81
Yoko Shoji-Moskowitz, Daisuke Asai, Kota Kodama, Yoshiki Katayama and Hideki Nakashima contd……
Protein Transduction: Cell Penetrating Peptides and Their 98 Therapeutic Applications Kylie M. Wagstaff and David A. Jans Design of Peptide-Based Vaccines for Cancer Geoffrey A. Pietersz, Apostolopoulos
Dodie
S.
Pouniotis
127 and
Vasso
Oncology Inhibitors of Protein: Geranylgeranyl Transferases
167
Farid El Oualid, Gijs A. van der Marel and Mark Overhand Voltage-Gated Sodium Channels: New Targets in Cancer 234 Therapy? Ludovic Gillet, Sébastien Roger, Marie Potier, Lucie Brisson, Christophe Vandier, Pierre Besson and Jean-Yves Le Guennec Antiinfectives Recent Advances in Antiviral Agents: Antiviral Drug 257 Discovery for Hepatitis Viruses Kyuichi Tanikawa Cardiovascular NO-Releasing Hybrids of Cardiovascular Drugs
272
Alma Martelli, Simona Rapposelli, Maria C. Breschi and Vincenzo Calderone Endocrinology Trends in the Development of New Drugs for Treatment of 309 Benign Prostatic Hyperplasia Katarzyna Kulig and Barbara Malawska contd….
Pain, Inflammation, and Immunology Targeting the Prostaglandin D2 Receptors DP1 and CRTH2 350 for Treatment of Inflammation Trond Ulven and Evi Kostenis Enabling Technologies Privileged Structures as Leads in Medicinal Chemistry
381
Luca Costantino and Daniela Barlocco Acetylcholinesterase Reprised: Molecular Modeling with the 423 Whole Toolkit Gerald H. Lushington, Jian-Xin Guo and Margaret M. Hurley
i
PREFACE This 5th volume of the book series “Frontiers in Medicinal Chemistry” consists of a compendium of useful reviews on topics of wide interest to researchers in the fields of Medicinal Chemistry, Drug Discovery and Chemical Biology. The contributions are separated into different therapeutic areas, along with two reviews on general enabling technologies. The objective of “Frontiers in Medicinal Chemistry” is to periodically publish collections of comprehensive overviews based on areas of topical interest, written by leading experts in their respective fields. Initial versions of these reviews have been published in the journals Current Medicinal Chemistry, Current Topics in Medicinal Chemistry, and Current Pharmaceutical Design, and the authors have had the opportunity to update their original manuscripts prior to publication in the current volume. The initial section of this volume entails three reviews in the area of Central Nervous System therapeutics. The first by Scheper et al. summarizes current understanding on the role of the -amyloid peptides in Alzheimer’s disease. The second by Münch and colleagues entails neuroprotection for both Alzheimer’s and Parkinson’s diseases, and the third by Blokland et al. is on the topic of phosphodiesterase inhibition to improve cognition. The Biologics section is next, containing reviews by Shoji-Moskowitz et al. on non-viral approaches for gene therapy, Jans and Wagstaff on peptides that can cross a membrane barrier, and Apostolopoulos and co-workers on peptidic vaccines for cancer. The next section has two reviews in the area of Oncology. The first by Overhand et al. deals with geranylgeranyl transferases, the second by Besson el al. focuses on voltage-gated sodium channels as targets for cancer. There are then four reviews that follow covering separate therapeutic areas. The first is a contribution in the area of Infectious Disease by Tanikawa on hepatitis B and C, Cardiovascular Diseases by Calderon et al. on nitric oxide releasing drugs, Endocrinology covering benign prostatic hypertrophy by Malawska and Kulig, and Inflammation on prostaglandin D2 receptor modulators by Ulven and Kostenis.
ii
Finally, topics in the last section on Enabling Technologies include the concept of privileged structures in medicinal chemistry by Costantino and Barlocco, and the use of molecular modeling with application to acetylcholinesterase by Lushington et al. We hope that Frontiers in Medicinal Chemistry becomes an invaluable resource for the benefit of researchers in various aspects of therapeutic drug discovery. We wish to thank the authors who have contributed to this volume, and Mahmood Alam, Samina Khan, Qurat-ulAin and Matthew Honan of Bentham Science Publishers for their efforts.
ALLEN B. REITZ Fox Chase Chemical Diversity Center, Inc. Doylestown, PA 18902 USA
M. IQBAL CHOUDHARY International Center for Chemical and Biological Sciences (HEJ Research Institute of Chemistry, Dr. Panjwani Center for Molecular Medicine & Drug Research) University of Karachi Karachi-75270 Pakistan
ATTA-UR-RAHMAN International Center for Chemical and Biological Sciences (HEJ Research Institute of Chemistry, Dr. Panjwani Center for Molecular Medicine & Drug Research) University of Karachi Karachi-75270 Pakistan
vi
Contributors Jeroen J.M. Hoozemans
Neurogenetics Laboratory, Amsterdam, The Netherlands
Sidhartha M. Chafekar
Neurogenetics Laboratory, Amsterdam, The Netherlands
Frank Baas
Neurogenetics Laboratory, Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Piet Eikelenboom
Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Wiep Scheper
Neurogenetics Laboratory, Amsterdam, The Netherlands
Kirubakaran Shanmugam
Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, Australia
Annette E. Maczurek
Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, Australia
Megan L. Steele
Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, Australia
Obdulio Benavente-García
Furfural Español-Nutrafur, Alcantarilla, Murcia, Spain
Julián Castillo
Furfural Español-Nutrafur, Alcantarilla, Murcia, Spain
Gerald Münch
Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, Australia
Arjan Blokland
Department of Psychology and Neuroscience, EURON, Maastricht University,P.O. Box 616, 6200 MD Maastricht, The Netherlands
Rudy Schreiber
Sepracor, Inc., 84 Waterford Drive, Marlborough MA, 01752, USA
Jos Prickaerts
Department of Psychiatry and Neuropsychology, Brain & Behavior Institute, EURON, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
Yoko Shoji-Moskowitz
CREST, JAPAN;FOLIGO Therapeutics, Inc. USA
Daisuke Asai
CREST, JAPAN; Department of Microbiology, St. Marianna University School of Medicine, Japan, Department of Biomedical Engineering, Duke University, USA
vii
Kota Kodama
CREST, JAPAN; FOLIGO Therapeutics, Inc. USA Creative Research Institution, Hokkaido University, Japan
Yoshiki Katayama
CREST, JAPAN; Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Japan
Hideki Nakashima
CREST, JAPAN; Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Japan
Kylie M. Wagstaff
Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia
David A. Jans
ARC Centre of Excellence for Biotechnology and Development, Australia
Geoffrey A. Pietersz
Bio-organic and Medicinal Chemistry Laboratory, Australia
Dodie S. Pouniotis
Immunology and Vaccine Laboratory, Centre for Immunology, Burnet Institute, Commercial Road, Melbourne, VIC, 3004, Australia
Vasso Apostolopoulos
Immunology and Vaccine Laboratory, Centre for Immunology, Burnet Institute, Commercial Road, Melbourne, VIC, 3004, Australia
Farid El Oualid
Netherlands Cancer Institute, Division of Cell Biology, 1066 CX Amsterdam, The Netherlands
Gijs A. van der Marel
Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands
Mark Overhand
Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands
Ludovic Gillet
U921 Inserm, Nutrition Croissance Cancer; Université de Tours; Faculté de Médecine, 10 Bd Tonnellé, 37032 TOURS France
Sébastien Roger
U921 Inserm, Nutrition Croissance Cancer; Université de Tours; Faculté de Médecine, 10 Bd Tonnellé, 37032 TOURS France
Marie Potier
U921 Inserm, Nutrition Croissance Cancer; Université de Tours; Faculté de Médecine, 10 Bd Tonnellé, 37032 TOURS France
viii
Lucie Brisson
U921 Inserm, Nutrition Croissance Cancer; Université de Tours; Faculté de Médecine, 10 Bd Tonnellé, 37032 TOURS France
Christophe Vandier
U921 Inserm, Nutrition Croissance Cancer; Université de Tours; Faculté de Médecine, 10 Bd Tonnellé, 37032 TOURS France
Pierre Besson
U921 Inserm, Nutrition Croissance Cancer; Université de Tours; Faculté de Médecine, 10 Bd Tonnellé, 37032 TOURS France
Jean-Yves Le Guennec
U921 Inserm, Nutrition Croissance Cancer; Université de Tours; Faculté de Médecine, 10 Bd Tonnellé, 37032 TOURS France
Kyuichi Tanikawa
Professor Emeritus, Kurume University, President, International Institute for Liver Research, International Institute for Liver Research, Alley II 202, Tsubuku-honmachi 636-1, Kurume 830-0047, Japan
Alma Martelli
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie,Università degli Studi di Pisa, Via Bonanno, 6, I-56126 Pisa, Italy
Simona Rapposelli
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Pisa,Via Bonanno, 6, I-56126 Pisa, Italy
Maria C. Breschi
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie,Università degli Studi di Pisa, Via Bonanno, 6, I-56126 Pisa, Italy
Vincenzo Calderone
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie,Università degli Studi di Pisa, Via Bonanno, 6, I-56126 Pisa, Italy
Katarzyna Kulig
Department of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Jagiellonian University Medical College, Medyczna 9 str., 30-688 Kraków, Poland
Barbara Malawska
Department of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Jagiellonian University Medical College, Medyczna 9 str., 30-688 Kraków, Poland
Trond Ulven
Department of Physics and Chemistry, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark
Evi Kostenis
Institute for Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany
ix
Luca Costantino
University of Modena e Reggio Emilia, Dipartimento di Scienze Farmaceutiche, Via Campi 183, 41100 Modena, Italy
Daniela Barloccob
University of Milano, Dipartimento di Scienze Farmaceutiche “Pietro Pratesi”, Via L. Mangiagalli 25, 20133 Milano, Italy
Gerald H. Lushington
Molecular Graphics and Modeling Laboratory, University of Kansas, Lawrence, KS 66045 USA
Jian-Xin Guo
Molecular Graphics and Modeling Laboratory, University of Kansas, Lawrence, KS 66045 USA
Margaret M. Hurley
Weapons and Materials Research Directorate, U.S. Army Research Laboratory, Aberdeen Proving Ground, MD 21005, USA
Frontiers in Medicinal Chemistry, 2010, 5, 1-14
1
Always Around, Never the Same: Pathways of Amyloid Beta Induced Neurodegeneration Throughout the Pathogenic Cascade of Alzheimer’s Disease Jeroen J.M. Hoozemansa, Sidhartha M. Chafekara, Frank Baasa,b, Piet Eikelenboomb and Wiep Schepera,* a
Neurogenetics Laboratory, bDepartment of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Abstract: There is an increasing amount of evidence showing the importance of intermediate aggregation species of amyloid (A) in the pathogenic cascade of Alzheimer’s disease (AD). Different A assembly forms may mediate diverse toxic effects at different stages of the disease. Mouse models for AD suggest that intraneuronal accumulation of A oligomers might be involved in AD pathogenesis at a very early stage of the disease. The detrimental effect of oligomeric A on synaptic efficacy is suggested to be an early event in the pathogenic cascade. Also early neuronal responses as activation of the unfolded protein response are processes likely to be associated with the increased occurrence of oligomeric or low fibrillar A in AD pathology. In later stages of AD pathology, the fibrillarity of A increases, concomitantly with a neuroinflammatory response, followed by tau related neurofibrillary changes in end stage pathology. We will review recent findings in in vitro cell models, in vivo mouse models, and post mortem AD brain tissue in view of the effects of different A peptide species on neurodegeneration during AD pathogenesis. Insight into the role of different A species during AD pathogenesis is essential for the development of disease modifying drugs and therapeutical strategies.
Keywords: Alzheimer’s disease, amyloid , aggregation, ER stress, neuroinflammation, neurotoxicity, pathological cascade, unfolded protein response 1. INTRODUCTION Alzheimer’s disease (AD) is characterized by progressive memory loss and other cognitive and behavioral deficits and is the most common cause of dementia. Deposits of aggregated proteins are a prominent neuropathological hallmark of AD: intracellular aggregates of tau in the neurofibrillary tangles and extracellular aggregates of -amyloid (A) in the senile plaques. AD thus represents a prime example of a protein folding disease [1, 2]. According to the widely supported amyloid cascade hypothesis, increased levels or a conformational change of A is the primary cause of AD pathogenesis [3, 4]. A is formed *Corresponding author: Tel: 0031-20-5664959; Fax: 0031-20-5669312; E-mail:
[email protected] Allen B. Reitz / Atta-ur-Rahman / M. Iqbal Choudhary (Eds.) All rights reserved – © 2010 Bentham Science Publishers.
2 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Hoozemans et al.
by proteolytic cleavage of the amyloid precursor protein (APP) by a combined action of and -secretases [5]. Important support for the central role of A in AD comes from the familial variants of the disease. To date, mutations in three genes (APP, Presenilin 1 and Presenilin 2) have been shown to cause AD in an autosomal dominant fashion [6]. All these mutations can directly be linked to altered or increased A formation, and more specifically to increased A1-42 levels. Mutations in APP lead to preferential amyloidogenic processing and presenilins play a role in the proteolytic cleavage of APP. In addition, Down’s syndrome patients have a trisomy of chromosome 21, which contains the APP gene and typically develops early onset AD [7]. Stronger evidence for a gene dosage effect comes from a recent report on a family that carries a duplication of the APP locus only, resulting in early onset AD [8]. Alzheimer’s disease has an average duration of 8 years after clinical symptoms occur. During this time but also long before clinical symptoms are apparent, the brain is subject to pathological changes. Study of post mortem human brain tissue has resulted in a pathological staging of Alzheimer’s disease, the Braak score [9, 10]. Although the Braak score does not represent a temporal scale, there is good correlation between the Braak score for neurofibrillary changes and the clinical course of AD as determined by the cognitive status [11, 12]. This suggests that the pathological staging indeed reflects the temporal sequence of events in the pathogenic cascade. The first two stages of the Braak score for neurofibrillary changes, stage I and II, present with mild to severe alteration of the transenthorinal region. Stages III and IV are characterized by the severe involvement of the enthorinal and transenthorinal region, while the isocortex gradually becomes mildly affected. Stages V and VI are marked by the severe occurrence of neurofibrillary changes in the isocortex. While in Braak stage I to III the temporal cortex is almost devoid of neurofibrillary changes, lowfibrillar A deposits can be detected in these cases, indicating a role for A very early in the disease. Recent data suggest that oligomeric A, and especially intracellular localized A, plays a significant role in AD pathology. However, difficulty in the detection of oligomeric and intracellular A in AD mouse models and even more so in AD brain tissue, has hampered the study of the role of these A species in the pathogenic cascade. It is still elusive in what stage of disease these A oligomers are involved. In view of development of therapeutics directed against oligomeric forms of A it is crucial to place the A oligomers in AD pathogenesis and to define associated pathological hallmarks. In this review we will show that AD associated disease mechanisms like the stress response in the endoplasmic reticulum (ER) and neuroinflammation can be placed in different disease stages alongside the occurrence of different A conformation changes. Compiling information from human brain tissue, mouse models and in vitro studies, we will show that in all these stages A appears to show a different face with regard to the aggregation state and the cellular processes that are affected. We have combined this in a model explaining the role of the different conformations of A in disease mechanisms occurring throughout the pathogenic cascade of AD. 2. A AGGREGATION Electron microscopy and more recently (time-lapse) atomic force microscopy analyses have greatly contributed to visualizing different A aggregation intermediates that are formed in vitro before formation of the mature 6- to 10-nm diameter fibrils with the characteristic cross- structure [13-15]. The aggregation conditions in vitro are very artificial, using high concentrations of pure A, therefore caution is warranted in translating these data directly to the aggregation process in human brain.
Amyloid Beta Induced Neurodegeneration
Frontiers in Medicinal Chemistry, 2010, Vol. 5
3
Here we will use the definitions for A aggregation forms as proposed by Ross and Poirier [16]; oligomeric aggregates are small globular assemblies, protofibrils are soluble fibrilshaped structures, thinner and shorter than a mature fibril and fibrillar aggregates are stable, insoluble and highly structured aggregates. Although oligomers and protofibrils are usually considered as intermediates in fibril formation, there is no definite proof that they are “on” the fibrillization pathway or whether they represent a pathway “off” fibril formation. Fibrillization of A appears to proceed in two phases: a rate-limiting nucleation step in which a “seed” for further aggregation is formed, followed by an extension phase [17, 18]. Fibril growth in vitro proceeds by the addition of monomers to the ends of the fibrils [12, 19, 20]. The aggregation process is highly dependent on the A concentration. In vitro, unphysiologically high concentrations are required, but it is likely that in vivo such a high concentration can be achieved locally in intracellular compartments or by binding to proteins or lipids [17]. A1-42 was shown to nucleate easier than A1-40 [17], which may be why subtle changes in the A1-42/1-40 ratio induce AD pathology. Transgenic mice that secrete high levels of A1-42 in the absence of APP overexpression, show massive amyloid pathology, in contrast to transgenic A1-40 mice [21]. These experiments underscore the importance of A1-42 in amyloid deposition, and it was suggested that A1-42 is required for nucleation in vivo. A very interesting insight in A aggregation kinetics comes from the Arctic APP mutation. The conversion of the amino acid Glutamic acid to Glycine at position 22 in A is the only mutation in the A peptide itself that gives rise to a classical AD phenotype, despite resulting in lower A1-42 levels [22]. This was shown not to be due to increased fibrillization, but rather to a change in aggregation kinetics that accelerates protofibril formation [23]. The exact nature of the nucleation seed in vivo is not known. It is very likely that in the crowded environment inside neurons or the brain parenchyma, binding of A to other proteins or lipids contributes to seeding. For example A bound to the ganglioside GM1 was shown to have a different conformation that appeared to act as a seed for aggregation, thereby greatly enhancing fibril formation [24]. 3. INTRA- VERSUS EXTRA-CELLULAR A A is secreted into the extracellular space and ultimately deposited in the extracellular plaques in AD brain. This in combination with the toxicity of extracellular A in vitro, provides strong evidence for A exerting its toxic action from the outside of the cell. More recently, the role of intracellular A has gained a lot of attention and intraneuronal A is currently viewed as an early event in AD pathogenesis prior to extracellular A deposition [25]. A is produced intracellularly in a variety of subcellular compartments, including the endoplasmic reticulum (ER), trans-Golgi network and lysosomes. Therefore, by definition, it spends time inside neurons on its way out. LaFerla and colleagues were the first to describe the presence of intracellular A in neurons in AD brain [26] and since then several reports showing intraneuronal A accumulation have been published (reviewed in [27]). In human neurons intracellular oligomeric A aggregates have been detected [28]. In AD brain, neurons were shown to contain thioflavin Sreactive deposits [26], suggesting accumulation of fibrillar A although this finding was not confirmed by others [29]. It is not known whether intracellular aggregation of A is a prerequisite for toxicity. In human post mortem brain A is most easily detected in the endo-/lysosomal system [30-32], possibly because the acidic environment favours fibrillization. In addition, it has
4 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Hoozemans et al.
been found freely distributed in the perikaryon of neurons, indicating that A can be translocated from membranous compartments into the cytosol [33]. It is unclear whether A in the endo-/lysosomal system is derived from re-uptake from the extracellular space or whether it is directly formed in these compartments. In transgenic mice, intraneuronal A aggregates were found associated with the ER, Golgi and mitochondria [34]. It appears that intracellular A deposition is dependent on the levels of A, as intracellular A pathology is more prominent in models with higher A production. This may imply that if the concentration is sufficiently high, A is retained inside the cell, maybe because the high local concentration causes it to aggregate in intracellular compartments. Evidence for a correlation between the level of A and the site of accumulation comes from studies in a transgenic mouse model that produces very high levels of A due to the presence of four familial FAD mutations. These mice exhibit intraneuronal rather than extracellular thioflavin-S positive A aggregates [35]. Interestingly, these mice show more extensive neuronal loss than models that predominantly have extracellular deposits, suggesting that intracellular A is more toxic. Also a transgenic mouse harboring the Swedish APP mutation, leading to increased A levels, combined with the Arctic mutation (tg-APPArcSwe model) results in intraneuronal A aggregation [36]. In this respect it is interesting to mention sporadic Inclusion Body Myositis (sIBM). In sIBM myotubes, A exclusively forms intracellular inclusion bodies that co-localize with several ER chaperones [37]. The cause of the intracellular localisation of A deposits in sIBM is not known, but it is likely that the different cellular environment is an important determinant. It is tempting to speculate that the local concentration of intracellular A is much higher in muscle cells, possibly because their secretory capacity will be lower than that of neurons. In any case, the sIBM example indicates that also in man, conditions can be found where aggregation and deposition of A is exclusively intracellular with degeneration as result. Intuitively it seems logical that there is equilibrium between extra- and intracellular pools of A. Intracellular A decreases with plaque load [29, 32], although more intraneuronal A correlating with a higher plaque load has also been reported [38]. More direct experimental evidence for a balance between extra- and intracellular A pools comes from A vaccination experiments in the triple transgenic AD mouse model. This model shows intracellular A accumulation before plaque formation [39]. In the same model, immunization results in clearance of extracellular A before the clearance of intracellular A and after dissipation of the immunizing antibody the intraneuronal accumulation of A reappeared before the extracellular A deposits [40]. Because antibodies obviously can not enter the intracellular space, this points to a direct connection between intra- and extracellular A pools. 4. MECHANISMS OF A INDUCED NEURODEGENERATION In vitro, both oligomeric as well as fibrillar preparations of A induce cell death in virtually any cell in culture, but oligomeric preparations do so more potently. The mechanism underlying effects of A on cell viability is not exactly known, although a plethora of cellular processes is disturbed by A. It is likely that several degenerative pathways act simultaneously. Here we will focus on cellular processes that can be attributed to specific A forms and can be placed in the pathogenic cascade. We will compare recent data from different experimental models in order to show the significance of the different aggregation species in the induction of specific neurodegenerative pathways in the pathological cascade in AD.
Amyloid Beta Induced Neurodegeneration
Frontiers in Medicinal Chemistry, 2010, Vol. 5
5
4.1. Synaptic Dysfunction There are several lines of evidence indicating that synaptic dysfunction is one of the first presentations of AD pathology and probably of A induced toxicity. Synaptic dysfunction in human or transgenic animal brains manifests for example as deficits of neurotransmitters, decreased synapse density and changed electrophysiological parameters (reviewed in [41]). For example the decreasing number of synapses in AD brain correlates better with disease progression than cell loss or plaque load [42]. Especially mouse models for AD have been very instructive in this matter. Many of these models show loss of synapses before plaque formation and the actual loss of neurons [43, 44]. Recent studies using two-photon microscopy elegantly show the manifestation of this in decreased synaptic contacts [45]. These effects are observed before plaque deposition, indicating this may be an effect of nonfibrillar A. It has been suggested that the earliest cellular changes in AD are caused by intracellular A. Although there is little doubt that intracellular A exists, real proof for its role in toxicity is difficult to obtain. A immunization in a transgenic mouse model that shows intracellular A accumulation early in the pathogenesis, clears the intracellular A and cures early cognitive deficits [44]. From these experiments, it is very tempting to conclude a primary role for intracellular A, however, thusfar experiments really distinguishing between A acting inside the cell and secreted A acting from the extracellular space have not been performed. The role of extracellular A is corroborated by the inhibition LTP by oligomeric A specifically [46]. This is reversed by passive immunization against oligomeric A [47]. Oligomeric A was shown to colocalize with clusters of PSD-95, a marker for post-synaptic terminals, on dendritic arbors of hippocampal cultures [48]. The data further show that A targets specific synaptic sites, which may provide a basis for the selective loss of synapses in AD. A may directly affect the presence of receptors in the synaptic cleft, as it has been shown that oligomeric A induces endocytosis of NMDA receptors [49]. However, other mechanisms as the activation of oxidative/nitrosative stress signaling cascades (reviewed in [50]) or reductions in the levels of proteins involved in synaptic transmission like PSD-95 and the glutamate receptor subunit GluR1 [51] have also been reported. In AD brain, loss of proteins involved in dendritic spine dynamics like the kinase PAK and the spine regulatory protein drebrin is observed [52]. In the same study, oligomeric A induced loss of PAK activity and drebrin in cultured neurons. In conclusion there are several lines of evidence suggesting that early A aggregation intermediates are causative to synaptic dysfunction in AD, however this does not exclude a role for intracellular A. 4.2. Unfolded Protein Response One clear example of aggregation state specific effects is on calcium homeostasis. Oligomeric A was shown to induce calcium influx [53]. Although the mechanism is unknown, the data suggested that it was not through the formation of pores in the membrane, which had previously been suggested as a mechanism of A toxicity. It is possible that A binds to a receptor and thus initiates a signaling cascade. Disturbance of Ca2+ homeostasis could have dramatic effects including defects in synaptic transmission, membrane dynamics and dysfunction of Ca2+ binding proteins. Interestingly, oligomeric A also induces release of Ca2+ from intracellular stores, i.e. the endoplasmic reticulum [53], which may have severe effects on the function of the ER in protein synthesis and folding. The presence of misfolded proteins in the ER triggers a cellular stress response called the unfolded protein response (UPR) intended to protect the cell against the toxic buildup of misfolded proteins [54, 55]. Recently, our group showed the activation of the UPR in neu-
6 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Hoozemans et al.
rons in AD brain [56]. In the temporal cortex and the hippocampus of AD cases protein levels of the ER chaperone BiP/GRP78 are increased, which is indicative for UPR activation. At the immunohistochemical level intensified staining of BiP/GRP78 was observed in neurons of AD cases. In addition, immunohistochemistry for phosphorylated pancreatic ER kinase (pPERK) and phosphorylated eukaryotic initiation factor 2 (p-eIF2), a substrate for PERK, indicates activation of the UPR only in AD neurons and not in non-demented control cases Interestingly, we find that Rab6, a protein involved in retrograde trafficking from the Golgi to the ER is upregulated in AD in a manner that correlates strongly with the levels of ER stress [57]. Our data indicate that the Rab6 pathway is a post-ER protein quality mechanism, and therefore it appears that an array of protein quality control in the secretory pathway is activated during AD pathogenesis [27]. Activation of protein quality control in the secretory pathway is in this case not secondary to decreased proteasomal activity, as the latter is observed only in the final stages of AD [58]. Because our data indicate that both activation of the UPR as well as Rab6 upregulation precede tangle formation and occur as early as Braak stage III [57], it is a relatively early response, likely to be mediated by oligomeric or low fibrillar A. Extracellular A peptides can induce the UPR in neuronal cells [59, 60]. In addition, data from our own lab show that oligomeric A, but not fibrillar A induces ER stress [61]. This may imply that if A induces a signaling cascade, and that the signal is transmitted to the ER, possibly via its effects on Ca2+ signaling [62]. An alternative possibility is the uptake of A and concomitant transport to the ER. Our data show preferential uptake of oligomeric A in some cell types, but we found no evidence as yet for actual transport to the ER [63]. Whether the oligomer specific activation of the UPR is caused by disturbed Ca2+ homeostasis remains to be shown. 4.3. Neuroinflammation and Microglial Activation The neuroinflammatory response in AD pathology is closely associated with the deposition of A plaques. Increased levels of cytokines, complement proteins and acute phase proteins can be detected in the vicinity of A plaques [64]. Since there is no apparent influx of leukocytes and immunoglobulins are not detected, it is generally believed that these inflammatory proteins are synthesized locally in the brain [65]. Intracerebral A plaques are associated with complement factors, 1-antichymotrypsin, apolipoprotein E (ApoE), clusterin, serum amyloid P component (SAP) and proteoglycans [66]. The occurrence of these amyloid associated proteins is closely related with the fibrillarity of the A plaques. Some amyloid associated factors, like C1q and ApoE, enhance the aggregation and fibril formation of newly formed A peptides. Since non- to low-grade fibrillar A can have direct neurotoxic effects [67], the binding of amyloid associated factors that enhance fibril formation may be beneficial. A plaques that have accumulated SAP and C1q are associated with clusters of activated microglia [68]. Microglia are considered to be brain-resident macrophages involved in the maintenance of homeostasis within the brain and are rapidly activated in response to neuronal damage and stress [69]. In AD brain, microglia are most likely recruited to remove the A. Cultured microglia can phagocytose A, although their ability to degrade aggregated A is limited [70]. In addition, A associated proteins, such as proteoglycans and complement proteins could also reduce the phagocytosis of A by microglia [71, 72]. While attempting to remove the A, microglia become activated and release reactive oxygen species, pro-inflammatory cytokines, excitotoxins, and proteases, all potentially neurotoxic substances. The A induced microglial activation, as measured by cytokine release is
Amyloid Beta Induced Neurodegeneration
Frontiers in Medicinal Chemistry, 2010, Vol. 5
7
reduced by peptides and drugs like minocycline and tetracycline that function as -sheet breakers [73, 74]. This indicates that the fibrillarity of A is important for microglial activation. In addition, the neuroinflammatory response and the microglial activation in AD are observed in a disease stage (Braak IV-V) which can be discriminated from other stages in that it involves a reaction to the presence of fibrillar A. Although the neuroinflammatory response induced by A could be viewed as a potential contributor to AD neurodegeneration, some inflammatory proteins may have beneficial effects by inducing microglial mediated A removal [75], or enhancing A aggregation and fibril formation reducing the levels of neurotoxic non- to low-grade fibrillar Aß. The role of inflammation as a double-edged sword in neurodegenerative disorders attracts much interest in current AD research [76]. This is not surprising because eliminating pathogenic stimuli, such as the removal of fibrillar A deposits is an essential characteristic of the inflammatory process and interesting from therapeutical point of view. 5. THE MANY FACES OF A IN THE PATHOLOGICAL CASCADE OF AD For AD therapy it will be important to determine disease stages and to verify at which stage different disease processes are involved. Thusfar, it is not feasible to study pathogenic pathways at the molecular level in living AD patients. The combination of AD human post mortem data, results from AD mouse models, and cellular models can give an indication of which disease mechanisms are involved in different stages of AD pathogenesis. In our own studies we investigated the mid-temporal cortex of non-demented control and AD cases grouped according to the Braak stage for neurofibrillary changes [9]. The activation of the UPR already occurs in Braak stage III-IV and therefore seems a disease mechanism more likely to be related to the occurrence of intra- or extracellular oligomeric A or low fibrillar A. Extracellular A peptides, especially oligomeric A, induce ER stress in vitro. The increase in UPR activation coincides with the increase of A deposits, suggesting a direct link between A and ER stress. In addition, there is a weak colocalization of UPR markers with hyperphosphorylated tau and the increased UPR activation is already present in the temporal cortex when moderate neurofibrillary changes are observed (Braak stage IIIIV). UPR activation increases concomitant with plaques containing hyperphosphorylated tau (neuritic plaques) but precedes the increased incidence of neurofibrillary tangles. In vitro experiments show that induction of the UPR results in activation of glycogen synthase kinase 3 (GSK-3) [77]. GSK-3 is involved in a remarkably broad spectrum of ADassociated events, especially in the phosphorylation of tau, a prerequisite for the formation of dystrophic neurites and neurofibrillary tangles. The UPR could therefore be directly involved in early A plaque associated neurofibrillary changes via GSK-3. The neuroinflammatory response in AD pathology is closely associated with the deposition of A plaques. The occurrence of amyloid associated proteins is closely related with the fibrillarity of the A plaques and with the increased occurrence of high fibrillar A deposits, the neuroinflammatory response is augmented with a central role for activated microglia. This disease stage (Braak IV-V) can be discriminated from previous stages in that it involves a reaction to the presence of fibrillar A. Although initiated to remove the pathogenic A aggregates, the neuroinflammatory response could aggravate other disease mechanisms, i.e. increased APP production, A formation and plaque development, UPR activation, neurofibrillary changes and the formation of neurofibrillary tangles, the latter occurring predominantly in the last stage of the pathological cascade (Braak V-VI).
8 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Hoozemans et al.
6. THERAPEUTIC OPPORTUNITIES IN THE EARLY STAGES OF AD PATHOLOGY An obvious approach for AD therapy would be to reduce A production, especially A1to inhibit fibrillar A aggregation, and to induce A clearance. In the next section we will focus on possible therapeutic approaches that target the presence and effects of A early in the pathological cascade.
42,
Inhibiting the proteolytic cleavage of APP by - and -secretase inhibitors could block the production of A, which presumably would slow or halt the progression of the disease. However, much is still elusive on how these secretases are regulated and how they are involved in the pathogenesis of sporadic AD. In addition, the side-effects of -secretase inhibition on for example Notch processing may be detrimental. A variety of experimental studies indicate that a subset of classical non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, flurbiprofen, indomethacin and sulindac also possess A1-42-lowering properties in both AD transgenic mice and cell cultures of peripheral, glial and neuronal origin [78-80]. In addition, there are indications that certain NSAIDs inhibit A1-42 formation by direct modulation of -secretase activity [81]. Recently it is demonstrated that these NSAIDs have an allosteric effect on -secretase by which these drugs selectively reduce A1-42 but do not affect processing of other -secretase targets [82, 83]. Another approach for therapeutic intervention that could prevent A aggregation and deposition is immunization with A peptides or vaccination with antibodies directed against the A peptide. The first report on immunization of PDAPP transgenic mice with the A peptide showed reduced amyloid plaque formation [84]. Subsequent reports not only confirmed the potential of immunization strategies to induce clearance of A, but also indicated the potential of reducing cognitive dysfunction (reviewed by [85]). An immunization approach could work on different conformations of A and in different pathological stages. First, immunization increases the efflux of A out of the brain, into the periphery where it is degraded [86]. Peripheral administration of an antibody directed against A could results in a rapid decrease of oligomeric and low fibrillar A in the brain in an early stage of the disease. Second, antibodies directed against A can reduce the cytotoxic effect which A, especially the oligomeric forms, elicits on neuronal cells [87]. And third, antibodies directed against A could enhance the clearance of A by stimulating Fc receptor mediated phagocytosis of A by microglia in later stages of the disease [88]. Although promising in preclinical studies, the first human trial with A immunization halted prematurely due to the development of meningoencephalitis in 18 of the 298 patients enrolled in this trial [89]. Also AD transgenic mouse studies have shown, besides a clearance of parenchymal A deposits, an increase in vascular amyloid and microhemorrhages after passive immunotherapy [90, 91]. This indicates that immunization therapy has to develop towards a strategy where A is efficiently removed without increasing the toxic A species at other sites of the brain. In addition, at later stages in AD pathology immunization therapy could be used in combination with agents that suppress the detrimental effects of the neuroinflammatory response [92]. The therapeutic approaches mentioned above are aimed at the synthesis of A and disrupting the different conformational changes of A. Another approach is to target the cellular response to the different conformational forms A. Pharmacological induction of molecular chaperones may protect against aggregate toxicity [93]. The therapeutic potential of such a strategy is best illustrated by treatment of SODG93A mice, a model for amyotrophic lateral sclerosis, with arimoclomol, a co-inducer of heat shock proteins [94]. This treatment
Amyloid Beta Induced Neurodegeneration
Frontiers in Medicinal Chemistry, 2010, Vol. 5
9
resulted in decreased neuronal loss and consequently improved motorfunction, as well as increased lifespan. Another way to employ protein quality control to tackle neurodegeneration is via the UPR. Recently, the compound salubrinal was identified as an inhibitor of eIF2 de-phosphorylation and shown to protect against ER stress-induced cell death [95, 96]. Salubrinal is protective in a Parkinson’s disease cell model [97], indicating its potential for the treatment of neurodegenerative diseases. A drawback is that constitutive phosphorylation of eIF2 is unlikely to present a long-term treatment opportunity [98], therefore more selective targeting should be investigated. Valproate, a drug widely prescribed in the treatment of bipolar disorder and epilepsy, has been shown to increase the levels of BiP/GRP78 and other ER chaperones [99, 100]. Although valproate increases ER chaperones it has been reported that ER stress induced cellular dysfunction is reduced by valproate through inhibition of GSK-3/ [101]. Valproate could work protective in AD reducing ER stress and reducing tau phosphorylation by GSK-3. Currently, clinical trails have been started investigating the effect of valproate on AD patients. A very interesting finding was recently reported by Kondo and colleagues. They report that a transcription factor called OASIS specifically stimulates BiP/GRP78 upregulation (a positive response), but downregulates the ER stress induced cell death pathways [102]. OASIS is specifically induced in astrocytes, but factors with similar properties may exist in neurons as well, and present an ideal therapeutic target by stimulating positive and downregulating negative responses through a single protein. In conclusion, lowering A synthesis or stimulating A removal is promising in the sense that it removes the pathogen, although an undesired side-effect may be the generation of more toxic oligomeric A by dissolving fibrillar A. Alternatively, targeting quality control by either diminishing destructive or stimulating protective responses is attractive as well, because it makes use of the cell’s own mechanisms that have evolved to specifically deal with this problem. However, the presence and role of oligomeric and intracellular A in AD pathology and the disease stage they are involved is still not completely understood. For future therapies it will be necessary to characterize these molecular pathways and place them more precisely in the temporal sequence of the pathological cascade. ACKNOWLEDGEMENTS Work discussed in this review was financially supported by the Internationale Stichting Alzheimer Onderzoek (ISAO grants 02504 and 04503) and a fellowship of the Anton Meelmeijer Center for Translational Research to WS. Part of this work has been supported by a grant from the European Commission FP6 (ADIT, contract n. LSHB-CT-2005511977). REFERENCES [1] [2] [3] [4] [5] [6] [7]
Selkoe, D. J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol., 2004, 6, 1054-1061. Taylor, J. P.; Hardy, J.; Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science, 2002, 296, 1991-1995. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12, 383-388. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-356. Annaert, W.; De Strooper, B. A cell biological perspective on Alzheimer's disease. Annu. Rev. Cell Dev. Biol., 2002, 18, 25-51. Hutton, M.; Perez-tur, J.; Hardy, J. Genetics of Alzheimer's disease. Essays Biochem., 1998, 33, 117-131. Lott, I. T.; Head, E.: Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol. Aging, 2005, 26, 383-389.
10 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [8]
[9] [10] [11]
[12] [13] [14] [15] [16] [17]
[18] [19]
[20] [21]
[22]
[23]
[24] [25] [26]
[27] [28] [29]
Hoozemans et al.
Rovelet-Lecrux, A.; Hannequin, D.; Raux, G.; Meur, N. L.; Laquerriere, A.; Vital, A.; Dumanchin, C.; Feuillette, S.; Brice, A.; Vercelletto, M.; Dubas, F.; Frebourg, T.; Campion, D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet., 2006, 38, 24-26. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol., (Berl), 1991, 82, 239-259. Braak, H.; Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol.Aging, 1995, 16, 271-278. Bancher, C.; Braak, H.; Fischer, P.; Jellinger, K. A. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett., 1993, 162, 179182. Riley, K. P.; Snowdon, D. A.; Markesbery, W. R. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann. Neurol., 2002, 51, 567-577. Goldsbury, C. S.; Wirtz, S.; Muller, S. A.; Sunderji, S.; Wicki, P.; Aebi, U.; Frey, P. Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors. J. Struct. Biol., 2000, 130, 217-231. Harper, J. D.; Wong, S. S.; Lieber, C. M.; Lansbury, P. T., Jr. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry, 1999, 38, 8972-8980. Lashuel, H. A.; Hartley, D.; Petre, B. M.; Walz, T.; Lansbury, P. T., Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 2002, 418, 291. Ross, C. A.; Poirier, M. A. Opinion: What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol., 2005, 6, 891-898. Harper, J. D.; Lansbury, P. T., Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem., 1997, 66, 385-407. Teplow, D. B. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid., 1998, 5, 121-142. Nichols, M. R.; Moss, M. A.; Reed, D. K.; Lin, W. L.; Mukhopadhyay, R.; Hoh, J. H.; Rosenberry, T. L. Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry, 2002, 41, 61156127. Tseng, B. P.; Esler, W. P.; Clish, C. B.; Stimson, E. R.; Ghilardi, J. R.; Vinters, H. V.; Mantyh, P. W.; Lee, J. P.; Maggio, J. E. Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry, 1999, 38, 10424-10431. McGowan, E.; Pickford, F.; Kim, J.; Onstead, L.; Eriksen, J.; Yu, C.; Skipper, L.; Murphy, M. P.; Beard, J.; Das, P.; Jansen, K.; Delucia, M.; Lin, W. L.; Dolios, G.; Wang, R.; Eckman, C. B.; Dickson, D. W.; Hutton, M.; Hardy, J.; Golde, T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron, 2005, 47, 191-199. Nilsberth, C.; Westlind-Danielsson, A.; Eckman, C. B.; Condron, M. M.; Axelman, K.; Forsell, C.; Stenh, C.; Luthman, J.; Teplow, D. B.; Younkin, S. G.; Naslund, J.; Lannfelt, L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci., 2001, 4, 887-893. Lashuel, H. A.; Hartley, D. M.; Petre, B. M.; Wall, J. S.; Simon, M. N.; Walz, T.; Lansbury, P. T., Jr. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J. Mol. Biol., 2003, 332, 795-808. Hayashi, H.; Kimura, N.; Yamaguchi, H.; Hasegawa, K.; Yokoseki, T.; Shibata, M.; Yamamoto, N.; Michikawa, M.; Yoshikawa, Y.; Terao, K.; Matsuzaki, K.; Lemere, C. A.; Selkoe, D. J.; Naiki, H.; Yanagisawa, K. A seed for Alzheimer amyloid in the brain. J. Neurosci., 2004, 24, 4894-4902. Wirths, O.; Multhaup, G.; Bayer, T. A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. J. Neurochem., 2004, 91, 513-520. LaFerla, F. M.; Troncoso, J. C.; Strickland, D. K.; Kawas, C. H.; Jay, G.: Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J. Clin. Investing, 1997, 100, 310-320. Scheper, W.; Hol, E. M. Protein quality control in Alzheimer's disease: a fatal saviour. Curr. Drug Targets CNS Neurol. Disord., 2005, 4, 283-292. Walsh, D. M.; Tseng, B. P.; Rydel, R. E.; Podlisny, M. B.; Selkoe, D. J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry, 2000, 39, 1083110839. Gouras, G. K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J. P.; Haroutunian, V.; Buxbaum, J. D.; Xu, H.; Greengard, P.; Relkin, N. R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol., 2000, 156, 15-20.
Amyloid Beta Induced Neurodegeneration [30]
[31] [32]
[33] [34]
[35]
[36]
[37] [38] [39]
[40] [41] [42] [43]
[44] [45]
[46]
[47] [48]
[49] [50]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
11
Cataldo, A. M.; Petanceska, S.; Terio, N. B.; Peterhoff, C. M.; Durham, R.; Mercken, M.; Mehta, P. D.; Buxbaum, J.; Haroutunian, V.; Nixon, R. A. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol. Aging, 2004, 25, 1263-1272. D'Andrea, M. R.; Nagele, R. G.; Wang, H. Y.; Peterson, P. A.; Lee, D. H. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology, 2001, 38, 120-134. Mori, C.; Spooner, E. T.; Wisniewsk, K. E.; Wisniewski, T. M.; Yamaguch, H.; Saido, T. C.; Tolan, D. R.; Selkoe, D. J.; Lemere, C. A. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid., 2002, 9, 88-102. Fernandez-Vizarra, P.; Fernandez, A. P.; Castro-Blanco, S.; Serrano, J.; Bentura, M. L.; Martinez-Murillo, R.; Martinez, A.; Rodrigo, J. Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. Histol. Histopathol., 2004, 19, 823-844. Rodrigo, J.; Fernandez-Vizarra, P.; Castro-Blanco, S.; Bentura, M. L.; Nieto, M.; Gomez-Isla, T.; Martinez-Murillo, R.; Martinez, A.; Serrano, J.; Fernandez, A. P. Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience, 2004, 128, 73-89. Casas, C.; Sergeant, N.; Itier, J. M.; Blanchard, V.; Wirths, O.; van der, Kolk N.; Vingtdeux, V.; van de, Steeg E.; Ret, G.; Canton, T.; Drobecq, H.; Clark, A.; Bonici, B.; Delacourte, A.; Benavides, J.; Schmitz, C.; Tremp, G.; Bayer, T. A.; Benoit, P.; Pradier, L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol., 2004, 165, 1289-1300. Lord, A.; Kalimo, H.; Eckman, C.; Zhang, X. Q.; Lannfelt, L.; Nilsson, L. N.: The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol. Aging, 2006, 27, 67-77. Vattemi, G.; Engel, W. K.; McFerrin, J.; Askanas, V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am. J. Pathol., 2004, 164, 1-7. Fernandez-Vizarra, P.; Fernandez, A. P.; Castro-Blanco, S.; Serrano, J.; Bentura, M. L.; Martinez-Murillo, R.; Martinez, A.; Rodrigo, J. Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. Histol. Histopathol., 2004, 19, 823-844. Billings, L. M.; Oddo, S.; Green, K. N.; McGaugh, J. L.; LaFerla, F. M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron, 2005, 45, 675688. Oddo, S.; Caccamo, A.; Smith, I. F.; Green, K. N.; LaFerla, F. M. A Dynamic Relationship between Intracellular and Extracellular Pools of A{beta}. Am. J. Pathol., 2006, 168, 184-194. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science, 2002, 298, 789-791. Terry, R. D. Cell death or synaptic loss in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2000, 59, 1118-1119. Hsia, A. Y.; Masliah, E.; McConlogue, L.; Yu, G. Q.; Tatsuno, G.; Hu, K.; Kholodenko, D.; Malenka, R. C.; Nicoll, R. A.; Mucke, L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA, 1999, 96, 3228-3233. Oddo, S.; Caccamo, A.; Shepherd, J. D.; Murphy, M. P.; Golde, T. E.; Kayed, R.; Metherate, R.; Mattson, M. P.; Akbari, Y.; LaFerla, F. M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39, 409-421. Rutten, B. P.; Van der Kolk, N. M.; Schafer, S.; van Zandvoort, M. A.; Bayer, T. A.; Steinbusch, H. W.; Schmitz, C. Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am. J. Pathol., 2005, 167, 161-173. Walsh, D. M.; Klyubin, I.; Fadeeva, J. V.; Cullen, W. K.; Anwyl, R.; Wolfe, M. S.; Rowan, M. J.; Selkoe, D. J.Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002, 416, 535-539. Klyubin, I.; Walsh, D. M.; Lemere, C. A.; Cullen, W. K.; Shankar, G. M.; Betts, V.; Spooner, E. T.; Jiang, L.; Anwyl, R.; Selkoe, D. J.; Rowan, M. J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med., 2005, 11, 556-61. Lacor, P. N.; Buniel, M. C.; Chang, L.; Fernandez, S. J.; Gong, Y.; Viola, K. L.; Lambert, M. P.; Velasco, P. T.; Bigio, E. H.; Finch, C. E.; Krafft, G. A.; Klein, W. L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci., 2004, 24, 10191-10200. Snyder, E. M.; Nong, Y.; Almeida, C. G.; Paul, S.; Moran, T.; Choi, E. Y.; Nairn, A. C.; Salter, M. W.; Lombroso, P. J.; Gouras, G. K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci., 2005, 8, 1051-1058. Rowan, M. J.; Klyubin, I.; Wang, Q.; Anwyl, R. Mechanisms of the inhibitory effects of amyloid betaprotein on synaptic plasticity. Exp. Gerontol., 2004, 39, 1661-1667.
12 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [51]
[52]
[53] [54] [55] [56]
[57] [58]
[59]
[60] [61]
[62] [63] [64]
[65] [66] [67] [68]
[69] [70] [71]
Hoozemans et al.
Almeida, C. G.; Tampellini, D.; Takahashi, R. H.; Greengard, P.; Lin, M. T.; Snyder, E. M.; Gouras, G. K. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis., 2005, 20, 187-198. Zhao, L.; Ma, Q. L.; Calon, F.; Harris-White, M. E.; Yang, F.; Lim, G. P.; Morihara, T.; Ubeda, O. J.; Ambegaokar, S.; Hansen, J. E.; Weisbart, R. H.; Teter, B.; Frautschy, S. A.; Cole, G. M. Role of p21activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci., 2006, 9, 234-242. Demuro, A.; Mina, E.; Kayed, R.; Milton, S. C.; Parker, I.; Glabe, C. G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem., 2005, 280, 17294-17300. Forman, M. S.; Lee, V. M.; Trojanowski, J. Q. 'Unfolding' pathways in neurodegenerative disease. Trends Neurosci., 2003, 26, 407-410. Rutkowski, D. T. and Kaufman, R. J. A trip to the ER: coping with stress. Trends Cell Biol., 2004, 14, 2028. Hoozemans, J. J.; Veerhuis, R.; Van Haastert, E. S.; Rozemuller, J. M.; Baas, F.; Eikelenboom, P.; Scheper, W. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol. (Berl), 2005, 110, 165-172. Scheper, W.; Hoozemans, J. J. M.; Hoogenraad, C. C.; Rozemuller, A. J. M.; Eikelenboom, P.; Baas, F. Rab6 is increased in Alzheimer's disease brain and correlates with endoplasmic reticulum stress. Neuropathol. Appl. Neurobiol, 2007, 33, 523-532. van Leeuwen, F. W.; de Kleijn, D. P.; van den Hurk, H. H.; Neubauer, A.; Sonnemans, M. A.; Sluijs, J. A.; Koycu, S.; Ramdjielal, R. D.; Salehi, A.; Martens, G. J.; Grosveld, F. G.; Peter, J.; Burbach, H.; Hol, E. M. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science, 1998, 279, 242-247. Yu, Z.; Luo, H.; Fu, W.; Mattson, M. P. The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: suppression of oxidative stress and stabilization of calcium homeostasis. Exp. Neurol., 1999, 155, 302-314. Suen, K. C.; Lin, K. F.; Elyaman, W.; So, K. F.; Chang, R. C.; Hugon, J. Reduction of calcium release from the endoplasmic reticulum could only provide partial neuroprotection against beta-amyloid peptide toxicity. J. Neurochem., 2003, 87, 1413-1426. Chafekar, S. M.; Hoozemans, J. J. M.; Zwart, R.; Baas, F.; Scheper, W. A beta(1-42) induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid Redox Signal., 2007, 9, 22452254. Demuro, A.; Mina, E.; Kayed, R.; Milton, S. C.; Parker, I.; Glabe, C. G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem., 2005, 280, 17294-17300. Chafekar, S. M.; Baas, F.; Scheper, W. Oligomer-specific A beta toxicity in cell models is mediated by selective uptake. Biochim. Biophys. Acta-Mol. Basis Dis., 2008, 1782, 523-531. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B. L.; Finch, C. E.; Frautschy, S.; Griffin, W. S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I. R.; McGeer, P. L.; O'Banion, M. K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F. L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G. Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21, 383-421. Eikelenboom, P.; Zhan, S. S.; van Gool, W. A.; Allsop, D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci., 1994, 15, 447-450. Veerhuis, R.; Boshuizen, R. S.; Familian, A. Amyloid associated proteins in Alzheimer's and prion disease. Curr. Drug Targets. CNS. Neurol. Disord., 2005, 4, 235-248. Klein, W. L.; Krafft, G. A.; Finch, C. E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci., 2001, 24, 219-224. Veerhuis, R.; Van Breemen, M. J.; Hoozemans, J. M.; Morbin, M.; Ouladhadj, J.; Tagliavini, F.; Eikelenboom, P. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol. (Berl), 2003, 105, 135-144. Ling, E. A.; Wong, W. C. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia, 1993, 7, 9-18. Paresce, D. M.; Chung, H.; Maxfield, F. R. Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J. Biol. Chem., 1997, 272, 29390-29397. Shaffer, L. M.; Dority, M. D.; Gupta-Bansal, R.; Frederickson, R. C.; Younkin, S. G.; Brunden, K. R. Amyloid beta protein (A beta) removal by neuroglial cells in culture. Neurobiol. Aging, 1995, 16, 737745.
Amyloid Beta Induced Neurodegeneration [72] [73] [74]
[75] [76] [77] [78]
[79] [80] [81]
[82] [83]
[84]
[85] [86]
[87]
[88]
[89] [90]
[91]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
13
Webster, S. D.; Yang, A. J.; Margol, L.; Garzon-Rodriguez, W.; Glabe, C. G.; Tenner, A. J. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp. Neurol., 2000, 161, 127-138. Familian, A.; Boshuizen, R. S.; Eikelenboom, P.; Veerhuis, R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia, 2006, 53, 233-240. Takata, K.; Kitamura, Y.; Umeki, M.; Tsuchiya, D.; Kakimura, J.; Taniguchi, T.; Gebicke-Haerter, P. J.; Shimohama, S. Possible involvement of small oligomers of amyloid-beta peptides in 15-deoxy-delta 12, 14 prostaglandin J2-sensitive microglial activation. J. Pharmacol. Sci., 2003, 91, 330-333. Rogers, J.; Strohmeyer, R.; Kovelowski, C. J.; Li, R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia, 2002, 40, 260-269. Wyss-Coray, T. and Mucke, L. Inflammation in neurodegenerative disease--a double-edged sword. Neuron, 2002, 35, 419-32. Song, L.; De Sarno, P.; Jope, R. S. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem, 2002, 277, 44701-44708. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.; Pietrzik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 2001, 414, 212216. Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.; McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. NSAIDs and enantiomers of flurbiprofen target gammasecretase and lower Abeta 42 in vivo. J. Clin. Investig, 2003, 112, 440-449. Morihara, T.; Chu, T.; Ubeda, O.; Beech, W.; Cole, G. M. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J. Neurochem., 2002, 83, 1009-1012. Weggen, S.; Eriksen, J. L.; Sagi, S. A.; Pietrzik, C. U.; Ozols, V.; Fauq, A.; Golde, T. E.; Koo, E. H. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem., 2003, 278, 31831-31837. Beher, D.; Clarke, E. E.; Wrigley, J. D.; Martin, A. C.; Nadin, A.; Churcher, I.; Shearman, M. S. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem., 2004, 279, 43419-43426. Lleo, A.; Berezovska, O.; Herl, L.; Raju, S.; Deng, A.; Bacskai, B. J.; Frosch, M. P.; Irizarry, M.; Hyman, B. T. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med., 2004, 10, 1065-1066. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; JohnsonWood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-177. Gelinas, D. S.; DaSilva, K.; Fenili, D.; George-Hyslop, P.; McLaurin, J. Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101 (Suppl 2), 14657-14662. DeMattos, R. B.; Bales, K. R.; Cummins, D. J.; Dodart, J. C.; Paul, S. M.; Holtzman, D. M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98, 8850-8855. McLaurin, J.; Cecal, R.; Kierstead, M. E.; Tian, X.; Phinney, A. L.; Manea, M.; French, J. E.; Lambermon, M. H.; Darabie, A. A.; Brown, M. E.; Janus, C.; Chishti, M. A.; Horne, P.; Westaway, D.; Fraser, P. E.; Mount, H. T.; Przybylski, M.; George-Hyslop, P. Therapeutically effective antibodies against amyloidbeta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med., 2002, 8, 1263-1269. Bard, F.; Cannon, C.; Barbour, R.; Burke, R. L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med., 2000, 6, 916-9. Orgogozo, J. M.; Gilman, S.; Dartigues, J. F.; Laurent, B.; Puel, M.; Kirby, L. C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B. F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61, 46-54. Wilcock, D. M.; Rojiani, A.; Rosenthal, A.; Subbarao, S.; Freeman, M. J.; Gordon, M. N.; Morgan, D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation., 2004, 1, 24. Pfeifer, M.; Boncristiano, S.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P. M.; Jucker, M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science, 2002, 298, 1379.
14 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [92]
[93] [94] [95]
[96] [97] [98] [99]
[100] [101] [102]
Hoozemans et al.
Rozemuller, A. J.; van Gool, W. A.; Eikelenboom, P. The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications. Curr. Drug Targets. CNS. Neurol. Disord., 2005, 4, 223-233. Soti, C.; Nagy, E.; Giricz, Z.; Vigh, L.; Csermely, P.; Ferdinandy, P. Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol., 2005, 146, 769-780. Kieran, D.; Kalmar, B.; Dick, J. R.; Riddoch-Contreras, J.; Burnstock, G.; Greensmith, L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med., 2004, 10, 402-405. Boyce, M.; Bryant, K. F.; Jousse, C.; Long, K.; Harding, H. P.; Scheuner, D.; Kaufman, R. J.; Ma, D.; Coen, D. M.; Ron, D.; Yuan, J. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science, 2005, 307, 935-939. Wiseman, R. L. and Balch, W. E. A new pharmacology--drugging stressed folding pathways. Trends Mol. Med., 2005, 11, 347-350. Smith, W. W.; Jiang, H.; Pei, Z.; Tanaka, Y.; Morita, H.; Sawa, A.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alphasynuclein-induced toxicity. Hum. Mol. Genet., 2005, 14, 3801-3811. Wiseman, R. L.; Balch, W. E. A new pharmacology--drugging stressed folding pathways. Trends Mol. Med., 2005, 11, 347-350. Wang, J. F.; Bown, C.; Young, L. T. Differential display PCR reveals novel targets for the moodstabilizing drug valproate including the molecular chaperone GRP78. Mol. Pharmacol., 1999, 55, 521527. Bown, C. D.; Wang, J. F.; Young, L. T. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology, 2000, 39, 2162-2169. Kim, A. J.; Shi, Y.; Austin, R. C.; Werstuck, G. H. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci., 2005, 118, 89-99. Kondo, S.; Murakami, T.; Tatsumi, K.; Ogata, M.; Kanemoto, S.; Otori, K.; Iseki, K.; Wanaka, A.; Imaizumi, K. OASIS, a CREB/ATF-family member, modulates UPR signalling in astrocytes. Nat. Cell Biol., 2005, 7, 186-194.
Frontiers in Medicinal Chemistry, 2010, 5, 15-57
15
Novel Neuroprotective Therapies for Alzheimer’s and Parkinsons’s Disease Kirubakaran Shanmugam1, Annette E. Maczurek1, Megan L. Steele1, Obdulio Benavente-García2, Julián Castillo2 and Gerald Münch1,* 1
Department of Pharmacology, School of Medicine, and Molecular Medicine Research Group, University of Western Sydney, Campbelltown, Australia; 2Furfural Español-Nutrafur, Alcantarilla, Murcia, Spain
Abstract: One of the major age-related damaging agents are reactive oxygen species (ROS). The brain is more vulnerable to oxidative stress than other organs as concomitant low activity and capacity of antioxidative protection systems allow for increased exposure of target molecules to ROS. Since neurons are postmitotic cells, they have to live with cellular damage accumulated over many decades. Increased levels of ROS (also termed “oxidative stress”), produced by normal mitochondrial activity, inflammation and excess glutamate levels, are proposed to accelerate neurodegenerative processes characteristic for Alzheimer’s disease and Parkinson’s disease. This review presents evidence for the importance of oxidative stress in the pathogenesis of these diseases and explains the nature of different types of ROS mediating neuronal damage. Furthermore, the potential beneficial effects of neuroprotective treatments, including synthetic and plant deroved antioxidants, energy supplements and anti - glutamatergic drugs are discussed.
Keywords: Oxidative stress, Alzheimer’s disease, Parkinson’s disease, neuroprotection, antioxidants, NMDA receptor antagonists, bioenergetic drugs. 1. NEURODEGENERATIVE DISEASES – A GROWING BURDEN IN THE AGING POPULATION Neurodegenerative diseases are initially characterized by subtle changes in the normal function of neurons, which is followed by overt neuronal dysfunction and cell death in later stage of the disease. Age is the single most important risk factor for the development of many neurodegenerative disorders including Parkinson’s (PD) and Alzheimer’s disease (AD). In 2006, 26.6 million people were living with Alzheimer’s disease worldwide. According to the American Alzheimer’s Association, this number is set to exceed 100 million by 2050, at which time one in 85 people will be living with the disease, due to rapidly ageing populations and longer life expectancy. Patients with neurodegenerative diseases not only suffer emotionally and physically but also represent a significant financial and *Corresponding author: Tel: ++61 2 9852 4718; Fax: ++61 2 9852 7730; E-mail:
[email protected] Allen B. Reitz / Atta-ur-Rahman / M. Iqbal Choudhary (Eds.) All rights reserved – © 2010 Bentham Science Publishers.
16 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
emotional burden for caregivers, society and community. Thus, it is becoming increasingly important to find the cause(s) of neurodegenerative diseases and, based on these findings, develop and introduce novel therapies that prevent such diseases by providing neuroprotection. 2. NEURODEGENERATIVE DISORDERS 2.1. Alzheimer Disease Symptoms Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that gradually destroys a person’s memory and ability to learn, make judgments, communicate with the social environment and carry out daily activities. In the course of the disease, shortterm memory is affected first, caused by neuronal dysfunction and cell death in the hippocampus and amygdala. As the disease progresses further, neurons also die in other cortical regions of the brain. At that stage, sufferers often experience dramatic changes in personality and behaviour, such as anxiety, suspiciousness or agitation, as well as delusions or hallucinations. Epidemiology AD prevalence in the different age groups is 1 % (65-69 years), 3% (70-74 years), 6 % (75-79 years), 12% (80-84 years), and 25% (85 & over) [1]. As the society ages, the number of Alzheimer's disease patients will increase by 27% by 2020, 70% by 2030, and nearly 300% by 2050, unless science finds a way to slow the progression of the disease or prevent it. Alzheimer’s disease advances at widely different rates, and therefore the duration of the illness varies between 3 and 20 years. Neuropathology and Biochemistry AD is characterized by two characteristic lesions, amyloid plaques and neurofibrillary tangles, which are present in high numbers in the grey matter of affected brain areas. Neurofibrillary tangles are intracellular deposits formed by hyperphosphorylated and extensively crosslinked tau protein. Tau is a microtubule associated protein that regulates a variety of properties of neuronal microtubules, especially their stability and orientation. In AD, however, tau is hyperphosphorylated and forms fibrillar inclusions. Presumably this lead to neuronal dysfunction by disturbing cytoskeletal functions of neurons resulting in impaired axonal transport processes [2]. Senile plaques are the second characteristic hallmark in Alzheimer disease. These extracellular protein deposits are mainly composed of -amyloid peptide (A), which forms sheeted fibrils and become insoluble. A is derived from the -amyloid precursor protein (APP), an integral membrane protein that is processed by - and -secretases. In a variety of cell culture models, A was shown to cause toxicity to neurons by various mechanism, many of which involving oxidative stress. For example, 4-hydroxynonenal and malondialdehyde, both markers of lipid peroxidation, were found in the hippocampus of patients with AD. Markers of protein oxidation such as protein nitration are also increased in the hippocampus and neocortex of individuals with AD. The fact that A binds strongly to metal ions like copper and iron and catalyses the formation of the toxic hydroxyl radical from hydrogen peroxide strongly suggests that may be causally involved in oxidative stress in neurons. Amyloid plaques, which can be present in the brain for decades, are a target for modifica-
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
17
tion with advanced glycation endproducts (AGEs), i.e. sugar or carbonyl compounds attaching to lysine and arginine residues of long-lived proteins. AGEs have been found not only in amyloids, but also in other proteins with slow turnover such as eye lens crystalline or cartilage and skin collagen. In AD, A and AGE are both present in senile plaques and are resistant to degradation by macrophages due to extensive cross-linking. A and AGE are able to chemoattract and activate microglial cells that surround these senile plaques. AGEs and A bind to the same receptor, i.e. the receptor for glycation endproducts (RAGE), and activate signal pathways involved in the induction of oxidative and nitrosative stress and proinflammatory effectors [3]. Inflammation, as evidenced by the activation of microglia and astroglia, is another hallmark of AD. Inflammation, particularly the induction of superoxide production (“oxidative burst”), is an important source of oxidative stress in AD patients. The inflammatory process occurs mainly around the amyloid plaques and is characterized by pro-inflammatory substances released from activated microglia [4]. ROS are the most prominent molecules in the inflammatory process, along with prostaglandins, IL-1, IL-6, M-CSF and TNF- [5-7]. 2.2. Parkinson’s Disease Epidemiology and Symptoms Parkinson’s disease (PD) is a progressive, degenerative disease of unknown etiology characterised by rhythmic tremor of the limbs, stooped posture, slowness of voluntary movements, and mask-like facial expression. Idiopathic PD is the most common form of parkinsonism, which designates a group of movement disorders that have similar features and symptoms. Parkinson’s disease is called “idiopathic” because its cause is unknown, in contrast to other forms of parkinsonism, where a cause has been established or is suspected. The disease is quite frequent – about 4 people in every thousand have PD. Symptoms of Parkinson’s disease may appear at any age, but the average age of onset is 60. Neuropathology and Biochemistry Parkinson’s results from the degeneration of dopaminergic neurons in the substantia nigra that develop inclusions called Lewy bodies. These deposits are composed of aggregated alpha synuclein and ubiquitin. Ubiquitin is covalently attached to damaged or aged proteins, in order to mark them for degradation in the proteasome. Alpha synuclein is a synaptic protein of unknown function. When dopamine levels are depleted, the neuronal populations in the basal ganglia, to which the dopaminergic neurons project, become unable to coordinate and control the primary motor system, resulting in loss of prompt and smooth movement of limbs and trunk. Parkinson’s disease patients have lost 80% or more of their dopamine-producing cells before symptoms appear, highlighting the great spare capacity normal human beings possess. There is plenty of evidence that oxidative stress is occurring in PD. Partial deficiency of mitochondrial complex I leads to enhanced production of ROS and therefore to an inhibition of complex I [8]. Damaged neurones show reduced mitochondrial cytochrome c-oxidase activity, high concentrations of iron [9] as well as ROS release [10]. An increase in lipid peroxidation products [11], reactive protein carbonyls [12] and DNA oxidation [9] provide further evidence for oxidative stress in PD. Inflammation may also occur in this neurodegenerative disorder, since reactive microglia and activated complement components are found in affected brain regions [13].
18 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
3. MECHANISMS OF NEURODEGENERATION 3.1. Oxidative Stress 3.1.1. Inflammation and Glia-Derived Oxidative Burst One important source of ROS is the oxidative burst of activated macrophages and microglia, which release superoxide via the enzymatic activity of NADPH-oxidase. Under normal circumstances the human body is able to scavenge these radicals but oxidant (particularly superoxide) production is dramatically increased in some inflammatory situations. Such inflammation is mediated through resident brain microglia or immigrated peripheral monocytes and macrophages. Their normal function is to destroy bacteria or virus-infected cells with an oxidative burst of O2.- and its dismutation product H2O2, as well as HOCl and NO [14, 15]. These oxidants are generated by four differente enzymes, i.e. NADPH oxidase, superoxide dismutase, myeloperoxidase and nitric oxide synthase. NADPH oxidase is inactive in resting phagocytes, but exposure to various stimuli (i.e. immune complexes, complement 5a, -amyloid, AGEs) leads to its activation, i.e. catalysis of the conversion of molecular oxygen to superoxide. 2 O2 + NADPH 2 O2-
+ NADP+ + H+
The oxidation of halide ions to hypohalous acid at the expense of hydrogen peroxide is carried out by the enzyme myeloperoxidase [16]: Cl- + H2O2 OCl-
+ H2O
Hypochlorite can then further react with hypochlorite, ammonia or amines, the precursors of chloramines, a group of microbicidal oxidized halogens [17]. 3.1.2. Superoxide Production by Mitochondria In the human body, 20% of the total oxygen consumption is needed for the brain, which is quite intriguing given that the brain takes only 2% space of the total tissue volume [18]. About 0.15 - 2% of the oxygen consumed in neuronal mitochondria is incompletely reduced to generate superoxide anions by electron leakage from the electron transport chain (Chance, Sies, and Boveris 1979). These superoxide anions are usually converted by the enzyme superoxide dismutase (SOD) to hydrogen peroxide and then further converted to water by catalase or glutathione peroxidase [19]. Neurons in human brain are highly vulnerable to oxidative stress not only because of high oxygen consumption (and therefore high superoxide production), but also due to poor antioxidative mechanisms, particularly catalase activity, in comparison to other organs in the human body. The cell membranes in the brain are especially vulnerable to attack by hydroxl radicals as the double bonds of polyunsaturated fatty acids are easily oxidized. There are many different species of oxygen free radicals including superoxide, hydrogen peroxide and the hydroxyl radical, which are generated by reduction of molecular oxygen in three steps, and their generation and will be described in detail below.
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
19
3.2. Reactive Oxygen Species 3.2.1. Superoxide Superoxide (O2.-) is a precursor for hydroxyl radicals; it is necessary for the formation of hydrogen peroxide and also acts as a reducing agent of transition metals. Most of the superoxide produced in human brain is generated by the electron transport chain of the mitochondria by incomplete reduction of molecular oxygen. eO2
O2._
An increase in O2.- production also occurs when Ca2+ concentrations increase, as is the case during NMDA receptor overstimulation. Lipid metabolism is a second minor pathway for O2.- formation. When Ca2+ enters neurons, phospholipase A2 is activated and arachidonic acid (AA) is formed [20]. Cyclooxygenase then converts AA to prostaglandins, with O2.generated as a by-product [21]. O2- formed within the neurons does not appear to cross plasma membrane [22] and is therefore only found in the intracellular environment following damage to the neuronal membrane. Superoxide is more reactive in organic solutions than in aqueous ones and can therefore damage hydrophobic membranes. Although O2.- on its own may have little significance in terms of toxicity, its conversion to peroxynitrite and hydroxyl radicals greatly increases neurotoxicity. 3.2.2. Hydrogen Peroxide Hydrogen peroxide (H2O2) is not a free radical per se, but belongs to the category of ROS. It is not particularly reactive but it is the main source of hydroxyl radicals in the presence of transition metal ions [23]. It is also involved in the production of hypochlorous acid (HOCl) by neutrophils during oxidative burst [24]. H2O2 is generated in the dismutation reaction during which two molecules of superoxide are converted into one molecule of H2O2 plus molecular oxygen: -
2 O2 + 2 H+
O2 + H2O2
O2, the substrate, reacts with itself to give an oxidized product (i.e. oxygen) and a reduced product (i.e. H2O2). Superoxide dismutase (SOD) is the enzyme responsible for this reaction that exists as a copper-zinc enzyme in the cytoplasm and as manganese isoform in the mitochondria. 3.2.3. Hydroxyl Radical The reactions of the hydroxyl radical, which is the most damaging free radical by far, can have devastating effects in any tissue type. The hydroxyl radical is a third generation species of radical which is derived from hydrogen peroxide. Hydrogen peroxide in turn, is derived from the superoxide radical through the action of SOD, and then reduced to hydroxyl radicals in the presence of transition metals such iron or copper. It reacts with any molecule including macromolecules such as DNA, membrane lipids, proteins, and carbohydrates. In DNA, the hydroxyl radical can induce strand breaks as well as chemical changes in the deoxyribose and in the purine and pyrimidine bases. Damaged proteins, many of them crucial enzymes in neurons, lose their efficiency and cellular function deteriorates. Protein oxidation mediated by hydroxyl radicals has been proposed as an explanation for the functional deficits associated with aging in many tissues and brain aging and neurodegeneration in particular.
20 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
The conversion of hydrogen peroxide to the hydroxyl radical depends on the presence of transition metals such as copper or iron. There is evidence that these metals accumulate in aged brain, and they may therefore contribute to neurodegenerative disorders. Some brain regions and some types of brain cells , for example oligodendrocytes, show above-average concentrations of iron [25] while their antioxidative protection systems are rather weak. Being transition metals, iron can exist in the oxidized (+III) or reduced (+ II) forms and likewise copper as (+II) or (+ I), which makes them important cofactors for many enzymes. Free transition metals may, however, generate ROS via the Fenton reaction. Here, Fe2+ is able to transfer one electron to H2O2, thus producing the hydroxy radical: Fe 2+ + H2O2 Fe3+ + .OH + OH.The Haber-Weiss reaction also can form .OH in an interaction between O2.- and H2O2 in the presence of Fe2+ or Fe3+ [26]. The body has developed chaperones to prevent such metaldependent hydroxyl radical generation. Free copper is generally bound to cytochrome C oxidase, Cu/Zn superoxide dismutase and caeruloplasmin whilst iron is mainly bound to ferritin. This prevents the inadvertent release of the metals and limits their availability to catalyze the Haber-Weiss reaction. 3.2.4. Nitric Oxide Nitric Oxide (NO) is the another radical proposed to be involved in neurodegeneration and is produced by various NO-synthetases. Ca2+ activated neuronal nitric oxide synthases (nNOS, bNOS, cNOS, TypeI) catalyze the oxidation of arginine to citrulline and nitric oxide, utilizing molecular oxygen: Arginine + O2 + NADPH
NO + citrulline + NADP+
In response to increased intracellular Ca2+, nNOS interacts with Ca2+/calmodulin (CaM), forms a complex with the cofactor tetrahydrobiopterin (BH4) and translocates from the plasma membrane to the cytoplasm. The dephosphorylation of nNOS by calcineurin initates the production of NO. A further source of NO is the inducible nitric oxide isoform, which is upregulated in glia in response to pro-inflammatory stimuli present in AD and PD brains. NO then has the capacity to activate several pathways, predominantly cGMP-regulated signalling pathways, via the activation of guanylate cyclase (GC). NO undergoes a further reaction with O2. – radicals, to form peroxynitrite (ONOO-), one of the most potent oxidants in biological systems: NO.
+ O2 -
ONOO-
Peroxynitrite causes nitration of tyrosine, phenylalanine and tryptophan in proteins as well as the oxidation of lipids, DNA and proteins. Lipid peroxidation is a significant problem for neurons, as the destruction of lipidic cell membranes means that ionic gradients can no longer be maintained. Enhanced release of glutamate from presynaptic terminals further exacerbates this damage. The half-life of peroxynitrite is very short, and it decomposes in a liquid environment into further reactive oxygen- and nitrogen species, i.e. hydroxyl radicals and various nitrogen oxides (NxOy). 4. OVERSTIMULATION OF GLUTAMATE RECEPTORS (EXCITOTOXICITY) Overstimulation of glutamate receptors, called excitotoxicity, is a further mechanism of neuronal cell death in neurodegeneration [27]. Glutamate is the major excitatory neurotransmitter in the mammalian CNS and is present in millimolar concentrations in the gray matter. Once released it can act on ionotropic and metatropic receptors, two general recep-
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
21
tors for glutamate. Metabotropic receptors are linked to G-proteins, which activate phospholipase C (PLC) or adenylcyclase (AC). Activated PLC catalyses the cleavage of L-3phosphatidyl-inositol-4,5-bisphosphate (PIP2) into inositol–1,4,5, trisphosphate (IP3) and diacylglycerol (DAG). IP3 is responsible for intracellular release of Ca2+ from the endoplasmic reticulum. Released Ca2+ is involved in the activation of protein kinase C (PKC) in neurons, which then phosphorylates cytosolic proteins [28, 29]. Ionotropic receptors form ion channels, and are subdivided into three further forms according to their respective agonists, i.e. kainic acid (KA), N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA). KA and AMPA receptors are thought to subserve primarily rapid excitatory neurotransmission in the CNS and are mainly permeable to Na+ and K + but not to Ca2+. In contrast, NMDA receptors are permeable to Ca2+ and respond more slowly to glutamate. It is therefore believed that they will not function as mediators of rapid synaptic transmission but mediate the neurotoxic effects of glutamate in the adult brain (reviewed in [30]. A characteristic feature of the NMDA receptor is the so-called magnesium block, which must be released in a voltage-dependent manner for activation. It could been shown that glutamate becomes more neurotoxic when intracellular energy levels are reduced [31]. Since ATP levels are decreased in AD, neurons are more sensitive to the neurotoxic action of glutamate, because ATP production and functional Na+, K+-ATPases are necessary to generate a resting potential to maintain the voltage-dependent Mg2+ block of the NMDA receptor channel. Relief of the Mg2+ block enables the excitatory amino acids to act persistently at the NMDA receptor, resulting in its opening and subsequent neuronal damage. Activation of NMDA receptors increases cytoplasmatic calcium levels and subverts of cytoplasmic Ca2+ homeostasis. The increased intracellular Ca2+ concentration leads to enhanced metabolic stress on mitochondria, resulting in excessive oxidative phosphorylation and production of ROS e.g., via the activation of Ca2+dependent nitric oxide synthases[32]. Ca2+ toxicity is also mediated by activation of proteolytic enzymes like calpains which are able to degrade essential proteins, or endonucleases that degrade DNA. O2.- and H2O2 are produced by xanthine oxidase, which arises from proteolytic cleavage of xanthine dehydrogenase by calcium–dependent enzymes to. Morover, Ca2+ activates phospholipase A2 (PLA2) catalyzing the production of arachidonic acid, which in turn, is transformed by cyclooxygenases to prostaglandins, with O2.- formed as a byproduct. Lipton et al. (Lipton et al. 1993) have shown evidence indicating the presence of alternative redox states of NO: the radical form and the ionic form. Radical form of NO easily permeates the cell membrane and reacts with superoxide anion to produce neurotoxicity when it yields peroxynitrite (ONOO). This suggests that NO is a key substance in NMDA receptor-mediated glutamate neurotoxicity in the CNS although this evidence does not exclude the possible involvement of other mediators in the glutamate-induced neurotoxicity (Akaike et al. 1999). In summary, excitotoxicity also appears to involve oxidative stress which makes an antioxidant therapy a promising alternative to NMDA receptor antagonists. 5. NEUROPROTECTION 5.1 Introduction to the Principles of Neuroprotection As discussed above, the role of oxidative stress in neurodegenerative disorders such as PD and AD is well documented. It should therefore be possible to provide neuroprotection
22 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
by manipulating the redox state of the cells, e.g., by increasing the antioxidant capacity of the cells or by decreasing the pro-oxidative conditions in cells in the human brain. There are several therapeutic approaches for providing such neuroprotection, including supplementation of the patient with antioxidants, energy enhancing or anti-glutamatergic drugs. Antioxidants are used because of their ability to scavenge ROS and thus preventing damage to neurons. Since many plant-derived antioxidants are present in certain foods in different combinations, we will sometimes describe the positive effects of the foods rather than those of the isolated ingredients. In addition, energy supplementation is supposed to neuronal resistance to glutamate and ROS induced damages and initiate repair processes. Anti-glutamatergic drugs will decrease pathophysiological calcium influx and calcium-related injury including mitochondrial dysfunction. In the subsequent sections, a variety of natural and synthetic neuroprotective drugs or foods supplements are described, and evidence for their beneficial effects in cell culture and animal models of AD and PD as well as clinical evidence for their efficacy will be discussed. 5.2. Antioxidants Antioxidants are low molecular weight substances which either block the production of free radicals or neutralize them by absorbing the unpaired electron, thereby turning into a radical that is less reactive. Endogenous antioxidant systems include anti-oxidative enzymes (e.g. glutathione peroxidase and catalase) and thiol based scavengers (e.g. glutathione). However, therapeutic manipulation of anti-oxidative enzymes is at a very early stage, since their expression is genetically determined and therefore difficult to increase by synthetic drugs without changing overall expression profiles. By contrast, exogenous antioxidants such as vitamins C and E have long been supplied with food in order to boost antioxidative defenses in age-related diseases. More and more foods, particularly those containing plantderived antioxidants, are now offered by commercial vendors. Even in the absence of double-blind placebo controlled clinical trials, various antioxidants or antioxidant-rich plant extracts are therefore used as a therapeutic option in PD and AD. 5.1.1. Vitamin C Occurrence Vitamin C (ascorbate) is synthesized from glucose in the liver of most mammals. Guinea pigs, higher primates and humans, however, have lost the ability to synthesize the vitamin and are relying on dietary supplementation [33]. Vitamin C is found in high concentrations in many fruits and vegetables, including citrus fruits, kiwis and tomatoes. The recommended daily allowance of vitamin C is 75 mg. Function and Chemical Reactions Vitamin C is a hydrophilic vitamin and can exist as a partially oxidized ascorbyl free radical or as dehydroascorbic acid (DHA) in the presence of mild oxidants, depending on how many electrons are lost. The latter form is very short-lived (with a half life of about 6 minutes) and it is reduced back to the monoanion form (e.g. by vitamin E), which is the most common form of ascorbate at physiological pH [34]. Hydrolysis of the lactone ring in DHA leads to the irreversible conversion to 2,3-diketo-1-gulonic acid (Fig. 1). Besides its functions in the synthesis of the amino acid hydroxyproline, as major building block of collagen in connective tissue and bones, and in the absorption of iron, ascorbate plays a role as an antioxidant, protecting cells against oxidative stress, particularly in the cytosolic components of the cell, due to its reducing potential of its carbon-carbon double bond. It mediates its antioxidant activity in the cytosol by donating two hydrogens and electrons to ROS like
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
23
peroxyl and hydroxyl radicals, superoxide, singlet oxygen and peroxynitrite [35]. When associated with the plasma membrane, however, it is a powerful reductant of the tocopherol (vitamin E) radical which is the most active form of tocopherol against peroxyl radicals.
Fig. (1). Oxidation of vitamin c (ascorbic acid) via dehydroascorbic acid as intermediate.
Neuroprotective Effects in Cell Culture and Animal Models Since neurons have a tenfold higher oxidative metabolism than glial cells, vitamin C is an important antioxidant molecule in this cell type, and there is evidence that it also scavenges glutamate-generated ROS [36]. Using human cortical neurons it could be shown that ascorbic acid inhibits Hydrogen peroxide, TNF-, dopamine or -amyloid peptide induced apoptosis. This occurs through preventing the loss of mitochondrial membrane potential and DNA fragmentation [37]. These findings are concurrent with the results from Lockardt and colleagues, who have shown that vitamin C can attenuate the neurotoxic effect of betaamyloid in rat hippocampal cultures [38]. In PD, an increase in oxidative stress is observed by treatment of patients with levodopa, which is metabolized by monoaminooxidases in a radical-generating reaction. In an appropriate cell culture mode, levodopa proved toxic for the human neuroblastoma cell line NB69. Tocopherol lacks significant preventive effect on levodopa toxicity, but ascorbic acid in millimolar concentrations prevents levodopa toxicity and quinone formation [39]. In a similar study, the role of ascorbic acid on dopamine (DA) oxidation-mediated cytotoxicity was studied using a different cell system, the neuronal cell line PC12. DA cytotoxicity was slightly attenuated by ascorbic acid, whereas the cytotoxicity of 6-hydroxydopamine (6OHDA), a DA oxidation product, was actually potentiated [40]. Neuroprotective Effects in Alzheimer and Parkinson Patients Vitamin C, among other antioxidants, is often recommended for PD and AD patients. Epidemiological studies, however, yielded conflicting results. In the Rotterdam study, 5395
24 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
participants, who did not display any signs or symptoms of AD, were analyzed in respect of the future onset of the disease. It was demonstrated that persons with a higher intake of vitamin C had a reduced risk of developing AD, compared to the ones with lower intake. An intake of 133 mg/day compared to 95 mg/day of vitamin C led to a 34% decrease in the development of AD [41]. In contrast, the Chicago Health and Aging Project (CHAP), in which 3838 healthy persons took part (of whom 815 persons, with the average age of 72 years, completed the study), found no relation between the time of onset of AD and the intake of vitamin C from supplements (Morris et al. 2002). Plasma vitamin C in PD patients are significantly lower than in controls which may evidence that oxidative stress is involved in PD [42]. However, no convincing positive epidemiological studies or clinical trials with vitamin C alone, in PD patients, have been reported so far. 5.1.2. Vitamin E Occurrence Vitamin E (-tocopherol) is known as an essential nutrient since 1968. It is only produced in plants, particularly in wheat germ, plant oils, nuts and soybeans. The daily requirement is reported as 30 mg/d, but this varies between ages and country. Function and Chemical Reactions Vitamin E is a term for a group of tocopherols and tocotrienols of which -tocopherol is the most active one. It is lipid-soluble and consists of a chromane ring with an isoprenoid side chain (Fig. 2).
Fig. (2). Chemical structure of vitamin E (tocopherol).
Since it is hydrophobic and concentrated in cell membranes, its main mechanism is the prevention of lipid peroxidation and other radical-driven oxidative events involving fatty acids [43, 44]. Vitamin E is regenerated by vitamin C, as was shown in both liposomal membrane systems and in homogeneous solutions [45]. Neuroprotective Effects in Cell Culture and Animal Models It has been demonstrated that vitamin E has indirect neuroprotective effects through the suppression of microglial activation [46]. LPS-activated microglia showed attenuated expression of inflammatory mediators such as IL-1, TNF- or NO when co-cultured with vitamin E. Therefore vitamin E has a therapeutic use in AD, since neurotoxic microglialneuronal interactions are implicated in the pathogenesis in this type of dementia. Further relationship between AD and vitamin E is the prevention of protein oxidation and ROS production induced by -amyloid. It has been shown that this does not occur by inhibiting the A fibril formation but rather by scavenging the A associated free radicals [47].
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
25
In a PD cell culture model, dopamine triggered apoptosis in PC12 cells, only the thiolcontaining compounds, reduced glutathione (GSH), N-acetyl-cysteine (NAC), and dithiothreitol (DTT) were markedly protective, while vitamin E had no effect. The thiol antioxidants and vitamin C but not vitamin E, prevented dopamine autooxidation and production of dopamine-melanin [48]. Neuroprotective Effects in Alzheimer and Parkinson Patients The effect of vitamin E in AD patients was investigated in the Rotterdam study. A daily intake of 15.5 mg of vitamin E compared to an intake less than 10.5 mg/day decreases the risk of developing AD to 43% [41]. This finding was further confirmed in the Chicago Health and Aging Project, where a vitamin E intake of more than 11.4 I.U/d resulted in a 70% reduced risk for AD development compared to an intake of less than 6.21 I.U/d. The positive effect of vitamin E was not only significant, but dose-dependent and seemed to have an increased protective role when taken over a longer period of time [49]. In a further study, the combination of vitamin E and C in AD patients was evaluated. Use of vitamin E and C (ascorbic acid) supplements in combination was associated with reduced AD prevalence (adjusted odds ratio, 0.22; 95% confidence interval, 0.05-0.60) and incidence (adjusted hazard ratio, 0.36; 95% confidence interval, 0.09-0.99). A trend toward lower AD risk was also evident in users of vitamin E and multivitamins containing vitamin C, but no evidence of a protective effect with use of vitamin E or vitamin C supplements alone, with multivitamins alone, or with vitamin B–complex supplements was observed. In a epidemiological study, a total of 371 incident PD cases were ascertained in the Nurses' Health Study, which comprised 76,890 women who were followed for 14 years, and the Health Professionals Follow-Up Study, which comprised 47,331 men who were followed for 12 years. In this study, the risk of PD was significantly reduced among men and women with high intake of dietary vitamin E. Since the beneficial effects were only seen with vitamin E from foods (not from synthetic sources), the authors suggest that other constituents of foods rich in vitamin E may be protective [50]. In contrast, the community-based Rotterdam Study in the Netherlands collected data of 5342 independently living individuals without dementia between 55 and 95 years of age, including 31 participants with PD. In this study, vitamin E was protective, and the association of the relative risk with vitamin E intake was dose dependent [51]. Vitamin E (and deprenyl) was tested by the Parkinson Study Group in the “Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism” (DATATOP) trial. However, deprenyl delayed the onset of disability associated with early, otherwise untreated Parkinson's disease, however, in contrast to the expectation of the authors, a-tocopherol proved to be ineffective in the DATATOP study [52]. 5.1.3. Lipoic Acid Occurrence Lipoic acid was first identified as a component of several human enzyme systems involved in the conversion of carbohydrates and fats into energy, such as pyruvate dehydrogenase, -ketoglutarate dehydrogenase. Lipoic acid was not classified as a vitamin because some small amounts can be synthesized by the human body. However, lipoic acid as a therapeutic drug comes from chemically synthesised sources since amounts of 600mg can not be taken up with the normal diet.
26 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
Function and Chemical Reactions Most antioxidants are either water or fat soluble. A few, such as lipoic acid, are both. This dual nature allows lipoic acid to function in both fatty and aqueous environment, an ability that is the reason why lipoic acid is often termed "universal antioxidant." Lipoic acid provides therapeutic benefits in numerous oxidative stress related conditions and diseases including diabetes and heart disease. Lipoic acid and its reduced form, dihydrolipoic acid (DHLA), show the ability to directly quench a variety of reactive oxygen species (singlet oxygen, superoxides, peroxyl and hydroxyl radicals, hypochlorite, and peroxynitrite), inhibit reactive oxygen generators and spare and regenerate other antioxidants. Lipoic acid can also regenerate a variety of antioxidants including glutathione, vitamins C and E, and the mitochondrial antioxidant coenzyme Q10 [53]. Neuroprotective Effects in Cell Culture and Animal Models Lipoic acid (LA) can protect cortical neurons against cell death induced by A and hydrogen peroxide. It could be shown that this occurs through the Akt signalling pathway [54]. In a further study, the effects of LA and its reduced form, dihydrolipoic acid DHLA, in neuron cultures treated with amyloid beta-peptide (A 25-35), were studied. Pretreatment of dissociated primary hippocampal cultures with LA significantly protected against A toxicity. In contrast, concomitant treatment of cultures with LA and Fe/H2O2 significantly potentiated the toxicity, most likely because LA has too be reduced to DHLA before exerting a antioxidant effect[55]. Using PC12 cells as a cell model in PD it could been shown, that pretreatment with R-lipoic acid prevents depletion of the thiol compound glutathione (GSH), impairment of mitochondrial complex I and ROS generation [56]. Neuroprotective Effects in Alzheimer and Parkinson Patients Oxidative stress and energy depletion are characteristic biochemical hallmarks of Alzheimer's disease (AD), thus antioxidants with positive effects on glucose metabolism such as lipoic acid should exert positive effects in these patients. Therefore, 600 mg lipoic acid was given daily to patients with AD and related dementias (receiving a standard treatment with acetylcholinesterase inhibitors) in an open study over an observation period of, on average, 337+/-80 days. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (mini-mental state examination: MMSE and AD assessment scale, cognitive subscale: ADAScog) [57]. Despite the encouraging data from cell culture models, no positive study with lipoic acid in PD patients has been reported so far. 5.3. Polyphenols Polyphenols are secondary plant compounds and can be subdivided into different compound classes depending on the substituents attached to the three ring systems. All polyphenols share a common structure with two phenolic rings structures which are capable of scavenging free radicals. Four classes of polyphenols are particulary interesting as antioxidant drugs in human nutrition: Flavanols, Flavonols and Anthocyanidins (Fig. 3). Polyphenols have developed in plants in response to stress, including protection against UV light. Plants often contain several different polyphenols, and it is difficult to judge the most potent antioxidant or neuroprotective compound in a plant derived food or beverage. Therefore, the next chapters can only describe the neuroprotective property of these food or plant preparations rather than been able to attribute these effects to a single polyphenol alone.
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
27
Fig. (3). Chemical structures of polyphenols including three classes of flavonoids (flavonols, flavanols, anthocyanidins) and trihydroxystilben.
5.3.1. Flavanones Occurrence Flavonoids are part of a family of naturally occurring polyphenolic compounds characterized by a common benzo--pyrone structure. Flavanones is one of the most important flavonoid family present in vegetables, especially in genus Citrus (family Rutaceae) [58]. Flavanones are the first step on the biosynthesis pathway of all the other flavonoid families. They represent a large number of compounds arising from the various combinations of multiple hydroxyls, methoxyl and O-glycoside group substituents on the basic benzo--pyrone (C6-C3-C6) [59]. The concentration of these compounds depends on the age of the plant, and the highest levels are detected in tissues showing pronounced cell divisions [60-64]. These compounds not only play an important physiological and ecological role but are also of commercial interest because of their multitude of applications in the food and pharmaceutical industries [58, 65-68]. Function and Chemical Reaction Epidemiological and animal studies point to a possible protective effect of flavanones against cardiovascular diseases and some types of cancer. Although flavanones have been studied for about 50 years, the cellular mechanisms involved in their biological action are still not completely known. Many of the pharmacological properties of these citrus flavonoids can be linked to the abilities of these compounds to inhibit enzymes involved in cell activation. In vitro, they have demonstrated their capacity to modify the activity of enzymatic systems in mammals (kinases, phospholipases, ATPase, lipooxygenases, cyclooxygenases, phosphodiesterases, etc), a correlation having been observed in some cases between the flavonoid structure and its enzymatic activity [58, 69-73]. The most important structural factors that may condition flavonoid activity are structure oxidation stage, substituents (position, number and nature of groups in both A and B ring of the flavonoid structure), and the presence of glycosylation [58, 74, 75]. Much of the above mentioned effects can be attributed to the abilities of flavanone type flavonoids to interact with the nucleotide binding sites of regulatory enzymes [75]. Research has also shown that citrus flavonoids are
28 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
potent radical scavengers, and thus, are able to help in many aging and degenerative events involving reactive oxygen species [58]. Neuroprotective Effects in Cell Culture and Animal Models Some studies demonstrate the effectiveness of Naringenin (NAR) in preventing the cognitive deficits. Thus, intracerebroventricular (ICV) injection of streptozotocin (STZ) causes cognitive impairment in rats, the STZ-injected rats received NAR (50 mg/kg/day p.o.) starting 1 day pre-surgery for 3 weeks. The learning and memory performance was assessed using passive avoidance paradigm, and for spatial cognition evaluation, radial eight-arm maze (RAM) task was used. The obtained results demonstrate the protection capacity of naringenin and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease [76]. Amyloid beta protein (Abeta)-induced free radical-mediated neurotoxicity is known as a leading hypothesis for a cause of Alzheimer's disease. Abeta increased free radical production and lipid peroxidation in PC12 nerve cells, resulting in apoptosis and cell death. The protective effect of naringenin, against Abeta-induced neurotoxicity was investigated using PC12 cells. Pretreatment with isolated naringenin and vitamin C prevented the generation of the Abeta-induced reactive oxygen species. Naringenin resulted in the decrease of Abeta toxicity in a manner of concentration dependence [77]. Naringenin inhibited acetylcholinesterase (AChE) inhibitors activity in a dose-dependent manner [78]. Also, the antiamnestic activity of naringenin in vivo was also evaluated using ICR mice with amnesia induced by scopolamine (1 mg/kg body weight). Naringenin, when administered to ICR mice at 4.5 mg/kg body weight, significantly ameliorated scopolamine-induced amnesia as measured in the passive avoidance test. Therefore, these results indicate that micromolecular induced in vitro oxidative cell stress is reduced by naringenin [77, 78]. Although the cause of dopaminergic cell death in Parkinson's disease (PD) remains unknown, oxidative stress has been strongly implicated. Unilateral infusion of 6-OHDA into the medial forebrain bundle produced a significant loss of tyrosine hydroxylase (TH)positive cells in the substantia nigra (SN) as well as a decreased of dopamine (DA) content in the striata in the vehicle-treated animals. Rats pretreated with naringenin showed a clear protection of the number of TH-positive cells in the SN and DA levels in the striata. The ability of naringenin to exhibit neuroprotection in the 6-OHDA model of PD may be related to their antioxidant capabilities and their capability to penetrate into the brain [79]. Peroxynitrite (ONOO-) is a reactive oxidant formed from superoxide (*O2(-)) and nitric oxide (*NO), that can oxidize several cellular components, including essential protein, nonprotein thiols, DNA, low-density lipoproteins (LDL), and membrane phospholipids. ONOOhas contributed to the pathogenesis of Alzheimer's disease. Because of the lack of endogenous enzymes to detoxify ONOO-, developing a specific ONOO- scavenger is remarkably important. Hesperetin can efficiently scavenge authentic ONOO-. Hesperetin exhibited significant inhibition on the nitration of bovine serum albumin (BSA) by ONOO- in a dosedependent manner. Hesperetin also manifested cytoprotection from cell damage induced by ONOO- and ROS [80]. The death of nigral neurons in Parkinson's disease is thought to involve the formation of the endogenous neurotoxin, 5-S-cysteinyl-dopamine. Hesperetin inhibits tyrosinase-induced formation of 5-S-cysteinyl-dopamine. This inhibition was not accompanied by the formation of cysteinyl-hesperetin adducts, indicating that it may inhibit via direct interaction with tyrosinase [81].
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
29
Liquiritigenin, a newly found agonist of selective estrogen receptor-beta, has neuroprotective activity against beta-amyloid peptide (Abeta) in rat hippocampal neurons. Some genes, including B-cell lymphoma/leukemia-2 (Bcl-2), neurotrophin 3 (Ntf-3) and amyloid beta (A4) precursor protein-binding, family B, member 1 (Apbb-1) were regulated by liquiritigenin, consequently, liquiritigenin exhibits neuroprotective effects against Abeta(25-35)-induced neurotoxicity and that it can decrease the secretion of Abeta(1-40) [82]. Flavanones from Sophora flavescens were examined for their inhibitory effects against beta-secretase. Lavandulyl flavanones showed potent beta-secretase (BACE1) inhibitory activities with IC(50)s in the range 2.6–8.4 M, thus, reduced A secretion dosedependently in transfected human embryonic kidney (HEK-293) cells [83]. Neuroprotective Effects in Alzheimer and Parkinson Patiens To our best knowledge, there are no published epidemiological data or clinical trials for flavanones. 5.3.2. Flavones Occurrence Flavones are, probably, the most widely distributed compounds of the flavonoids family on the plant kingdom. Structurally, they are similar to flavanones, and only show, as difference, the characteristic double bond between the carbons 2 and 3 of the generated C-ring [58]. Flavones occur in an almost bewildering array of derivatives that represent a large number of compounds arising from the various combinations of multiple hydroxyls, methoxyl and O-glycoside group substituents on the basic benzo--pyrone (C6-C3-C6) [59]. Similarly to flavanones, their formation normally depends on light, so they are mainly concentrated in the outer tissues, being their concentrations directly related with the age of the plant, and the highest levels are also detected in tissues showing pronounced cell growth [60-64]. Flavones are the flavonoids more developed on the pharmaceutical industry, mainly for their cardiovascular and vasoprotective properties [58, 65-68]. Function and Chemical Reaction Animal, epidemiological and pre-clinical studies have shown that flavones possesses a variety of pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial and, also, a possible protective effect some types of cancer. The ability of flavones to inhibit angiogenesis, to induce apoptosis, to prevent carcinogenesis in animal models, to reduce tumor growth in vivo and to sensitize tumor cells to the cytotoxic effects of some anticancer drugs suggests that flavones have cancer chemopreventive and chemotherapeutic potential. Modulation of ROS levels, inhibition of topoisomerases I and II, reduction of NFB and AP-1 activity, stabilization of p53, and inhibition of PI3K, STAT3, IGF1R and HER2 are possible mechanisms involved in the biological activities of the main flavones [84]. Much of the above mentioned effects can be attributed to the abilities of flavanones flavonoids to interact with the nucleotide binding sites of regulatory enzymes [75]. Several flavones are potent radical scavengers, and thus, are able to help in many aging and degenerative events involving reactive oxygen species [58]. A correlation has been observed in some cases between the flavonoid structure and its enzymatic activity [58, 69-73]. The most Important structural factors that may condition flavone activity are structure oxidation stage, substituents (position, number and nature of groups in both A and B ring of the flavonoid structure), and the presence of glycosylation [58, 74, 75]. Several flavonoids attenuate lipopolysaccharide-induced nitric oxide and tu-
30 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
mour necrosis factor production in murine microglia and macrophages and the structureactivity relationships of these flavonoids demonstrated three distinct principles: (i) flavonoid-aglycons are more potent than the corresponding glycosides, (ii) flavonoids with a 4'OH substitution in the B-ring are more potent than those with a 3'-OH-4'-methoxy substitution, (iii) flavonoids of the flavone type (with a C2=C3 double bond) are more potent than those of the flavanone type (with a at C2-C3 single bond) [85]. Neuroprotective Effects in Cell Culture and Animal Models In case of injury or disease, microglia is recruited to the site of the pathology and become activated as evidenced by morphological changes and expression of pro-inflammatory cytokines. Evidence suggests that microglia proliferate by cell division to create gliosis at the site of pathological conditions such as the amyloid plaques in Alzheimer's disease and the substantia nigra of Parkinson's disease patients. The hyperactivation of microglia contributes to neurotoxicity. Related with this consideration, several flavones were as tested by the hypothesis that antioxidant and anti-inflammatory compounds modulate the progression of cell cycle and induce apoptosis of the activated cells [86]. Apigenin, luteolin and polymethoxyflavones are the most studied compounds from this flavone family. Several of these natural flavones act as non-peptidic BACE-1 inhibitors and potently inhibit BACE-1 activity and reduce the level of secreted A in primary cortical neurons [87]. Apigenininduced cell cycle arrest preferentially in the G2/M phase. Apigenin induces apoptosis significantly in early and late stages. The induction of apoptosis by apigenin was confirmed using TUNEL assay, revealing that 25 microM apigenin significantly increased apoptosis in BV-2 cells [86]. Experiments performed to study the possible effects of exogenously administered apigenin (as 7-O-glucoside) on the cognitive performance in aged and LPS-treated mice (an animal model for AD) using passive avoidance and elevated plus-maze tasks, showed that chronic administration of the apigenin-7-glucoside (5-20 mg/kg i.p.) reverses cognitive deficits in aged and LPS-intoxicated mice which suggests that modulation of cyclooxygenase-2 and inducible nitric synthase by this flavone may be important in the prevention of memory deficits, one of the symptoms related to AD [88]. Recently, apigenin shows its ability to downregulate inflammatory markers and to protect neurons against microglial insult [89]. CD40 signaling is critically involved in microglia-related immune responses in the brain. It is well known that the activation of the signal transducer and activator of transcription (STAT) signaling pathway plays a central role in interferon-gamma (IFN-gamma)-induced microglial CD40 expression, and this expression is significantly induced by IFN-gamma and amyloid-beta (A beta) peptide. Apigenin and luteolin concentration-dependently suppressed IFN-gamma-induced CD40 expression. Apigenin and luteolin also suppressed microglial TNF-alpha and IL-6 production stimulated by IFN-gamma challenge in the presence of CD40 ligation. In addition, apigenin and luteolin markedly inhibited IFN-gamma-induced phosphorylation of STAT1 with little impact on cell survival [90]. Glycogen synthase kinase 3 (GSK-3) dysregulation is implicated in the two AD pathological hallmarks: beta-amyloid plaques and neurofibrillary tangles. GSK-3 inhibitors may abrogate AD pathology by inhibiting amyloidogenic gamma-secretase cleavage of amyloid precursor protein (APP). Luteolin, when applied to the Tg2576 mouse model of AD, decreases soluble Abeta levels, reduces GSK-3 activity, and disrupts PS1-APP association. In addition, we find that Tg2576 mice treated with diosmin, the flavone-glycoside most used in pharmaceuticals, also display significantly reduced Abeta pathology [91]. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
31
activation [92] and also protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway [93]. Short-term supplementation with citrus extracts rich in polymethoxyflavones, mainly tangeretin, protect nigrostriatal dopaminergic neurons to the dopaminergic neurotoxin 6hydroxydopamine lesions in a rat model of Parkinson's disease [94, 95]. Preadministration of tangeretin in mice enhanced expression of glucose-regulated protein (GRP) 78, (a molecular chaperone in the endoplasmic reticulum) in the substantia nigra pars compacta and protected dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin that induces both oxidative and endoplasmic reticulum stress [96]. Nobiletin, probably the most important citrus polymethoxylated flavone, restoring betaamyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats [97]. Treatment with 50 mg/kg of nobiletin (i.p.) for the consecutive 7 days before and after brain ischemia significantly inhibited delayed neuronal death in the hippocampal CA1 neurons in a 20-min bilateral common carotid arteries occlusion ischemia. The nobiletin treatment prevented the reduction in CaMKII, MAP2 and GluR1 protein levels in the hippocampal CA1 region, accompanied by restoration of both ERK and CREB phosphorylation and CaMKII auto-phosphorylation [98]. Nobiletin rescues olfactorybulbectomized-induced cholinergic neurodegeneration, accompanied by improvement of impaired memory in olfactory-bulbectomized mice [99]. The administration of nobiletin decreased the A burden and plaques in the hippocampus of APP-SL 7-5 Tg mice (transgenic mice that overexpress human APP695 harboring the double Swedish and London mutations) [100]. Neuroprotective Effects in Alzheimer and Parkinson Patiens It has been postulated that oxidative stress may play a key role in dementia. Thus, flavonoid intake, mainly flavones, could be associated with a lower incidence of dementia in a cohort of 1367 subjects above 65 years of age (Paquid). A questionnaire was used to evaluate their intake of flavonoids and subjects were followed-up for 5 years between 1991 and 1996 and the estimation of the relative risk of dementia show that the intake of flavonoids is inversely related to the risk of incident dementia [101]. The Rotterdam Study, a population-based, prospective cohort study conducted in the Netherlands included a total of 5395 participants who, at baseline (1990-1993), were aged at least 55 years, free of dementia, and non-institutionalized and had reliable dietary assessment. Participants were re-examined in 1993-1994 and 1997-1999 and were continuously monitored for incident dementia. After a mean follow-up of 6 years, 197 participants developed dementia, of whom 146 had Alzheimer disease; after adjustments, the use of antioxidant supplements with flavonoids was associated with lower risk of Alzheimer disease, however, lesser than vitamins C and E [41]. The Kame project tested whether consumption of fruit and vegetable juices, containing a high concentration of polyphenols, mainly flavone-glycosides, decreases the risk of incident probable Alzheimer's disease in the corresponding cohort, a population-based prospective study of 1836 Japanese Americans in King County, Washington, who were dementia-free at baseline (1992-1994) and were followed through 2001. The hazard ratio for probable Alzheimer's disease was 0.24 (95% confidence interval [CI], 0.09-0.61) comparing subjects who drank juices at least 3 times per week with those who drank less often than once per week with a hazard ratio of 0.84 (95% CI, 0.31-2.29) for those drinking juices 1 to 2 times
32 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
per week (p < 0.01). This inverse association tended to be more pronounced among those with an apo-lipoprotein epsilon-4 allele and those who were not physically active. Conversely, no association was observed for dietary intake of vitamins E, C, or betacarotene or tea consumption. Fruit and vegetable juices may play an important role in delaying the onset of Alzheimer's disease, particularly among those who are at high risk for the disease [102]. In the PAQUID (Personnes Agées Quid) study, the authors prospectively examined flavonoid intake in relation to cognitive function and decline among subjects aged 65 years or older. A total of 1,640 subjects free from dementia at baseline in 1990 and with reliable dietary assessment were re-examined four times over a 10-year period. Cognitive functioning was assessed through three psychometric tests (Mini-Mental State Examination, Benton's Visual Retention Test, "Isaacs" Set Test) at each visit. Information on flavonoid intake was collected at baseline, being the flavones apigenin and luteolin, as glucoside-forms, two of the most abundant. Flavonoid intake was associated with better cognitive performance at baseline (p = 0.019) and with a better evolution of the performance over time (p = 0.046). Subjects included in the two highest quartiles of flavonoid intake had better cognitive evolution than did subjects in the lowest quartile. After 10 years' follow-up, subjects with the lowest flavonoid intake had lost on average 2.1 points on the Mini-Mental State Examination, whereas subjects with the highest quartile had lost 1.2 points [103]. 5.3.3. Flavanols (Catechins, Epicatechins) Occurrence Catechins are flavanols of which epicatechin (EC), (-)-epigallocatechin (EGC) and (-)epicatechin gallate (EGCG) are the main ones present in fresh tea leaves [104]. Daily intakes in humans are up to 100 mg/day. Sources of flavanols are wine, apples, chocolate and black and green tea. One cup (237 ml) of green tea contains typically 30 to 130 mg of EGCG while black tea contains only 0 to 70 mg of EGCG (Fig. 4).
Fig. (4). Chemical structures of catechins (a type of flavanol), main antioxidant ingredients of green tea.
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
33
Function and Chemical Reactions It is documented that catechins scavenge free radicals in vitro systems [105]. Catechins are able to scavenge .NO in vitro [106] as well ONOO- [107], even if the mechanisms of scavenging radicals is still unknown. Singlet oxygen (1O2), O2.-, .OH, and peroxyl radicals . OOH are further radicals that are scavenged by catechins [108-110]. Their superb antioxidant activity is because of a low reduction potential compared to vitamin E, but not to vitamin C. Therefore EGCG and EGC are superior electron donators, which is concurrent with a better antioxidant activity. Neuroprotective Effects in Cell Culture and Animal Models Catechins in green tea are also capable of decreasing lipid peroxidation. Using pulse radiolysis, Bors and Michel have found that catechins rather than flavonols and flavones, are the antioxidative compounds in tea [111]. Catechins increase the activity of glutathione peroxidase and glutathione reductase, while decreasing the levels of lipid hydroperoxidases (LOOH), 4-hydroxysynonenal (4-HNE) and malondialdehyde (MDA) [112].The peroxidase activity of lipoxygenase and cyclooxygenase is one mechanism to increase oxidative stress, which can be inhibited by flavonoids and phenolic antioxidants in vitro [113]. Both enzymes increase oxidative stress because they take part in the synthesis of leukotrienes and prostaglandins, two molecules involved in inflammation. Xanthine oxidase is another enzyme inhibited by catechins. This enzyme reduces O2 to O2.- and H2O2 during the oxidation of xanthine and hypoxanthine to uric acid [104], catechins however inhibit the production of these ROS. But besides the inhibition of enzymes, catechins are also able to induce some enzymes including phase II enzymes for detoxification or antioxidant enzymes such as glutathione peroxidase (GPx)[114], catalase and superoxidase dismutase (SOD) [115]. EGCG has been shown to exert protective effects against A -induced neurotoxicity and regulate secretory processing of non-amyloidogenic APP. In a cell culture model of AD, EGCG was shown to be able to protect PC12 cells against A toxicity in a dose-dependent manner. In addition, EGCG enhances (approximately 6-fold) the release of the nonamyloidogenic and neurotrophic form of the amyloid precursor protein (sAPPalpha) into the conditioned media of human SH-SY5Y and PC12 neuroblastoma cells [116]. More recently, green tea catechins have been suggested to have the potential to prevent AD because of their anti-amyloidogenic, anti-oxidative, and anti-inflammatory properties, also activating adaptive cellular stress responses, called "neurohormesis", and suppress disease processes [117]. A further function of catechins in tea is the inhibition of up-regulation of enzymes that propagate inflammation resulting in cellular oxidative stress. For example it has been demonstrated that both green and black tea inhibit LPS-induced iNOS expression in macrophages by inhibiting the transcription factor for iNOS which is NF-B on its DNA binding activity and through phosphorylation of its inhibitor IB[118, 119]. A recent study shown that (-)-epigallocatechin-3-gallate exert neurorescue and mitochondrial stabilization actions across multimodal mechanisms [120]. Studies on the bioavailability and brain deposition of these polyphenols are the main elements to clarify their possible capacity as neuroprotective compounds. Long-term administration of green tea catechins [Polyphenon E (PE): 63% of epigallocatechin-3-gallate, 11% of epicatechin, 6% of (-)-epigallocatechin and 6% of (-)-epicatechin-gallate] prevents cognitive impairment in an animal model of AD, rats infused with Abeta1-40 into the cerebral ventricle. PE administration for 26 weeks significantly decreased the Abeta-induced
34 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
increase in the number of reference and working memory errors, with a concomitant reduction of hippocampal lipid peroxide (LPO; 40%) and cortico-hippocampal reactive oxygen species (ROS; 42% and 50%, respectively) [121]. Similarly, repeated daily exposure to grape seed extract catechins was found to significantly increase bioavailability catechin and epicatechin by 253 and 282% relative to animals receiving only a single acute extract dose. Epicatechin and catechin were not detectable in brain tissues of rats receiving a single dose but reached levels of 290.7 +/- 45.9 and 576.7 +/- 227.7 pg/g in brain tissues from rats administered the grape extract for 10 days [122]. The purpose of a further study was to investigate potential neuroprotective effects of tea extracts and possible signal pathway involved in a neuronal cell model of Parkinson's disease. 6-OHDA activated the iron dependent inflammatory redox sensitive nuclear factor-B in rat pheochromocytoma (PC12) and human neuroblastoma (NB) SH-SY5Y cells, respectively. Immunofluorescence and electromobility shift assays showed increased nuclear translocation and binding activity of NF-B after exposure to 6-OHDA in NB SH-SY5Y cells, with a concomitant disappearance from the cytoplasm. Introduction of Green tea extract before 6-OHDA inhibited both NF- nuclear translocation and binding activity induced by this toxin in NB SH-SY5Y cells. The authors conclude that neuroprotection was attributed to the potent antioxidant and iron chelating actions of the polyphenolic constituents of tea extracts, preventing nuclear translocation and activation of NF-B [123]. In an animal models of Parkinson's disease (PD), the effect of green tea toxicity of 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was investigated in mice. Both tea and the oral administration of EGCG prevented the loss of tyrosine hydroxylase (TH)-positive cells in the substantia nigra (SN) and of TH activity in the striatum. These treatments also preserved striatal levels of dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid (HVA). Also tea plus MPTP and EGCG plus MPTP treatments decreased expressions of neuronal NO synthase (nNOS) at the similar levels of EGCG treatment group [124]. However, new studies show certain controversies, thus short-term supplementation with plant extracts rich in different catechin structures (flavan-3-ols) protect nigrostriatal dopaminergic neurons in rat model of Parkinson's disease. Pretreatment of animals with a cocoa extract rich in procyanidins (polymeric flavan-3-ols; 100 mg/kg/day) significantly attenuated the 6-OHDA-induced dopaminergic loss. However, no significant protection was seen in animals supplemented with a grape seed extract, rich in catechins, (100 mg/kg/day), and a rich catechins cocoa extract (100 mg/kg/day) [95]. Despite the huge and increasing amount of the in vitro studies trying to unravel the mechanisms of action of dietary polyphenols, the research in this field is still incomplete, and questions about bioavailability, biotransformation, synergism with other dietary factors, mechanisms of the antioxidant activity, risks inherent to their possible pro-oxidant activities are still unanswered. Most of all, the capacity of the majority of these compounds to cross the blood-brain barrier and reach brain is still unknown [125]. Neuroprotective Effects in Alzheimer and Parkinson Patients In a study in the northern health region of England, risk factors for presenile AD (onset blow 65 years of age) were analysed in 109 patients. In this study, which was originally aimed to assess the impact of aluminium of dementia, no significant relationship between AD and exposure to tea and antacids was found [126].
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
35
A protective role of tea consumption for PD has been shown only in Asian countries, where green tea is a major beverage. A study in Hong Kong in which 215 PD patients and 313 controls took part found that a regular tea drinking is protective against PD [127]. In a study undertaken in Singapore, the relationship between coffee and tea drinking, cigarette smoking, and other environmental factors and risk of PD among 300 PD and 500 population (ethnic Chinese) was analysed. The authors calculated that 3 cups/day of tea for 10 years would lead to 28% risk reduction of PD [128]. However, a study in France showed the opposite. 140 patients and 240 hospital controls showed an increased risk by 90% to develop this dementia [129]. It is also reported from a study in Spain that there was no significant association between tea consumption and the risk of PD [130]. 5.3.4. Flavonols (Quercetin, Kaempferol) Occurrence Flavonols including quercetin and kaempferol are characterized by a keto group at the 4position in the heterocyclic C ring. They are present in red wine, onions, apples, tea and broccoli and in the leaves of the Gingko biloba tree. In a normal European diet, daily flavonol intakes of 3 – 64 mg have been reported. The Ginkgo tree and has evolved strategies to live for up to 1,000 years [131]. Because of the high antioxidant content of its leaves, the pharmaceutical industry has developed the standardised leaf extract EGb 761 to treat vascular and neurodegenerative diseases. This extract consists of 24% flavone glycosides (also called ginkgosides, mainly quercetin, kaempferol and isorhamnetin glycosides) and 6% lactone terpenes, consisting of ginkgolides A, B, C and J as well as bilobalide. The amount of ginkgolic acids is less than 0.0005%, because it has been described, that 100 M of it causes allergic symptoms and neuronal cell death [132, 133]. Neuroprotective Effects in Cell Culture and Animal Models It has been shown that quercetin or structurally similar flavonoids are potent neuroprotective antioxidants in red wine or related fruit derived foods. It is thought that the presence of 2,3 unsaturation together with an oxo function at position 4 in the ring C, co-planarity of the molecule and a 3’,4’-dihydroxy catechol structure in the B ring are responsible for the antioxidant scavenger activity [134]. The standardised leaf extract EGb 761 is mainly used for the treatment of vascular diseases and for neurodegenerative dementia. The antioxidant effects are mediated by the ginkgosides [135], however terpenes are also thought to contribute via their anti-inflammatory effects [136]. It has been demonstrated in rats that the protein level and activity of antioxidant enzymes is increased by EGb 761 and it is therefore believed that this drug exerts its effect by stabilization of the redox status as by radical scavenging [137], [138]. EGb 761 is also able to scavenge NO [139]. Since increased nNOS and iNOS expression is found in AD, EGb 761 has been proposed as therapeutic treatment for this type of dementia conditions. Oxidative damage caused by superoxide leakage from mitochondrial respiration can be decreased by EGb 761, most likely by increasing the messenger RNA (mRNA) and protein level of subunit I of mitochondrial NADH dehydrogenase. There is also plenty of evidence for neuroprotective activities of Gingko biloba extracts in AD specific disease models. A, the main compound of senile plaques in AD, originates from a larger amyloid precursor protein, the amyloid precursor protein (APP). This protein can then either be cleaved by - and -secretases, as described the neuropathology and biochemistry section of AD, or by -secretases that release a large and soluble extra cellular domain of APP, the so called APPs, that represents the non-toxic form of A. Using hippocampal slices cultures, it could be shown that EGb761 increases APPs release [140].
36 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
EGb761 has also been shown to decrease ROS in a neuroblastoma cell line that stably expresses an AD-associated double mutation, which exhibits both increased secretion and intracellular accumulation of Abeta when stimulated. This effect could also been shown in vivo using C. elegans that constitutively expresses human Abeta. Both, the cell line and C. elegans showed a rise in levels of hydrogen peroxide compared with wild type controls, before stimulating [141]. The effect of the flavonol kaempferol on A-induced toxicity in PC12 neuroblastoma and T47D human breast cancer cells was investigated and a protective effect of kaempferol (comparable to that observed with estradiol) was observed. Since the effects of the weak estrogen receptor agonists -estradiol and kaempferol were found to be similar to the effects of the strong estrogen receptor agonist -estradiol, the authors suggesting a mode of action independent from the nuclear estrogen receptor such as radical scavenging [142]. A beneficial effect of extracts of Ginkgo biloba leaves (EGb) was observed in the Parkinson disease (PD) model induced by MPTP. MPTP was microinjected into substantia nigra of rats to induce a behavior change of rotation. EGb treatment decreased the duration and frequency of the rotation of rats as well as the level of the lipid peroxidation product MDA. In addition, the decrease of DA levels was attenuated which indicates increased viability of dopaminergic neurons [143]. Similar positive effect were observed in the 6-hydroxydopamine (6OHDA) model, where neurotoxicity in the nigrostriatal dopaminergic system of the rat brain was attenuated by the EGb extract [144]. Neuroprotective Effects in Alzheimer and Parkinson Patients A study with 216 patients with mild to moderate degenerative dementia of AD or multiinfarct dementia was carried out. Patients were treated with 240 mg of EGb 761 or placebo for 24 weeks. Using memory functions, independence, coping skills and other parameters as the basis of measures, it was concluded that EGb 761 has clinical efficacy in AD patients [145]. In another study the potential association between the use EGb761 and AD was investigated. A case-control study was nested in a cohort of 1462 community-dwelling elderly woman aged over 75 years. 69 women with AD were compared with 345 women whose cognitive function remained normal. Analysis revealed that fewer women who developed AD had been prescribed EGb761 for at least 2 years but to establish a causal relationship, prospective studies have to be carried out to confirm these findings [146]. 5.3.5. Anthocyanins (Cyanidine and Others) Occurrence Anthocyanins are natural red and blue colours of plants and fruits, including various berries (strawberries, blueberries, raspberries, black currants) and red grapes. The average daily intake in humans is about 200 mg/day. Function and Chemical Reactions Anthocyanins also belong to the class of polyphenols and consist of 3 carbon rings with 2 aromatic (A and B) and one O-heterocyclic ring, which is positively charged (Fig. 3). Neuroprotective Effects in Cell Culture and Animal Models The effects of purple sweet potato anthocyanin (SPA) on lipid peroxidation, 1,1diphenyl-2-picryl-hydrazyl (DPPH) radicals and cognitive deficits were examined. SPA was shown to exhibit DPPH radical scavenging activities and to effectively inhibit lipid peroxidation initiated by Fe2+ and ascorbic acid in rat brain homogenates. Furthermore, SPA
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
37
markedly enhanced cognitive performance, assessed by passive avoidance test in ethanoltreated mice. These results demonstrate that anthocyanin prepared from purple sweet potato exhibits memory enhancing effects, which may be associated with its antioxidant properties [147]. In another study, Fischer 344 rats received dietary supplementation with fruit or vegetable extracts high in anthocyanins (e.g. blueberry (BB) or spinach, respectively). This diet decreased the age-related vulnerability to oxidative stress in these rats as assessed in vivo by examining reductions in neuronal signaling and behavioral deficits and in vitro via H2O2-induced decrements in striatal synaptosomal calcium buffering. Examinations have also revealed that BB supplementations are effective in antagonizing other age-related changes in brain and behavior, as well as decreasing indices of inflammation and oxidative stress in muscles. The authors conclude that anthocyanins show the most efficacy in penetrating the cell membrane and in providing antioxidant protection [148]. A diet rich in blueberries was also shown to prevent behavioural deficits in an AD model, the APP over expressing transgenic mouse. The authors believed that the protective effect is due to the enhancement of redox-sensitive memory-associated neuronal signalling and alterations in neutral sphingomyelin-specific phospholipase C activity [149]. 5.3.6. Isoflavones Occurrence Isoflavones are a subclass of flavonoid characterized by have a 3-phenyl chromen-4-one (3-phenyl-1,4-benzopyrone) structure instead a 2-phenyl chromen-4-one (3-phenyl-1,4benzopyrone) structure tipical of flavanones and flavones. They have a large structure variability and more of than 600 isoflavones have been identified. The primary dietary sources of isoflavones are soybeans (Glycine max) and soyfoods. It is often stated in the literature that many legumes and fruits and vegetables contain isoflavones; however, although these statements are technically correct they are misleading, because the amount in these foods is so small as to be nutritionally irrelevant. In contrast to many phytoallexins (substances that are formed by host tissue in response to physiological stimuli, infectious agents, or their products and that accumulate to levels that inhibit the growth of micro-organisms), isoflavones are always present in significant quantities in soybeans, because one of their primary functions is to stimulate nodulation genes in soil bacteria called Rhizobium. There are 12 different soybean isoflavone isomers. These are the three aglycones genistein (4',5,7-trihydroxyisoflavone), daidzein (4',7-dihydroxyisoflavone), and glycitein (7,4'dihydroxy-6-methoxyisoflavone), their respective -glycosides genistin, daidzin, and glycitin, and three -glucosides each esterified with either malonic or acetic acid having the three aglycones the higher concentrations. Red clover (Trifolium pratense) also contains a rich supply of isoflavones and, along with soybeans, is used as a source for the production of isoflavone supplements. Function and Chemical Reactions Many pottial health benefits have been linked to intake of soy products according to epidemiologial investigations [150]. Animal [151] and human [152] studies have also shown that consumption of soy isoflavones has beneficial impacts on the risk factors for cardiovascular disease including lowering liver or blood triglyceride, total and LDL cholesterol levels, increasing HDL cholesterol and the ratio of HDL/LDL cholesterol. Cellular and molecular biology studies have demonstrated that soy components modulate the key transcription factors involved in the regulation of lipid metabolism and their regulated downstream gene expression in animals and in vitro cultured human cells at transcriptional or posttrans-
38 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
lational levels [151]. However the most popular property of isoflavones is their effects like phytoestrogens. The isoflavones are strikingly similar in chemical structure to mammalian estrogens [153]. The phenolic ring is a key structural element of most compounds that bind to estrogen receptors [154]. When the structures of the isoflavone metabolite equol and estradiol are overlaid, they can be virtually superimposed. On the basis of structure alone, it is not surprising that isoflavones bind to estrogen receptors (ER); however, their actions are more those of partial estrogen agonist or antagonist. Isoflavones have been shown be effectives in diseases where hormonal receptors are involved, so can stimulate bone formation in menopauseal women [155]. In cell culture, genistein inhibited proliferation of humanbreast and prostate cancer cells stimulated by epidermal growth factor (EGF) independently of whether the cells expressed estrogen or androgen receptors, respectively [156]. In human studies, isoflavone have been shown reduce risk for breast [157] or prostate cancer [158]. May not be appreciated that the levels of intake of these biologically active phytoestrogens exceed by several orders of magnitude the levels of endogenous estrogens. Typical circulating concentrations of isoflavones can exceed endogenous estradiol concentrations by 100fold in adults [159]. Neuroprotective Effects in Cell Culture and Animal Models Isoflavone genistein show comparable levels of protection that estradiol against Ainduced deaths of cultured SH-SY5Y human neuroblastoma cells, which where blocked by an estrogen receptor antagonist, ICI 182,780 [160]. Genistein protects neurons from A induced damage via estrogen receptor-mediated pathway, and at the micromolar level, the neuroprotective effect of genistein is mediated mainly by its antioxidative properties [161], however have been suggest that also other mechanismes such antiinflammatory effects could be involved. Inflammation has been implicated in neurodegenerative disorders such as Alzheimer’s disease (AD). The main inflammatory players in AD are the glial cells which initiate the imflammatory response. One of the earliest neuropathological changes in AD is the accumulation of astrocytes at sites of A deposition. A induces inflammatory mediators, such as cyclooxygenase 2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin 1 (IL-1) and tumor necrosis factor (TNF-). All these effects were prevented when cells were pretreated with estradiol or genistein, demostrating their antiiflammatory effects in astrocytes culture [162]. Also an increse in PAAR- (peroxisome proliferator activated receptors) expression in astrocytes was detected suggesting that some of the antiinflammatory effects of genistein may be mediated and activated by PAAR-. Isoflavones also may exert these effects via direct modulation of protein and lipid kinase signalling pathways, for example via the inhibition of MAPK signalling cascades which regulate both iNOS and TNF- expression in activated glial cells [163]. In the other hand, related experiments in a primate model of menopause demonstrated that ingestion of soy containing isoflavones was correlated with the suppression of neurodegeneration-relevant phosphorylation of the microtubule-associated protein tau, while intake of Premarin (a hormone re-placement therapy that is commonly prescribed for women) was not correlated. These results indicate that genistein, and probably other related phytoestrogens, have pleiotropic actions, some of which may involve TGFb activity [164]. Neuroprotective Effects in Alzheimer and Parkinson Patients It is known that dementia and neurodegenerative diseases, AD or PD, rates are lower in Asian countries than in western countries. This fact has been associated to asian lifestyle and particularly to asian diet roich in fish and soy products. However, few epidemiological studies have been made to corroborate soy benefits on brain health.
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
39
One of these studies conducted in Hawaii called the Honolulu Heart Study came up with a surprising finding. The study looked at Japanese men residing in Hawaii and aimed to compare diet to risk of dementia. The researchers found that those men who ate tofu most frequently during their mid-40's to mid-60's showed the most signs of mental deterioration in their 70's to early 90's [165]. In this study of over 3000 men, intake of 26 foods, including tofu, was recorded between 1965 and 1967 and again in 1971 to 1974. Cognitive test performance was assessed between 1991 and 1993 and the researchers also looked at brain shrinkage through autopsy data of the men who died during the study. Tofu consumption of just two to four servings per week was associated with poorer test performance and more brain loss. Not only that, but the wives of men who ate tofu also showed more signs of dementia. The results of this study is not agree with that lower dementia rates in Asian countries and when Japanese lifestyle has actually been associated with better cognition in old age. Many have used this as an argument to show that the Hawaii study results must be wrong. But there is a possible biological explanation for the findings. Soybeans contain isoflavones, which are weak estrogens. They fall into the category of estrogen-like compounds known as selective estrogen receptor modulators (SERMS) [166]. This means that they have estrogenic effects in some tissues and anti-estrogenic effects in others. Estrogen may have a positive effect on brain tissue but the researchers of the Hawaii study suggested that isoflavones may have antiestrogenic effects on the brain. Results of three clinical studies suggest soy and isoflavones have beneficial effects on cognition. In the first published study, young adult men and women who consumed a high soy diet for 10 weeks experienced significant improvements in short-term and long-term memory and in mental flexibility [167]. The other two studies found that isoflavone supplements, when taken by postmenopausal women, improve cognitive function [168]. Even with these findings, we really have very little information on how soyfoods consumption might affect cognitive function. 5.3.7. Caffeoyl Compounds Occurrence Caffeoyl compounds are a large numbers of caffeoyl esters mainly sterified with sugars or quinic acid. These caffeoyl derivatives are widely distributed in many plants along the wide world. The main components of this phenolic group are Chlorogenic acid (3caffeoylquinic acid) (CGA) and Rosmarinic acid (RA). CGA widely exist in edible and medicinal plants being some of the most important green coffe and artichoke. RA is found in severals herbs in the Lamiaceae family, such as rosemary, thyme, sage or lemon balm. RA is the main phenolic compound in Rosemery plants [169]. In plants, rosmarinic acid is supposed to act as a preformed constitutively accumulated defence compound. In a retrospective review of the historical role of a number of European herbs we can found that the culinary herbs such as rosemary and sage have been widely used in the improvement of cognition and memory. In the other hand, Green (or raw) coffee is a major source of CGA in nature (5–12 g/100 g) [170]. Function and Chemical Reactions CGA and RA have been shown strong antioxidant activities against DPPH and ABTS radical in vitro models [171, 172]. TEAC value for RA was 1.6 times vs AA [173]. RA is able to protect lipid from peroxidation in the Thiobarbituric (TBARS) assay. In this model,
40 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
malonyldialdehyde formation was delayed when RA was used. The protection factor was 3.24 times vs AA [173]. RA have shown antiinflammatory and antiallergic properties. The oral supplementation of 200 mg of RA to patients with seasonal allergic rhinoconjunctivitis (SAR) during 21 days resulted in asignificantly decreased in responder rates for each symptom. RA also significantly decreased the numbers of neutrophils and eosinophils in nasal lavage fluid [174]. In a parallel animal study RA showed anti-inflammatory activity 5-hours after 12tetradecanoylphorbol 13-acetate (TPA) treatment with marked inhibition of neutrophil infiltration. Up regulation of ICAM-1, VCAM-1 cyclooxygenase-2 (COX-2), KC and MIP-2 by TPA were markedly reduced by pre-treatment with RA. Reactive oxygen radical production detected as thiobarbituric acid reactive substance (TBARS), lipid peroxide (LPO) and 8-hydroxy-2'deoxyguanosine (8OH-dG), by double treatment of TPA was reduced by pretreatment with RA [174]. CGA efficiently suppressed cytotoxicity and loss of GSH caused by peroxides in PC12 cells [175]. CGA showed a excellent elimination of ROS induced by t-BHP, Hydrogen peroxide or ferrous sulfate suggesting that may have protective properties against oxidative stress induced in CNS. CGA is also a potent inhibitor of the microsomal glucose-6phosphate translocase (G6PT), is thought to possess cancer chemopreventive properties. G6PT could regulate in glioma cells the intracellular signalling and invasive phenotype of brain tumor cells, and that can be targeted by the anticancer properties of CGA [176]. Neuroprotective Effects in Cell Culture and Animal Models Very recently the role of caffeic acid (CA) as neuroprotective agent has been studied. Pretreatment of the PC12 cells with 10 and 20 μg/ml of CA, for 1 h prior to A, significantly reverse the A-induced neurotoxicity. The suggested CA neuroprotective mechanism is by attenuating of intracellular calcium influx and decreasing tau phosphorylation by the reduction of GSK-3 activation [177]. As CA, also other caffeoyl compounds as RA and CGA have been shown neuroprotective effects in cell culture. RA from sage prevents the neurotoxicity induced by A42. Significant inhibitory effects were achieved at concentrations of 10-7 M [178]. RA reduced A42-induced ROS formation and lipid peroxidation in a concentration-dependent manner and also can inhibit the formation of fibrils from A destabilized preformed A fibrils in vitro. Therefore, in PC12 cells, RA may inhibit ROS formation directly or indirectly by preventing fibril formation from A [178]. As was described for CA, the neuroprotective mechanism of RA is based in the inhibition of tau hyperphosphorylation, but probably acting through the inhibition of p38 MAP kinase pathway instead of the inhibition of GSK-3 hyperphosphorylation as was described for CA. CGA also have shown neuroprotective properties in PC12 cells. CGA not only suppressed the generation of ROS, the decrease of activity in Gpx and the decrease of GSH, but also attenuated caspase-3 activation by MeHg, protecting PC12 cells against MeHg-induced apoptosis [179]. The antioxidant and neuroprotective effects of RA in animal model were examined. RA daily administrated to mice at dose of 0,25 mg/kg, after injection of A2535, prevented induced nitration of proteins, an indicator of peroxynitrite damage, in mice hippocampus. At this dose RA also prevented nitration of proteins and impairment of recognition memory induced by peroxynitrite suggesting that the memory protective effects of RA in the neurotoxicity of A2535 is due to its scavenging of peroxynitrite. This results suggest that RA can protect against memory impairments observed in AD [180].
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
41
Neuroprotective Effects in Alzheimer and Parkinson Patients Based on a retrospective review of the historical role of a number of European herbs in the improvement of memory and cognition, it was shown that spices such as rosemary, sage or lemon balm might potentially provide a natural remedy for AD [181]. Recently, severals clinical studies has shown that sage or lemon balm are effectives in the management of mild to moderate AD [33-35]. A recent study has shown that lemon balm modulates mood and cognitive performance when administered to young, healthy volunteers [182]. In addition, a parallel, randomized, double-blind placebo-controlled study assessed the efficacy and safety of lemon balm in 42 patients between 65 and 80 years with mild to moderate AD [183]. Subjects were treated for four months. The main efficacy measures were the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and the Clinical Dementia Rating-Sum of the Boxes (CDR-SB) scores. The CDR-SB provides a consensus-based global clinical measure by summing the ratings from six domains: memory, orientation, judgment, problem solving, community affairs, home and hobbies, and personal care. The results revealed that patients receiving lemon balm extract experienced significant improvements in cognition after 16 weeks of treatment. Improvements were seen on both the ADAS-cog and CDR-SB scores. Moreover, another similar study showed that patients with mild to moderate AD receiving sage extract experienced statistically significant benefits in cognition after 16 weeks of treatment [184]. The clinical relevance of these findings was emphasized by the improvements seen in both the ADAS-cog and CDR-SB measures in the sage extract group on both observed case and intention-to-treat analyses. 5.3.8. Hydroxystilbenes (Resveratrol) Occurrence Resveratrol (3, 4’, 5-trihydroxystilbene) is natural polyphenol, which differs in structure from the flavonoids having only two (aromatic) ring systems (Fig. 3). It is synthesized by plants in response to fungal infection, and helps the plant to survive due to its strong antifungal properties. In human beverages, high amounts of resveratrol are found in red wine – highlighting an interesting fact that fungi indirectly increase the beneficial effect of a food or beverage. Because it is released from the skin of grapes, the fermentation time is a major factor in its effectiveness. White wine (which contains very low levels of anthocyanins) has also a lower content of resveratrol compared to red wine due to its shorter maceration time. Function and Chemical Reactions The effects of resveratrol include inhibition of lipid peroxidation, chelation of copper, free-radical scavenging and anti-inflammatory activity (reviewed [185]). Neuroprotective Effects in Cell Culture and Animal Models Resveratrol also exerts its anti-oxidative action by enhancing the intracellular freeradical scavenger glutathione. Reveratol was able to protect SH-SY5Y neuroblastoma cells from A and H2O2 induced cell death and was also able to increase the level of reduced glutathione [186]. In a further study, the authors hypothesized that lipoproteins (LP) enhance the A-mediated toxicity to neurons and that uptake of oxidized LP by neuron leads to an acceleration of intracellular oxidative pathways and deteriorate cell death. Using PC12 cells it could be shown that the combination of Abeta and oxidized LP leads to an enhanced cell
42 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
death. However, this effect could been ameliorated by resveratrol, showing that it acts as a potent neuroprotective antioxidant [187]. Furthermore, the combination of trans-resveratrol and vitamin C and/or E were more effective in protecting cells than was any of these three antioxidants alone [188]. Neuroprotective Effects in Alzheimer and Parkinson Patients Moderated consumption of red wine - despite a high fat intake – is considered to be the cause of a low incidence of cardiovascular disease in France – the so-called “French paradox”. In line with this type of studies, a prospective community study in the Bordeaux area in France has demonstrated that the consumption of red wine significantly decreases the risk of AD. 3777 seniors (65 years and older) were observed in respect of their alcohol consumption and onset of dementia. In moderate drinkers who had 250 - 500 ml of red wine per day, red wine seemed to have a strong favourable effect, since the odds ratio was 0.28 compared to non-drinkers [189]. In a similar study, the Washington Heights Inwood-Columbia Aging Project, the intake of up to three daily servings of wine was associated with a lower risk of AD (hazard ratio=0.55) but intake of liquor, beer, and total alcohol was not associated with a lower risk of AD [190]. 5.4. Energy Supplementation There is evidence that bioenergetic dysfunction plays a role in many neuropathological disorders. Mitochondrial respiratory chain and oxidative phosphorylation system are responsible for the production of ATP and defects in energy production are therefore thought to be a cause for neurodegeneration. Energy depletion and neurodegenerative diseases are linked by various pathways, including free-radical generation, impaired calcium buffering and the mitochondrial permeability transition, all leading to cell death. During the failure of neutralisation of radicals, energy supplementation is another opportunity to ensure enough ATP levels for survival and for the repair of the damage occurring in the cell. Hence the application of bioenergetic drugs, including creatine and pyruvate, are further an option for neuroprotective treatment. 5.4.1. Creatine Occurrence Creatine (CR) can be produced endogenously by various organs such as pancreas, liver and kidney using arginine, glycine and methionine (Fig. 5), but can also be taken up by ingestion of meat products [191] or as a supplement in the form of Creatine monohydrate (CM). Latter is commercially available as a water soluble powder, in capsule or chewable. The daily recommended dose of creatine is about 5-10 g [192].
Fig. (5). Chemical structures of the pro-energetic compounds creatine and pyruvate.
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
43
Function and Chemical Reactions A healthy brain contains approximately 4.5 mM phosphocreatine (PCr) [193], which serves as an energy buffer in muscles and brain through transferring the phosphoryl group to ADP, catalyzed by cytosolic creatine kinase (CK). Neuroprotective Effects in Cell Culture and Animal Models CR can also function together with PCr as an energy buffer between the cytosol and mitochondria. The mitochondrial isoform of CK (MtCK) exists in octameric and dimeric forms. MtCK in its octameric form inhibits the opening of the mitochondrial permeability transition pore (MTP) [194], but dimerizes in the presence of radicals, allowing the MTP to open and impair mitochondrial respiration leading to cell death [195]. It has been shown that creatine attenuate these negative effects [195-197]. Furthermore creatine administration has been found to protect against glutamate and amyloid toxicity in rat hippocampal neurons in vitro, 198]. There is evidence from in vitro and animal experiments that oral creatine supplementation might prevent or slow down neurodegeneration in Huntington’s disease (HD). Neuroprotective Effects in Alzheimer and Parkinson Patients The importance of the substrates of CK, CR, and PCr, for normal brain function in man is emphasized by the fact that patients with genetic CRT-deficiency lack any detectable CR in the brain [199]and have severe neurological phenotypes including hypotonia, developmental speech delay, autism, and brain atrophy [199]. It has been documented that creatine concentrations are decreased in AD [200]. A randomized, double-blind, Phase II futility clinical trial shown that CR should be considered for definitive Phase III trials to determine if they alter the long term progression of Parkinson disease (PD). In 2007, the NIH National Institute of Neurological Disorders and Stroke (NINDS) has announced the launch of a large-scale double-blind, placebo-controlled, phase III clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease (PD). Though there is no data of clinical trials for creatine supplementation for AD have been published so far, in two studies, Cr supplementation has been shown to improve mental concentration as well as memory and learning in healthy human subjects. It is possible that this will also be true for early stage AD patients. 5.4.2. Pyruvate Function and Chemical Reactions A common feature of AD and PD is an impairment of glucose metabolism [201]. The resulting decrease in pyruvate (Fig. 5), which is an intermediate in glycolyis, is thought to cause a deficit of energy, which could be ameliorated by supplementation from exogenous sources. Pyruvate acts also as an antioxidant. Pyruvate and other -ketoacids can react nonenzymatically with H2O2 through a reaction in which carbon dioxide is liberated, and ketoacid is converted into the corresponding carboxylic acid [202].
R-RCCOOH + H2O2
RCOOH + CO2 + H2O
Pyruvate is shuttled by the H+-monocarbonylate cotransporter between the intracellular and extracellular space and can therefore scavenge H2O2 inside and outside the cell [203, 204]. However, the neuroprotective effects of pyruvate are decreased in high concentration since this leads to intracellular acidification, mainly generated by the H+ co-transport across
44 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
the plasma membrane [205, 206] and to a minor extent, from undissociated pyruvic acid [207]. Neuroprotective Effects in Cell Culture and Animal Models Mechanisms responsible for the neuroprotective effects of pyruvate are controversial. It was suggested that the neuroprotective effect of pyruvate is more likely due to its antioxidant effect rather through its improvement of energy metabolism, because the neuroprotection could be reproduced with other -ketoacids (which are able to react with H2O2) but not with lactate, another neuronal energy substrate [202]. However, it was also shown that the neuroprotective effect of pyruvate is not related to its ability to undergo a decarboxylation process by counteracting the deep decrease in the neuronal ATP content, indicating the neurons are protected by rescuing the cellular energy charge [208]. It was demonstrated that increased glutamate release such as that in excitotoxity, stimulates glycolysis in astrocytes and that the endproduct pyruvate may contribute to neuronal protection [209]. In addition, glial cells release more of the energy substrate lactate in the presence of glutamate. The release of glutamate from nerve terminals may therefore cause a negative feedback, increasing neurotoxicity [210]. Neuroprotective Effects in Alzheimer and Parkinson Patients Pyruvate administration for therapeutic use may provide benefit for patients, because unlike exogenous catalase, pyruvate and other alpha-ketoacids can cross the blood brain barrier [204, 211]. However, until now clinical trials with pyruvate in AD or PD patients are still missing. 5.5. NMDA Antagonists Function and Chemical Reactions Since excitotoxicity plays a role in AD as described above, several NMDA antagonists have been developed for the treatment of neurodegenerative disorders. Synthetic drugs like memantine, MK-801 or dizocilpine have made into different stages of clinical development, also natural components like kynurenic acid or quinolinic acid. However, the most promising NMDA receptor antagonist so far is memantine (Fig. 6). Memantine acts as a noncompetitive (channel-blocking) antagonist. It inhibits pathopysiological Ca2+ influx without blocking physiological activation of the NMDA receptor, which is important for learning and memory. Although the mode of action is not clearified yet it seems that memantine is combined and released with the ion channel depending on electric potential in the same way as the magnesium ion [212]. The main advantage of memantine is its low-moderate affinity in comparison to phencyclidine (PCP) and MK-801, which are high-affinity NMDA receptors antagonists and are therefore not practical due to adverse side effects such as schizophrenic symptoms [213]. Kynurenic acid is a natural metabolite of tryptophan and can antagonize non-NMDA as well as NMDA receptor activation [214]. Neuroprotective Effects in Cell Culture and Animal Models In a AD animal model, Sprague-Dawley rats received memantine and beta-amyloid 1-40 [Abeta(1-40)]. A(1-40) injections into hippocampus led to neuronal loss in the CA1 subfield, evidence of widespread apoptosis, and astrocytic and microglial activation and hypertrophy. Memantine treated animals had significant reductions in the amount of neuronal degeneration, pyknotic nuclei and glial fibrillary acidic protein (GFAP) immunostaining as
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
45
compared with vehicle treated animals. These data suggest that memantine, at therapeutically relevant concentrations, can protect against neuronal degeneration induced by A [215].
Fig. (6). Chemical structure of the NMDA-receptor antagonist memantine, an 1-aminoadamantan derivative.
Memantine was able to abolish toxic effects of glutamate in a rat model with parkinsonian syndromes. Already 5 mg/kg weakend the development of oligokinesea and muscular ricidity induced trough MPTP [216]. Neuroprotective Effects in Alzheimer and Parkinson Patients After successful clinical trials, memantine is now used as a therapeutic drug for AD in the EU and USA. In one of the clinical trials, 166 AD patients were treated with 10 mg/d of memantine. It was shown that there was an improvement in the care dependence subscore on the Behaviorial Rating Scale for Geriatric Patients (BGP) of 3.1 points compared to 1.1 points in the placebo group [206]. These data were consistent with another study, in which Reisberg and coworker analysed 252 patients with moderate-to-severe AD, who were treated with 20 mg of memantine daily for 28 weeks [217]. According to the result of the Clinician’s Interview-Based Impression of Change Plus (CIBIC-Plus) the change from baseline was significantly better with memantine compared to placebo. Two more studies reported statistically significant benefits of memantine. In a US-28-week placebo-controlled clinical trial memantine was determined for clinical efficacy and safety for people with Alzheimer´s disease. 20 mg/day of memantine caused a positive effect on cognition, mood and behaviour, however clinical detectable changes could not be observed [206]. In a further European trial, memantine was investigated in severely demented nursing home patients suffering from AD. Memantine-treated patients showed a functional and global improvement, reduced care dependency, compared to placebo-treated persons [218]. Positive effects of NMDA receptor antagonists such as Memantine have also been reported for PD patients. However, rather than being neuroprotective (which can only be demonstrated in long-term studies), these drugs are rather beneficial in PD patients by alleviating characteristic PD symptoms such as dyskinesia, suggesting an effect on glutamatergic signal transduction. In an open-fashion conducted study, 5 out of 14 PD patients improved their main Parkinson features whilst 6 further patients of this group improved their “off” episodes [219]. In a further case report, memantine was used with three cognitively impaired, dyskinetic Parkinsonian patients, and two seemed to benefit from this medication regarding their dyskinesia [220]. ACKNOWLEDGEMENTS We thank Steven Robinson and Peter Riederer for their helpful discussion. This study was supported by the Alzheimer Forschungs Initiative e.V and the DFG (Mu 1011-13).
46 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shanmugam et al.
ABBREVIATIONS AA
=
Arachidonic acid
A
=
Beta-amyloid peptide
AC
=
Adenyl cyclase
AD
=
Alzheimer Disease
AGE
=
Advanced Glycation Endproduct
AMPA
=
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
APP
=
Amyloid precursor protein
BB
=
Blueberry
BGP
=
Behaviorial Rating Scale for Geriatric Patients
BH4
=
Tetrahydrobiopterin
cGMP
=
Cyclic Guanyl monophosphate
CHAP
=
Chicago Health and Aging Project
CIBIC-Plus
=
Clinician’s Interview-Based Impression of Change Plus
CK
=
Creatine Kinase
CM
=
Creatine monhohydrate
CR
=
Creatine
DA
=
Dopamine
DAG
=
Diacylglycerol
DATATOP
=
Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism
DHA
=
Dehydroascorbic acid
DTT
=
Dithiothreitol
DHLA
=
Dihydrolipoic acid
DPPH
=
1,1-diphenyl-2-picryl-hydrazyl
EC
=
Epicatechin (EC)
EGb
=
Ginkgo Biloba
EGC
=
(-)-Epigallocatechin
EGCG
=
(-)-Epicatechin gallate
GC
=
Guanylate cyclase
GSH
=
Glutathione recuced
4-HNE
=
4-hydroxysynonenal
H2O2
=
Hydrogen peroxide
Mechanisms of Neuroprotection
Frontiers in Medicinal Chemistry, 2010, Vol. 5
HOCL
=
Hypochlorous acid
HVA
=
Homovanillic acid
IL-1
=
Interleukin 1 beta
IL-6
=
Interleukin 6
IP3
=
Inositol-1,4,5, trisphosphate
KA
=
Kainic acid
LA
=
Lipoic acid
LOOH
=
Lipid hydroperoxidases
LP
=
Lipoprotein
M-CSF
=
Macrophage-Colony stimulating factor
MDA
=
Malondialdehyde
NADH
=
Nicotine amide dinucleotide
NAC
=
N-acetyl-cysteine
NADH
=
Nicotine amide dinucleotide phosphate
NMDA
=
N-methyl-D-aspartate
MPTP
=
1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine
MtCK
=
Mitochondriale Creatine Kinase
MTP
=
Mitochondrial permeability transition pore
NO
=
Nitric oxide
NxOy
=
Nitrogen oxides
MMSE
=
Mini-mental state examination
=
Superoxide
OCl
=
Hypochlorite
OH
=
Hydroxyl radical
=
6-hydroxy dopamine
=
Peroxinitrite
PCP
=
Phencyclidine
PCr
=
Phosphocreatine
PD
=
Parkinson Disease
PIP2
=
L-3-phosphatidyl-inositol-4,5-bisphosphate
PKA
=
Protein kinase A
PKC
=
Protein kinase C
O2
-
6-OHDA ONOO
-
47
48 Frontiers in Medicinal Chemistry, 2010, Vol. 5
PLC
=
Phospholipase C
RAGE
=
Receptor for AGE
ROS
=
Reactive oxygen species
SN
=
Substantia nigra
SOD
=
Superoxide dismutase
SPA
=
Sweet potato anthocyanin
TH
=
Tyrosine hydrolase
TNF-
=
Tumour necrosis factor- alpha
Shanmugam et al.
REFERENCES [1] [2] [3]
[4] [5] [6] [7] [8] [9] [10] [11]
[12] [13] [14] [15] [16] [17]
[18] [19]
Yesavage, J. A.; O'Hara, R.; Kraemer, H.; Noda, A.; Taylor, J. L.; Ferris, S.; Gely-Nargeot, M. C.; Rosen, A.; Friedman, L.; Sheikh, J.; Derouesne, C. Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J. Psychiatr. Res., 2002, 36, 281-286. Braak, H.; Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging, 1995, 16, 271-278; discussion 278-284. Dukic-Stefanovic, S.; Gasic-Milenkovic, J.; Deuther-Conrad, W.; Münch, G. Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). J. Neurochem., 2003, 87, 2609-2615. Halliday, G.; Robinson, S. R.; Shepherd, C.; Kril, J. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol., 2000, 27, 1-8. Griffin, W. S.; Sheng, J. G.; Roberts, G. W.; Mrak, R. E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol., 1995, 54, 276-281. Meda, L.; Cassatella, M. A.; Szendrei, G. I.; Otvos, L., Jr.; Baron, P.; Villalba, M.; Ferrari, D.; Rossi, F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature, 1995, 374, 647-650. Pachter, J. S. Inflammatory mechanisms in Alzheimer disease: the role of beta-amyloid/glial interactions. Mol. Psychiatry., 1997, 2, 91-95. Tretter, L.; Sipos, I.; Adam-Vizi, V. Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochem. Res., 2004, 29, 569-577. Sanchez-Ramos JR, Övervik, E.; Ames, B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy2´-deoxyguanosine) is increased in nigro-striatum in Parkinson´s disease brain. Neurodegeneration, 1994, 3, 197-204. Bains, J. S.; Shaw, C. A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev., 1997, 25, 335-358. Dexter, D. T.; Holley, A. E.; Flitter, W. D.; Slater, T. F.; Wells, F. R.; Daniel, S. E.; Lees, A. J.; Jenner, P.; Marsden, C. D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord., 1994, 9, 92-97. Alam, Z. I.; Daniel, S. E.; Lees, A. J.; Marsden, D. C.; Jenner, P.; Halliwell, B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem., 1997, 69, 1326-1329. McGeer, P. L.; McGeer, E. G. Inflammation and the degenerative diseases of aging. Ann. N.Y Acad Sci., 2004, 1035, 104-116. Stamler, J. S.; Singel, D. J.; Loscalzo, J. Biochemistry of nitric oxide and its redox-activated forms. Science, 1992, 258, 1898-1902. Ischiropoulos, H.; Zhu, L.; Beckman, J. S. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem. Biophys., 1992, 298, 446-451. Hampton, M. B.; Kettle, A. J.; Winterbourn, C. C. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood, 1998, 92, 3007-3017. Thomas, E. L. Myeloperoxidase, hydrogen peroxide, chloride antimicrobial system: nitrogen-chlorine derivatives of bacterial components in bactericidal action against Escherichia coli. Infect. Immun., 1979, 23, 522-531. Raichle, M. E.; Gusnard, D. A. Appraising the brain's energy budget. Proc. Natl. Acad Sci. USA, 2002, 99, 10237-10239. Fridovich, I. Superoxide dismutases: an adaptation to a paramagnetic gas. J. Biol. Chem., 1989, 264, 77617764.
Mechanisms of Neuroprotection [20] [21] [22] [23] [24]
[25] [26] [27] [28]
[29] [30] [31] [32] [33] [34] [35] [36]
[37] [38]
[39] [40] [41] [42] [43] [44] [45] [46] [47]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
49
Dumuis, A.; Sebben, M.; Haynes, L.; Pin, J. P.; Bockaert, J. NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature, 1988, 336, 68-70. Needleman, P.; Turk, J.; Jakschik, B. A.; Morrison, A. R.; Lefkowith, J. B. Arachidonic acid metabolism. Annu. Rev. Biochem., 1986, 55, 69-102. Patel, M.; Day, B. J.; Crapo, J. D.; Fridovich, I.; McNamara, J. O. Requirement for superoxide in excitotoxic cell death. Neuron, 1996, 16, 345-355. Cheeseman, K. H.; Slater, T. F. An introduction to free radical biochemistry. Br. Med. Bull., 1993, 49, 481-493. Mutze, S.; Hebling, U.; Stremmel, W.; Wang, J.; Arnhold, J.; Pantopoulos, K.; Mueller, S. Myeloperoxidase-derived hypochlorous acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 1. J. Biol. Chem., 2003, 278, 40542-40549. Smith, K. J.; Kapoor, R.; Felts, P. A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol., 1999, 9, 69-92. Markesbery, W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med., 1997, 23, 134-147. Albin, R. L.; Greenamyre, J. T. Alternative excitotoxic hypotheses. Neurology, 1992, 42, 733-738. Weiss, S.; Ellis, J.; Hendley, D. D.; Lenox, R. H. Translocation and activation of protein kinase C in striatal neurons in primary culture: relationship to phorbol dibutyrate actions on the inositol phosphate generating system and neurotransmitter release. J. Neurochem., 1989, 52, 530-536. Nicoletti, F.; Magri, G.; Ingrao, F.; Bruno, V.; Catania, M. V.; Dell'Albani, P.; Condorelli, D. F.; Avola, R. Excitatory amino acids stimulate inositol phospholipid hydrolysis and reduce proliferation in cultured astrocytes. J. Neurochem., 1990, 54, 771-777. Greenamyre, J. T.; Porter, R. H. Anatomy and physiology of glutamate in the CNS. Neurology, 1994, 44, S7-13. Novelli, A.; Reilly, J. A.; Lysko, P. G.; Henneberry, R. C. Glutamate becomes neurotoxic via the Nmethyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res., 1988, 451, 205-212. Toledo-Pereyra, L. H.; Lopez-Neblina, F.; Toledo, A. H. Reactive oxygen species and molecular biology of ischemia/reperfusion. Ann. Transplant., 2004, 9, 81-3. Rose, R. C. Transport of ascorbic acid and other water-soluble vitamins. Biochim. Biophys. Acta., 1988, 947, 335-366. Winkler, B. S. In vitro oxidation of ascorbic acid and its prevention by GSH. Biochim. Biophys. Acta, 1987, 925, 258-264. Sies, H. Relationship between free radicals and vitamins: an overview. Int. J. Vitam. Nutr. Res. Suppl., 1989, 30, 215-223. Ciani, E.; Groneng, L.; Voltattorni, M.; Rolseth, V.; Contestabile, A.; Paulsen, R. E. Inhibition of free radical production or free radical scavenging protects from the excitotoxic cell death mediated by glutamate in cultures of cerebellar granule neurons. Brain Res., 1996, 728, 1-6. Medina, S.; Martinez, M.; Hernanz, A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic. Res., 2002, 36, 1179-1184. Lockhart, B. P.; Benicourt, C.; Junien, J. L.; Privat, A. Inhibitors of free radical formation fail to attenuate direct beta-amyloid25-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J. Neurosci. Res., 1994, 39, 494-505. Pardo, B.; Mena, M. A.; Fahn, S.; Garcia de Yebenes, J. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov. Disord., 1993, 8, 278-284. Choi, H. Y.; Song, J. H.; Park, D. K.; Ross, G. M. The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics. Neurosci. Lett., 2000, 296, 81-84. Engelhart, M. J.; Geerlings, M. I.; Ruitenberg, A.; van Swieten, J. C.; Hofman, A.; Witteman, J. C.; Breteler, M. M. Dietary intake of antioxidants and risk of Alzheimer disease. Jama., 2002, 287, 3223-3229. Rebec, G. V.; Barton, S. J.; Marseilles, A. M.; Collins, K. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport, 2003, 14, 1263-1265. Tappel, A. L. Vitamin E and free radical peroxidation of lipids. Ann. NY Acad Sci., 1972, 203, 12-28. Esterbauer, H.; Dieber-Rotheneder, M.; Striegl, G.; Waeg, G. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am. J. Clin. Nutr., 1991, 53, 314S-321S. Niki, E. Interaction of ascorbate and alpha-tocopherol. Ann. NY Acad Sci., 1987, 498, 186-199. Li, Y.; Liu, L.; Barger, S. W.; Mrak, R. E.; Griffin, W. S. Vitamin E suppression of microglial activation is neuroprotective. J. Neurosci. Res., 2001, 66, 163-170. Yatin, S. M.; Varadarajan, S.; Butterfield, D. A. Vitamin E prevents alzheimer's amyloid beta-peptide (142)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimers Dis., 2000, 2, 123-131.
50 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [48] [49]
[50] [51] [52] [53]
[54] [55] [56]
[57] [58] [59] [60] [61] [62]
[63]
[64] [65] [66] [67] [68]
[69] [70] [71]
Shanmugam et al.
Offen, D.; Ziv, I.; Panet, H.; Wasserman, L.; Stein, R.; Melamed, E.; Barzilai, A. Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2. Cell Mol. Neurobiol., 1997, 17, 289-304. Morris, M. C.; Evans, D. A.; Bienias, J. L.; Tangney, C. C.; Bennett, D. A.; Aggarwal, N.; Wilson, R. S.; Scherr, P. A. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA, 2002, 287, 3230-3237. Zhang, S. M.; Hernan, M. A.; Chen, H.; Spiegelman, D.; Willett, W. C.; Ascherio, A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology, 2002, 59, 1161-1169. de Rijk, M. C.; Breteler, M. M.; den Breeijen, J. H.; Launer, L. J.; Grobbee, D. E.; van der Meche, F. G.; Hofman, A. Dietary antioxidants and Parkinson disease: the Rotterdam Study. Arch Neurol., 1997, 54, 762-765. Miklya, I.; Knoll, B.; Knoll, J. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. Life Sci., 2003, 72, 2641-2648. Atwood, C. S.; Perry, G.; Zeng, H.; Kato, Y.; Jones, W. D.; Ling, K. Q.; Huang, X.; Moir, R. D.; Wang, D.; Sayre, L. M.; Smith, M. A.; Chen, S. G.; Bush, A. I. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry, 2004, 43, 560-568. Zhang, L.; Xing, G. Q.; Barker, J. L.; Chang, Y.; Maric, D.; Ma, W.; Li, B. S.; Rubinow, D. R. Alphalipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci. Lett., 2001, 312, 125-128. Lovell, M. A.; Xie, C.; Xiong, S.; Markesbery, W. R. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J. Alzheimers Dis., 2003, 5, 229-239. Bharat, S.; Cochran, B. C.; Hsu, M.; Liu, J.; Ames, B. N.; Andersen, J. K. Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy. Neurotoxicology, 2002, 23, 479-486. Hager, K.; Marahrens, A.; Kenklies, M.; Riederer, P.; Münch, G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch. Gerontol. Geriatr., 2001, 32, 275-282. Benavente-García, O.; Castillo, J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J. Agric. Food. Chem., 2008, 56, 6185-6205. Hodek, P.; Trefil, P.; Stiborová, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 2002, 139, 1-21. Benavente-Garcia, O.; Castillo, J.; del Rio Conesa, J. A. Changes in neodiosmin levels during the development of Citrus aurantium leaves and fruits. Postulation of a neodiosmin biosynthetic pathway. J. Agric. Food. Chem., 1993, 41, 1916-1919. Castillo, J.; Benavente, O.; Del Rio, J. A. Naringin and Neohesperidin Levels during Development of Leaves, Flower Buds, and Fruits of Citrus aurantium. Plant. Physiol., 1992, 99, 67-73. Castillo, J.; Benavente, O.; del Rio, J. A. Hesperetin 7-O-glucoside and prunin in Citrus species (C. aurantium and C. paradisi). A study of their quantitative distribution in immature fruits and as immediate precursors of neohesperidin and naringin in Citrus aurantium. J. Agric. Food. Chem., 1993, 41, 19201924. José Antonio Del, R.; María Cruz, A.; Obdulio, B.; Francisco, S.; Ana, O. Changes of Polymethoxylated Flavones Levels during Development of Citrus aurantium (cv. Sevillano) Fruits. Planta. Med, 1998, 575576. Ortuño, A. M.; Arcas, M. C.; Benavente-García, O.; Del Río, J. A. Evolution of polymethoxy flavones during development of tangelo Nova fruits. Food Chem., 1999, 66, 217-220. Bär, A.; Borrego, F.; Benavente, O.; Castillo, J.; del Rio, J. A. Neohesperidin dihydrochalcone: properties and applications. Food Sci. Technol., 1990, 23, 371-376. Del Rio, J. A.; Arcas, M. C.; Benavente-Garcia, O.; Ortuno, A. Citrus Polymethoxylated Flavones Can Confer Resistance against Phytophthora citrophthora, Penicillium digitatum, and Geotrichum Species. J. Agric. Food. Chem.,1998, 46, 4423-4428. Del Río, J. A.; Fuster, M. D.; Gómez, P.; Porras, I.; García-Lidón, A.; Ortuño, A. Citrus limon: a source of flavonoids of pharmaceutical interest. Food Chem., 2004, 84, 457-461. Marín, F. R.; Soler-Rivas, C.; Benavente-García, O.; Castillo, J.; Pérez-Alvarez, J. A. By-products from different citrus processes as a source of customized functional fibres. Food Chem., 2007, 100, 736741. Bravo, L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev., 1998, 56, 317-33. Le Marchand, L. Cancer preventive effects of flavonoids--a review. Biomed. Pharmacother., 2002, 56, 296-301. Martínez, C.; Yàñez, J.; Vicente, V.; Alcaraz, M.; Benavente-García, O.; Castillo, J.; Lorente, J.; Lozano, J. A. Effects of several polyhydroxylated flavonoids on the growth of B16F10 melanoma and Melan-a melanocyte cell lines: influence of the sequential oxidation state of the flavonoid skeleton. Melanoma Res., 2003, 13, 3-9.
Mechanisms of Neuroprotection [72]
[73] [74]
[75] [76] [77] [78] [79]
[80] [81] [82] [83] [84] [85]
[86] [87]
[88] [89]
[90]
[91] [92]
[93]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
51
Rodriguez, J.; Yáñez, J.; Vicente, V.; Alcaraz, M.; Benavente-García, O.; Castillo, J.; Lorente, J.; Lozano, J. A. Effects of several flavonoids on the growth of B16F10 and SK-MEL-1 melanoma cell lines: relationship between structure and activity. Melanoma Res,, 2002, 12, 99-107. Yanez, J.; Vicente, V.; Alcaraz, M.; Castillo, J.; Benavente-Garcia, O.; Canteras, M.; Teruel, J. A. Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr. Cancer, 2004, 49, 191-199. Benavente-García, O.; Castillo, J.; Lorente, J.; Alcaraz, M.; Yañez, J.; Martinez, C.; Vicente, V.; Lozano, J. A. Antiproliferative activity of several phenolic compounds against melanoma cell lines: relationship between structure and activity. Agro.Food Ind. High-Tech, 2005, 4, 30-34. Manthey, J. A.; Guthrie, N. Antiproliferative Activities of Citrus Flavonoids against Six Human Cancer Cell Lines. J. Agric. Food. Chem., 2002, 50, 5837-5843. Baluchnejadmojarad, T.; Roghani, M. Effect of naringenin on intracerebroventricular streptozotocininduced cognitive deficits in rat: a behavioral analysis. Pharmacology., 2006, 78, 193-197. Heo, H. J.; Kim, D.-O.; Shin, S. C.; Kim, M. J.; Kim, B. G.; Shin, D.-H. Effect of antioxidant flavanone, naringenin, from citrus junos on neuroprotection. J. Agric. Food. Chem., 2004, 52, 1520-1525. Heo, H. J.; Kim, M.-J.; Lee, J.-M.; Choi, S. J.; Cho, H.-Y.; Hong, B.; Kim, H.-K.; Kim, E.; Shin, D.-H. Naringenin from Citrus junos has an inhibitory effect on acetylcholinesterase and a mitigating effect on amnesia. Dement. Geriatr. Cogn. Disord., 2004, 17, 151-157. Zbarsky, V.; Datla, K. P.; Parkar, S.; Rai, D. K.; Aruoma, O. I.; Dexter, D. T. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res., 2005, 39, 1119-1125. Kim, J. Y.; Jung, K. J.; Choi, J. S.; Chung, H. Y. Hesperetin: a potent antioxidant against peroxynitrite. Free Radic. Res., 2004, 38, 761-769. Vauzour, D.; Vafeiadou, K.; Spencer, J. P. Inhibition of the formation of the neurotoxin 5-S-cysteinyldopamine by polyphenols. Biochem. Biophys. Res. Commun., 2007, 362, 340-346. Liu, R.-T.; Zou, L.-B.; Lü, Q.-J. Liquiritigenin inhibits Abeta(25-35)-induced neurotoxicity and secretion of Abeta(1-40) in rat hippocampal neurons. Acta Pharmacol. Sin., 2009, 30, 899-906. Hwang, E. M.; Ryu, Y. B.; Kim, H. Y.; Kim, D.-G.; Hong, S.-G.; Lee, J. H.; Curtis-Long, M. J.; Jeong, S. H.; Park, J.-Y.; Park, K. H. BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg. Med. Chem., 2008, 16, 6669-6674. López-Lázaro, M. Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem., 2009, 9, 31-59. Shanmugam, K.; Holmquist, L.; Steele, M.; Stuchbury, G.; Berbaum, K.; Schulz, O.; Benavente García, O.; Castillo, J. n.; Burnell, J.; Garcia Rivas, V.; Dobson, G.; Münch, G. Plant-derived polyphenols attenuate lipopolysaccharide-induced nitric oxide and tumour necrosis factor production in murine microglia and macrophages. Mol. Nutr. Food Res., 2008, 52, 427-438. Elsisi, N. S.; Darling-Reed, S.; Lee, E. Y.; Oriaku, E. T.; Soliman, K. F. Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci. Lett., 2005, 375, 91-96. Shimmyo, Y.; Kihara, T.; Akaike, A.; Niidome, T.; Sugimoto, H. Flavonols and flavones as BACE-1 inhibitors: Structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochimica. et Biophysica. Acta (BBA) - General Subjects, 2008, 1780, 819-825. Patil, C. S.; Singh, V. P.; Satyanarayan, P. S.; Jain, N. K.; Singh, A.; Kulkarni, S. K. Protective effect of flavonoids against aging- and lipopolysaccharide-induced cognitive impairment in mice. Pharmacology, 2003, 69, 59-67. Hansen, E.; Krautwald, M.; Maczurek, A. E.; Stuchbury, G.; Fromm, P.; Steele, M.; Schulz, O.; Garcia, O. B.; Castillo, J.; Körner, H.; Münch, G. A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. J. Alzheimers Dis., 2010, 19, 451464. Rezai-Zadeh, K.; Ehrhart, J.; Bai, Y.; Sanberg, P. R.; Bickford, P.; Tan, J.; Shytle, R. D. Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J. Neuroinflammation, 5, 41-41. Rezai-Zadeh, K.; Shytle, R. D.; Bai, Y.; Tian, J.; Hou, H.; Mori, T.; Zeng, J.; Obregon, D.; Town, T.; Tan, J. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease -amyloid production. J. Cell Mol. Med., 2009, 13, 574-588. Chen, H.-Q.; Jin, Z.-Y.; Wang, X.-J.; Xu, X.-M.; Deng, L.; Zhao, J.-W. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci. Lett., 2008, 448, 175-179. Wruck, C. J.; Claussen, M.; Fuhrmann, G.; Römer, L.; Schulz, A.; Pufe, T.; Waetzig, V.; Peipp, M.; Herdegen, T.; Götz, M. E. Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J. Neural. Transm.Suppl., 2007, 72, 57-67.
52 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [94]
[95] [96]
[97] [98]
[99]
[100]
[101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114]
[115] [116]
[117]
Shanmugam et al.
Datla, K. P.; Christidou, M.; Widmer, W. W.; Rooprai, H. K.; Dexter, D. T. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport., 2001, 12, 3871-3875. Datla, K. P.; Zbarsky, V.; Rai, D.; Parkar, S.; Osakabe, N.; Aruoma, O. I.; Dexter, D. T. Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of parkinson's disease. J. Am. Coll. Nutr., 2007, 26, 341-349. Takano, K.; Tabata, Y.; Kitao, Y.; Murakami, R.; Suzuki, H.; Yamada, M.; Iinuma, M.; Yoneda, Y.; Ogawa, S.; Hori, O. Methoxyflavones protect cells against endoplasmic reticulum stress and neurotoxin. Am. J. Physiol. Cell Physiol., 2007, 292, C353-361. Matsuzaki, K.; Yamakuni, T.; Hashimoto, M.; Haque, A. M.; Shido, O.; Mimaki, Y.; Sashida, Y.; Ohizumi, Y. Nobiletin restoring [beta]-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. Neurosci. Lett., 2006, 400, 230-234. Yamamoto, Y.; Shioda, N.; Han, F.; Moriguchi, S.; Nakajima, A.; Yokosuka, A.; Mimaki, Y.; Sashida, Y.; Yamakuni, T.; Ohizumi, Y.; Fukunaga, K. Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation. Brain Res., 2009, 1295, 218-229. Nakajima, A.; Yamakuni, T.; Haraguchi, M.; Omae, N.; Song, S.-Y.; Kato, C.; Nakagawasai, O.; Tadano, T.; Yokosuka, A.; Mimaki, Y.; Sashida, Y.; Ohizumi, Y. Nobiletin, a citrus flavonoid that improves memory impairment, rescues bulbectomy-induced cholinergic neurodegeneration in mice. J. Pharmacol. Sci., 2007, 105, 122-126. Onozuka, H.; Nakajima, A.; Matsuzaki, K.; Shin, R.-W.; Ogino, K.; Saigusa, D.; Tetsu, N.; Yokosuka, A.; Sashida, Y.; Mimaki, Y.; Yamakuni, T.; Ohizumi, Y. Nobiletin, a citrus flavonoid, improves memory impairment and A pathology in a transgenic mouse model of alzheimer's disease. J. Pharmacol. Exp. Ther., 2008, 326, 739-744. Commenges, D.; Scotet, V.; Renaud, S.; Jacqmin-Gadda, H.; Barberger-Gateau, P.; Dartigues, J. F. Intake of flavonoids and risk of dementia. Eur. J. Epidemiol., 2000, 16, 357-363. Dai, Q.; Borenstein, A. R.; Wu, Y.; Jackson, J. C.; Larson, E. B. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am. J. Med., 2006, 119, 751-759. Letenneur, L.; Proust-Lima, C.; Le Gouge, A.; Dartigues, J. F.; Barberger-Gateau, P. Flavonoid Intake and Cognitive Decline over a 10-Year Period. Am. J. Epidemiol., 2007, kwm036-kwm036. Higdon, J. V.; Frei, B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr., 2003, 43, 89-143. Rice-Evans, C. Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Proc. Soc. Exp. Biol. Med., 1999, 220, 262-266. Haenen, G. R.; Bast, A. Nitric oxide radical scavenging of flavonoids. Methods Enzymol., 1999, 301, 490503. Pannala, A. S.; Rice-Evans, C. A.; Halliwell, B.; Singh, S. Inhibition of peroxynitrite-mediated tyrosine nitration by catechin polyphenols. Biochem. Biophys. Res. Commun., 1997, 232, 164-168. Nanjo, F.; Mori, M.; Goto, K.; Hara, Y. Radical scavenging activity of tea catechins and their related compounds. Biosci. Biotechnol. Biochem., 1999, 63, 1621-163. Guo, Q.; Zhao, B.; Shen, S.; Hou, J.; Hu, J.; Xin, W. ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers. Biochim. Biophys. Acta, 1999, 1427, 13-23. Zhao, B.; Guo, Q.; Xin, W. Free radical scavenging by green tea polyphenols. Methods Enzymol., 2001, 335, 217-231. Bors, W.; Michel, C. Antioxidant capacity of flavanols and gallate esters: pulse radiolysis studies. Free Radic Biol. Med., 1999, 27, 1413-1426. Skrzydlewska, E.; Ostrowska, J.; Farbiszewski, R.; Michalak, K. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. Phytomedicine., 2002, 9, 232-238. Laughton, M. J.; Evans, P. J.; Moroney, M. A.; Hoult, J. R.; Halliwell, B. Inhibition of mammalian 5lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability. Biochem. Pharmacol., 1991, 42, 1673-1681. Khan, S. G.; Katiyar, S. K.; Agarwal, R.; Mukhtar, H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res., 1992, 52, 4050-4052. Agarwal, R.; Katiyar, S. K.; Khan, S. G.; Mukhtar, H. Protection against ultraviolet B radiation-induced effects in the skin of SKH-1 hairless mice by a polyphenolic fraction isolated from green tea. Photochem. Photobiol., 1993, 58, 695-700. Levites, Y.; Amit, T.; Mandel, S.; Youdim, M. B. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)epigallocatechin-3-gallate. FASEB J., 2003, 17, 952-954. Kim, J.; Lee, H. J.; Lee, K. W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J.Neurochem., 2010, 112, 1415-1430.
Mechanisms of Neuroprotection [118]
[119] [120]
[121] [122]
[123] [124]
[125] [126] [127]
[128] [129]
[130] [131] [132] [133]
[134] [135] [136] [137] [138]
[139] [140]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
53
Lin, Y. L.; Tsai, S. H.; Lin-Shiau, S. Y.; Ho, C. T.; Lin, J. K. Theaflavin-3,3'-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kappaB in macrophages. Eur. J. Pharmacol., 1999, 367, 379-388. Lin, Y. L.; Lin, J. K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by downregulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol. Pharmacol., 1997, 52, 465-472. Mandel, S. A.; Amit, T.; Weinreb, O.; Reznichenko, L.; Youdim, M. B. H. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci. Ther., 2008, 14, 352-365. Haque, A. M.; Hashimoto, M.; Katakura, M.; Hara, Y.; Shido, O. Green tea catechins prevent cognitive deficits caused by A[beta]1-40 in rats. J. Nutr .Biochem., 2008, 19, 619-626. Ferruzzi, M. G.; Lobo, J. K.; Janle, E. M.; Cooper, B.; Simon, J. E.; Wu, Q. L.; Welch, C.; Ho, L.; Weaver, C.; Pasinetti, G. M. Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. J. Alzheimers Dis., 2009, 18, 113-124. Levites, Y.; Amit, T.; Youdim, M. B.; Mandel, S. Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J. Biol. Chem., 2002, 277, 30574-30580. Choi, J. Y.; Park, C. S.; Kim, D. J.; Cho, M. H.; Jin, B. K.; Pie, J. E.; Chung, W. G. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology, 2002, 23, 367-374. Rossi, L.; Mazzitelli, S.; Arciello, M.; Capo, C.; Rotilio, G. Benefits from dietary polyphenols for brain aging and alzheimer’s disease. Neurochem. Res., 2008, 33, 2390-2400. Forster, D. P.; Newens, A. J.; Kay, D. W.; Edwardson, J. A. Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. J. Epidemiol. Commun. Health., 1995, 49, 253-258. Chan, D. K.; Woo, J.; Ho, S. C.; Pang, C. P.; Law, L. K.; Ng, P. W.; Hung, W. T.; Kwok, T.; Hui, E.; Orr, K.; Leung, M. F.; Kay, R. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J. Neurol. Neurosurg. Psychiatry., 1998, 65, 781-784. Tan, E. K.; Tan, C.; Fook-Chong, S. M.; Lum, S. Y.; Chai, A.; Chung, H.; Shen, H.; Zhao, Y.; Teoh, M. L.; Yih, Y.; Pavanni, R.; Chandran, V. R.; Wong, M. C. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J. Neurol. Sci., 2003, 216, 163-167. Preux, P. M.; Condet, A.; Anglade, C.; Druet-Cabanac, M.; Debrock, C.; Macharia, W.; Couratier, P.; Boutros-Toni, F.; Dumas, M. Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France. Neuroepidemiology, 2000, 19, 333-7. Morano, A.; Jimenez-Jimenez, F. J.; Molina, J. A.; Antolin, M. A. Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain. Acta Neurol. Scand., 1994, 89, 164-170. Bilia, A. R. Ginkgo biloba L. Fitoterapia., 2002, 73, 276-279. Ahlemeyer, B.; Selke, D.; Schaper, C.; Klumpp, S.; Krieglstein, J. Ginkgolic acids induce neuronal death and activate protein phosphatase type-2C. Eur. J. Pharmacol., 2001, 430, 1-7. Chatterjee, S. S.; Kondratskaya, E. L.; Krishtal, O. A. Structure-activity studies with Ginkgo biloba extract constituents as receptor-gated chloride channel blockers and modulators. Pharmacopsychiatry, 2003, 36 Suppl 1, S68-77. Dajas, F.; Rivera-Megret, F.; Blasina, F.; Arredondo, F.; Abin-Carriquiry, J. A.; Costa, G.; Echeverry, C.; Lafon, L.; Heizen, H.; Ferreira, M.; Morquio, A. Neuroprotection by flavonoids. Braz. J. Med. Biol. Res., 2003, 36, 1613-1620. Bedir, E.; Tatli, II; Khan, R. A.; Zhao, J.; Takamatsu, S.; Walker, L. A.; Goldman, P.; Khan, I. A. Biologically active secondary metabolites from Ginkgo biloba. J. Agric. Food Chem., 2002, 50, 3150-3155. Kidd, P. M. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern. Med. Rev., 1999, 4, 144-161. Bridi, R.; Crossetti, F. P.; Steffen, V. M.; Henriques, A. T. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother. Res., 2001, 15, 449-451. Colak, O.; Sahin, A.; Alatas, O.; Inal, M.; Yasar, B.; Kiper, H. The effect of Ginkgo biloba on the activity of catalase and lipid peroxidation in experimental strangulation ileus. Int. J. Clin. Lab Res., 1998, 28, 6971. Marcocci, L.; Packer, L.; Droy-Lefaix, M. T.; Sekaki, A.; Gardes-Albert, M. Antioxidant action of Ginkgo biloba extract EGb 761. Methods Enzymol., 1994, 234, 462-475. Colciaghi, F.; Borroni, B.; Zimmermann, M.; Bellone, C.; Longhi, A.; Padovani, A.; Cattabeni, F.; Christen, Y.; Di Luca, M. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol. Dis., 2004, 16, 454-460.
54 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [141] [142] [143]
[144] [145] [146]
[147]
[148] [149]
[150] [151]
[152] [153] [154] [155]
[156] [157] [158]
[159] [160] [161] [162]
[163]
Shanmugam et al.
Smith, J. V.; Luo, Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J. Alzheimers Dis., 2003, 5, 287-300. Roth, A.; Schaffner, W.; Hertel, C. Phytoestrogen kaempferol (3,4',5,7-tetrahydroxyflavone) protects PC12 and T47D cells from beta-amyloid-induced toxicity. J. Neurosci. Res., 1999, 57, 399-404. Yang, S. F.; Wu, Q.; Sun, A. S.; Huang, X. N.; Shi, J. S. Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Pharmacol. Sin., 2001, 22, 1089-1093. Kim, M. S.; Lee, J. I.; Lee, W. Y.; Kim, S. E. Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson's disease. Phytother. Res., 2004, 18, 663-666. Kanowski, S.; Herrmann, W. M.; Stephan, K.; Wierich, W.; Horr, R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry, 1996, 29, 47-56. Andrieu, S.; Gillette, S.; Amouyal, K.; Nourhashemi, F.; Reynish, E.; Ousset, P. J.; Albarede, J. L.; Vellas, B.; Grandjean, H. Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J. Gerontol. A. Biol. Sci. Med. Sci., 2003, 58, 372-377. Cho, J.; Kang, J. S.; Long, P. H.; Jing, J.; Back, Y.; Chung, K. S. Antioxidant and memory enhancing effects of purple sweet potato anthocyanin and cordyceps mushroom extract. Arch. Pharm. Res., 2003, 26, 821-825. Galli, R. L.; Shukitt-Hale, B.; Youdim, K. A.; Joseph, J. A. Fruit polyphenolics and brain aging: nutritional interventions targeting age-related neuronal and behavioral deficits. Ann. NY Acad Sci., 2002, 959, 128-132. Forbes, J. M.; Thallas, V.; Thomas, M. C.; Founds, H. W.; Burns, W. C.; Jerums, G.; Cooper, M. E. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J., 2003, 17, 1762-1764. Anderson, J. W.; Johnstone, B. M.; Cook-Newell, M. E. Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med., 1995, 333, 276-282. Moriyama, T.; Kishimoto, K.; Nagai, K.; Urade, R.; Ogawa, T.; Utsumi, S.; Maruyama, N.; Maebuchi, M. Soybean BETA-conglycinin diet suppresses serum triglyceride levels in normal and genetically obese mice by induction of beta-oxidation, downregulation of fatty acid synthase, and inhibition of triglyceride absorption. Biosci. Biotechnol. Biochem., 2004, 68, 352-359. Anthony, M. S.; Clarkson, T. B.; Williams, J. K. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am. J. Clin. Nutr., 1998, 68, 1390S-1393. Setchell, K.; Adlercreutz, H. Mammalian lignans and phytoestrogens: recent studies on their formation, metabolism and biological role in health and disease. In: I.R. Rowland, Ed. Role of the gut flora, toxicity and cancer. Academic Press: London, 1988, pp. 315-345. Leclercq, G.; Heuson, J. C. Physiological and pharmacological effects of estrogens in breast cancer. Biochim. Et. Biophysi. Acta, 1979, 560, 427-455. Ma, D. F.; Qin, L. Q.; Wang, P. Y.; Katoh, R. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur. J. Clin. Nutr., 2008, 62, 155-161. Kim, H.; Peterson, T. G.; Barnes, S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr., 1998, 68, 1418S1425. Ingram, D.; Sanders, K.; Kolybaba, M.; Lopez, D. Case-control study of phyto-oestrogens and breast cancer. The Lancet, 1997, 350, 990-994. Nagata, Y.; Sonoda, T.; Mori, M.; Miyanaga, N.; Okumura, K.; Goto, K.; Naito, S.; Fujimoto, K.; Hirao, Y.; Takahashi, A.; Tsukamoto, T.; Akaza, H. Dietary isoflavones may protect against prostate cancer in japanese men. J. Nutr., 2007, 137, 1974-1979. Tham, D. M.; Gardner, C. D.; Haskell, W. L. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J. Clin. Endocrinol. Metab., 1998, 83, 22232235. Bang, O. Y.; Hong, H. S.; Kim, D. H.; Kim, H.; Boo, J. H.; Huh, K.; Mook-Jung, I. Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol. Dis., 2004, 16, 21-28. Zeng, H.; Chen, Q.; Zhao, B. Genistein ameliorates [beta]-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis. Free Radic. Biol. Med., 2004, 36, 180-188. Valles, S. L.; Dolz-Gaiton, P.; Gambini, J.; Borras, C.; Lloret, A.; Pallardo, F. V.; Vi; ntilde; a, J. Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes. Brain Res., 2010, 1312, 138-144. Vauzour, D.; Vafeiadou, K.; Rodriguez-Mateos, A.; Rendeiro, C.; Spencer, J. P. E. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr., 2008, 3, 115-126.
Mechanisms of Neuroprotection [164]
[165] [166] [167] [168] [169]
[170] [171]
[172] [173]
[174] [175] [176]
[177] [178]
[179] [180]
[181] [182] [183]
[184] [185] [186]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
55
Kim, H.; Xu, J.; Su, Y.; Xia, H.; Li, L.; Peterson, G.; Murphy-Ullrich, J.; Barnes, S. Actions of the soy phytoestrogen genistein in models of human chronic disease: potential involvement of transforming growth factor beta. Biochem. Soc.Trans., 2001, 29, 216-222. White, L. R.; Petrovitch, H.; Ross, G. W.; Masaki, K.; Hardman, J.; Nelson, J.; Davis, D.; Markesbery, W. Brain aging and midlife tofu consumption. J. Am. Coll. Nutr., 2000, 19, 242-255. Brzezinski, A.; Debi, A. Phytoestrogens: the ''natural'' selective estrogen receptor modulators? Eur. J. Obstet. Gynecol. Reprod.Biol., 1999, 85, 47-51. File, S.; Jarrett, N.; Fluck, E.; Duffy, R.; Casey, K.; Wiseman, H. Eating soya improves human memory. Psychopharmacology, 2001, 157, 430-436. File, S. E.; Hartley, D. E.; Elsabagh, S.; Duffy, R.; Wiseman, H. Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function. Menopause (New York, N.Y.), 2005, 12, 193-201. del Bano, M. J.; Lorente, J.; Castillo, J.; Benavente-Garcia, O.; del Rio, J. A.; Ortuno, A.; Quirin, K. W.; Gerard, D. Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of Rosmarinus officinalis: antioxidant activity. J. Agric.Food Chem., 2003, 51, 4247-4253. Farah, A.; Monteiro, M.; Donangelo, C. M.; Lafay, S. Chlorogenic acids from green coffee extract are highly bioavailable in humans. J. Nutr., 2008, 138, 2309-2315. Lee, D. H.; Ha, N.; Bu, Y. M.; Choi, H. I.; Park, Y. G.; Kim, Y. B.; Kim, M. Y.; Kim, H. Neuroprotective effect of Buddleja officinalis extract on transient middle cerebral artery occlusion in rats. Biol. Pharm. Bull., 2006, 29, 1608-1612. Watanabe, S.; Misawa, N.; Sakagami, H. DPPH radical scavenging activity of chlorogenic acid related compounds and their effects against mouse macrophage-like cells. Mem. Seitoku Jr. Coll. Nutr., 2003, 34, 7-12. Sánchez-Campillo, M.; Gabaldon, J. A.; Castillo, J.; Benavente-García, O.; Del Baño, M. J.; Alcaraz, M.; Vicente, V.; Alvarez, N.; Lozano, J. A. Rosmarinic acid, a photo-protective agent against UV and other ionizing radiations. Food Chem. Toxicol., 2009, 47, 386-392. Osakabe, N.; Takano, H.; Sanbongi, C.; Yasuda, A.; Yanagisawa, R.; Inoue, K. i.; Yoshikawa, T. Antiinflammatory and anti-allergic effect of rosmarinic acid (RA); inhibition of seasonal allergic rhinoconjunctivitis (SAR) and its mechanism. Biofactors, 2004, 21, 127-132. Pavlica, S.; Gebhardt, R. Protective effects of ellagic and chlorogenic acids against oxidative stress in PC12 cells. Free Radic Res,, 2005, 39, 1377-1390. Belkaid, A.; Currie, J.-C.; Desgagnés, J.; Annabi, B. The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression. Cancer Cell Int., 2006, 6, 7-7. Sul, D.; Kim, H.-S.; Lee, D.; Joo, S. S.; Hwang, K. W.; Park, S.-Y. Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. Life Sci., 2009, 84, 257-262. Iuvone, T.; De Filippis, D.; Esposito, G.; D'Amico, A.; Izzo, A. A. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid- peptide-induced neurotoxicity. J.Pharmacol. Exp. Ther., 2006, 317, 1143-1149. Li, Y.; Shi, W.; Li, Y.; Zhou, Y.; Hu, X.; Song, C.; Ma, H.; Wang, C.; Li, Y. Neuroprotective effects of chlorogenic acid against apoptosis of PC12 cells induced by methylmercury. Environ. Toxicol. Pharmacol., 2008, 26, 13-21. Alkam, T.; Nitta, A.; Mizoguchi, H.; Itoh, A.; Nabeshima, T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by A[beta]25-35. Behav. Brain Res., 2007, 180, 139-145. Perry, E. K.; Pickering, A. T.; Wang, W. W.; Houghton†, J.; P; Perry, N. S. L. Medicinal Plants and Alzheimer's Disease: from ethnobotany to phytotherapy. J. Pharm. Pharmacol., 1999, 51, 527-534. Kennedy, D. O.; Scholey, A. B.; Tildesley, N. T. J.; Perry, E. K.; Wesnes, K. A. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol. Biochem. Behav., 2002, 72, 953-964. Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A. H.; Khani, M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J. Clin. Pharm. Ther., 2003, 28, 53-59. Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.; Khani, M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J. Neurol. Neusurg. Psychiatry., 2003, 74, 863-866. Fremont, L. Biological effects of resveratrol. Life Sci., 2000, 66, 663-673. Savaskan, E.; Olivieri, G.; Meier, F.; Seifritz, E.; Wirz-Justice, A.; Muller-Spahn, F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology, 2003, 49, 380-383.
56 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [187] [188] [189]
[190] [191] [192] [193] [194]
[195] [196] [197]
[198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213]
Shanmugam et al.
Sun, W. G.; Liao, H. L.; Huang, Z. S. Intervention effect of Chinese herbal medicine on changes of immune system in senile dementia. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2001, 21, 716-718. Chanvitayapongs, S.; Draczynska-Lusiak, B.; Sun, A. Y. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport, 1997, 8, 1499-1502. Orgogozo, J. M.; Dartigues, J. F.; Lafont, S.; Letenneur, L.; Commenges, D.; Salamon, R.; Renaud, S.; Breteler, M. B. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev. Neurol. (Paris), 1997, 153, 185-192. Luchsinger, J. A.; Tang, M. X.; Siddiqui, M.; Shea, S.; Mayeux, R. Alcohol intake and risk of dementia. J. Am. Geriatr. Soc., 2004, 52, 540-546. Juhn, M. S.; Tarnopolsky, M. Oral creatine supplementation and athletic performance: a critical review. Clin J Sport Med, 1998, 8, 286-97. Tarnopolsky, M. A.; Beal, M. F. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol., 2001, 49, 561-574. Bottomley, P. A.; Cousins, J. P.; Pendrey, D. L.; Wagle, W. A.; Hardy, C. J.; Eames, F. A.; McCaffrey, R. J.; Thompson, D. A. Alzheimer dementia: quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy. Radiology, 1992, 183, 695-699. Brdiczka, D.; Beutner, G.; Ruck, A.; Dolder, M.; Wallimann, T. The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition. Biofactors, 1998, 8, 235-242. O'Gorman, E.; Beutner, G.; Dolder, M.; Koretsky, A. P.; Brdiczka, D.; Wallimann, T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett., 1997, 414, 253-257. Pulido, S. M.; Passaquin, A. C.; Leijendekker, W. J.; Challet, C.; Wallimann, T.; Ruegg, U. T. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett., 1998, 439, 357-362. Koufen, P.; Ruck, A.; Brdiczka, D.; Wendt, S.; Wallimann, T.; Stark, G. Free radical-induced inactivation of creatine kinase: influence on the octameric and dimeric states of the mitochondrial enzyme (Mib-CK). Biochem. J., 1999, 344 Pt 2, 413-417. Brewer, G. J.; Wallimann, T. W. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J. Neurochem., 2000, 74, 1968-1978. De Grauw, T. J.; Cecil, K. M.; Byars, A. W.; Salomons, G. S.; Ball, W. S.; Jakobs, C. The clinical syndrome of creatine transporter deficiency. Mol. Cell Biochem., 2003, 244, 45-48. Pettegrew, J. W.; Panchalingam, K.; Klunk, W. E.; McClure, R. J.; Muenz, L. R. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging, 1994, 15, 117-132. Beal, M. F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol., 1992, 31, 119-130. Desagher, S.; Glowinski, J.; Premont, J. Pyruvate protects neurons against hydrogen peroxide-induced toxicity. J Neurosci, 1997, 17, 9060-7. Poole, R. C.; Halestrap, A. P. Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am. J.Physiol., 1993, 264, C761-782. Garcia, C. K.; Goldstein, J. L.; Pathak, R. K.; Anderson, R. G.; Brown, M. S. Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: implications for the Cori cycle. Cell, 1994, 76, 865-873. Nedergaard, M.; Goldman, S. A. Carrier-mediated transport of lactic acid in cultured neurons and astrocytes. Am. J. Physiol., 1993, 265, R282-289. Areosa, S. A.; Sherriff, F. Memantine for dementia. Cochrane Database Syst. Rev., 2003, CD003154. Bakker, E. P.; van Dam, K. The movement of monocarboxylic acids across phospholipid membranes: evidence for an exchange diffusion between pyruvate and other monocarboxylate ions. Biochim. Biophys. Acta., 1974, 339, 285-289. Maus, M.; Marin, P.; Israel, M.; Glowinski, J.; Premont, J. Pyruvate and lactate protect striatal neurons against N-methyl-D-aspartate-induced neurotoxicity. Eur. J. Neurosci., 1999, 11, 3215-3224. Pellerin, L.; Magistretti, P. J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad Sci. USA., 1994, 91, 10625-10629. Tsacopoulos, M.; Magistretti, P. J. Metabolic coupling between glia and neurons. J. Neurosci., 1996, 16, 877-885. Oldendorf, W. H. Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids. Am. J. Physiol., 1973, 224, 1450-1453. Kato, T. Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801. Nippon Yakurigaku Zasshi, 2004, 124, 145-151. Medvedev, I. O.; Malyshkin, A. A.; Belozertseva, I. V.; Sukhotina, I. A.; Sevostianova, N. Y.; Aliev, K.; Zvartau, E. E.; Parsons, C. G.; Danysz, W.; Bespalov, A. Y. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology, 2004, 47, 175-183.
Mechanisms of Neuroprotection [214] [215] [216] [217] [218]
[219] [220]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
57
Stone, T. W. Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin. Investig. Drugs, 2001, 10, 633-645. Miguel-Hidalgo, J. J.; Alvarez, X. A.; Cacabelos, R.; Quack, G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res., 2002, 958, 210-221. Kucheryanu, V. G.; Kryzhanovskii, G. N. Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Bull Exp. Biol. Med., 2000, 130, 629-632. Reisberg, B.; Doody, R.; Stoffler, A.; Schmitt, F.; Ferris, S.; Mobius, H. J. Memantine in moderate-tosevere Alzheimer's disease. N. Engl. J. Med., 2003, 348, 1333-1341. Winblad, B.; Poritis, N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry., 1999, 14, 135-146. Rabey, J. M.; Nissipeanu, P.; Korczyn, A. D. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural. Transm. Parkinson Dis. Dement. Sect., 1992, 4, 277-282. Lokk, J. Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure. Lakartidningen, 2004, 101, 2003-2006.
58
Frontiers in Medicinal Chemistry, 2010, 5, 58-80
Improving Memory: A Role for Phosphodiesterases Arjan Blokland1,*, Rudy Schreiber2 and Jos Prickaerts3 1
Department of Psychology and Neuroscience, EURON, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands; 2Sepracor, Inc., 84 Waterford Drive, Marlborough MA, 01752, USA; 3Department of Psychiatry and Neuropsychology, Brain & Behavior Institute, EURON, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands Abstract: During the last decennia, our understanding of the neurobiological processes underlying learning and memory has continuously improved, leading to the identification of targets for the development of memory-enhancing drugs. Here we review a class of drugs which has more recently been identified: the phosphodiesterase (PDE) inhibitors. An overview is given of the different PDEs that are known and we focus on three PDEs which have been identified as possible relevant targets for memory improvement: PDE2, PDE4 and PDE5. PDEs differ in the substrate, i.e. cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP), being hydrolyzed. Since these cyclic nucleotides have been suggested to play distinct roles in processes of memory, selective PDE inhibitors preventing the breakdown of cAMP and/or cGMP could improve memory. The present data suggest that PDE4 (cAMP) is involved in acquisition processes, although a possible role in late consolidation processes cannot be excluded. PDE5 (cGMP) is involved in early consolidation processes. Since PDE2 inhibition affects both cAMP and cGMP, PDE2 inhibitors may improve both memory processes. The field of PDEs is highly dynamic and new isoforms of PDEs are still being described. This may lead to the discovery and development of new memory enhancing drugs that selectively inhibit such isoforms. Such drugs may exert their effects only in specific brain areas and hence possess an improved side effect profile.
Keywords: cGMP, cAMP, consolidation, long-term potentiation, cognition enhancer. INTRODUCTION Although memories are always available, it is well known that the ability to recall information from memory is dependent on several factors [1]. For example, the memory for acquired information is better if the context in which the information has been learned is the same as the context in which the memory has to be retrieved (state-dependent learning). Also, the ability to store or retrieve information seems to be dependent on the time of day. This time-of-day effect may be related to circadian rhythms of various biological factors. *Corresponding author: Tel: (31) 43 3881903; Fax: (31) 43 3884125; E-mail:
[email protected] Allen B. Reitz / Atta-ur-Rahman / M. Iqbal Choudhary (Eds.) All rights reserved – © 2010 Bentham Science Publishers.
Improving Memory
Frontiers in Medicinal Chemistry, 2010, Vol. 5
59
Besides these intra-individual differences, there are also great inter-individual differences in the memory performance. Some people can easily and quickly remember ten pages of a complex biochemistry chapter, whereas others need at least ten hours to learn just one page. However, the person who faces difficulties with biochemistry may be much better in remembering the lyrics of a song than a good biochemistry student. Thus, memory as such does not seem to be a stable phenomenon but the performance may fluctuate under influence of various intra- and inter-individual factors under normal physiological conditions. Until now, numerous biological factors have been identified which mediate the memory performance. Neurotransmitters, neuromodulators, intracellular molecules, hormones, plant extracts and nutritional ingredients all improve or impair the memory performance under specific conditions [2-8]. Psychopharmacological, and especially animal experiments, have provided valuable insights into the role of different biological mechanisms that underlie memory functions and the discovery and development of cognitive-enhancing drugs. However, more work is needed to understand the relationship between specific memory functions and the specificity of the biological mechanisms underlying these functions. This information becomes even more relevant considering the impairments in memory functions in aging and pathological conditions. With respect to aging, the relative and total number of aged people will increase considerably in the next decades, which will lead to an increase in the complaints these people are facing. Aside from many other bodily dysfunctions, impairments in memory have a strong negative impact on the daily activities and quality of life of aged people. The loss of cognitive functions is even more serious in pathological conditions like (Alzheimer’s) dementia. But also in depressed and schizophrenic patients prominent memory deficits are present [9, 10] . Cleary, there is a high need for drugs that counteract conditions in which the memory performance is deteriorated. The aim of this paper is twofold: first, to provide a more general overview of memory and the drugs that have been shown to improve performance. A second aim is to review the effects of specific PDE inhibitors on long-term potentiation, a measure of synaptic plasticity and a proposed neurophysiological substrate of memory, and to evaluate their effects on memory functions. MEMORY SYSTEMS As mentioned before, memory is not a static entity. On top of that, there is ample evidence that memory should not be seen as one entity but that it comprises several (sub)systems [11]. In Fig. (1) a schematic representation of the temporal aspects and memory structures is presented. A first dimension in memory systems is the temporal aspect. Neuropsychological studies have provided strong evidence for the existence of a short-term and a long-term memory storage. This short-term storage has also been referred to as the working memory [12]. It has also been proposed that new information first has to be acquired. This stage has been related to the working memory and attention processes. Subsequently, the new memory is stored and it has been suggested that there are two stages of storing new information. This has been referred to as an early consolidation and a late consolidation phase [13, 14]. Both phases are required to store new information in the long-term memory. The long-term memory can be further divided into a procedural and declarative memory system. The latter can be subdivided into a declarative and nondeclarative system. An important note to make is that the memory needs to be retrieved from memory before it can be assured that the new information was stored. This suggests that if a memory cannot
60 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Blokland et al.
be recalled this indicates that the memory has not been stored or that the information cannot be retrieved. These two possibilities should always be considered before drawing conclusions in case a subject cannot recall information.
A Information
Early/Late Consolidation Sensory Store (0.5 – 3 s)
Attention
STM/WM (10 – 15 s)
Retrieval
LTM (15 s and longer)
Rehearsal
B Working memory
Visual Sketch Pad
Central Executive
Phonological Loop
Long-Term Memory
Declarative
Episodic
Non-Declarative
Semantic
Fig. (1). Aspects of the memory systems: A) temporal features. Forgetting can occur in the STM/WM due to not attending to the new information. Forgetting can also occur in the LTM. B) Structure of memory. The working memory, according to Baddeley (2003) is composed of two parallel systems which are supervised by the Central Executive. The long-term memory can be divided in different subsystems. The declarative memory system represents facts of a subject and the non-declarative system hold information about skills. The episodic memory is information that is unique for each individual subject whereas the semantic memory is information of general knowledge. STM: Short-term memory; WM: Working memory; LTM: Long-term memory.
The ability of subjects to store information in one of the abovementioned subsystems (temporal aspects and memory systems, see Fig. 1) also seems to depend on the type of memory that has to be stored. Thus, the memory for visual information seems to be different from the memory for spatial, verbal, and emotional information. Taken all these factors into account, memory can be considered as a mosaic pattern having temporal-, memory type-, and modality type-like dimensions.
Improving Memory
Frontiers in Medicinal Chemistry, 2010, Vol. 5
61
NEUROBIOLOGY OF MEMORY There is ample evidence that memory functions are modulated by biological mechanisms and a key question is what might be the best manner to improve memory performance without adverse drug effects. Various classes of drugs improve memory functions in man, and in animal studies the number of drugs with cognition-enhancing properties is even greater. Most of these effects have been observed in different models. One of these models evaluates the effects of drugs in aged subjects suffering from cognitive deficits. Other models involve drug-induced memory impairments, of which amnesia induced by the muscarinic antagonist scopolamine is the best known [15, 16]. But also acute depletion of the precursor for serotonin, tryptophan, and treatment with the glutamatergic antagonist, ketamine, have been used to induce memory impairments in humans [17-19] and animals [20, 21]. There are additional memory deficit models available in animal research. For example, lesions of brain structures that are affected by neurodegenerative diseases can be modeled in animals [2225]. Finally, genetic models have been developed that mimic the pathological stages in Alzheimer’s disease [26, 27]. Each of these models assumes a specific neurobiological deficit underlying the memory impairment in a disease [28-30]. A prominent example is the scopolamine model, which assumes that cognitive deficits in dementia are primarily related to a cholinergic deficit [31]. Role of Neurotransmitters Various neurotransmitters have been implicated in processes of learning and memory. Acetylcholine has received a lot of attention since the early eighties, mainly based on the observation that dementia was associated with a reduction in cholinergic markers related to impairments in cognitive functions in dementia [32]. Triggered by these findings, drugs have been developed which enhance the cholinergic neurotransmission: acetylcholinesterase inhibitors and nicotinic agonists. Acetylcholinesterase inhibitors block the enzyme that breaks down acetylcholine in the synaptic cleft and are marketed to improve cognitive functions in mild to moderate Alzheimer’s disease [33, 34]. It is well known that nicotine improves cognitive functions in man [35, 36]. But both acetylcholinesterase inhibitors and nicotine possess peripheral side effects which hamper their clinical use. Preclinical studies attempted to find drugs that possess a more central mechanism of action to prevent these undesirable side effects. Recently, drugs have been developed that bind to a specific subtype of the nicotine receptors and which appear to have less side effects than nicotine [37]. These drugs have a very promising profile for cognition-enhancement in animal studies [38-40]. Nevertheless, at present no nicotinic treatments are available for humans suggesting that this is not a very successful approach yet. But also other neurotransmitters have been implicated in cognitive functions. In general, for each neurotransmitter studies can be found which support its involvement in memory [41]. However, the effects can, at least to some extent, be differentiated with regards to the specific aspects of cognition which these neurotransmitters affect. Several reviews are available in which these topics are dealt with [2, 8, 42-45]. Noteworthy is that the most widely used drug in the world, caffeine, also has shown to improve memory functions in man [46]. This effect has been linked to the activation of the adenosine receptors. Role of Other Biochemical Mechanisms Glucose improves memory functions consistently in animals and human. Although some evidence supports a peripheral mechanism of action, the exact mechanism still needs to be resolved [7].
62 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Blokland et al.
Hormones also modulate memory performance [47], especially ACTH and corticosterone. These stress hormones are particularly involved in emotional memories [48] and related to the age-related decline in memory functions [49]. Finally, there are various plant extracts that have been claimed to improve memory functions, of which the most well known is Ginkgo Biloba [50]. PHOSPHODIESTERASE INHIBITORS PDEs and LTP In addition to the drugs which improve memory performance involving the mechanisms mentioned in the previous section, there is accumulating evidence that inhibition of PDE activity may consist of a particular interesting mechanism for memory enhancement [14, 5153]. This is related to the substrates of PDEs, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both cyclic nucleotides play an important role in intracellular signaling [54-56], and in processes of neuroplasticity such long term potentiation (LTP). Importantly, in contrast with current cognitive-enhancing drugs, which target single neurotransmitter systems, drugs which intervene with second messenger systems modulate multiple biochemical systems and may therefore offer superior efficacy in the treatment of cognitive disorders. LTP in the hippocampus, a pivotal brain structure for memory consolidation, is considered as a neurophysiological correlate of learning and memory [57]. Briefly, a short-lasting (<1 s) stimulation of the perforant path towards the CA1 stratum radiatum of the hippocampus induces long-lasting (hours to days) effects on synaptic connectivity of neurons in the hippocampus. It is assumed that this long-lasting change in the connectivity between neurons may represent the synaptic plasticity underlying formation of new networks for new memories. Since the discovery of LTP, a vast amount of studies has accumulated in which the molecular mechanisms underlying LTP have been investigated [58-60]. The insights which were gained from these studies provided molecular tools to improve LTP and subsequently memory. Among the various molecules that are involved in LTP, cAMP and cGMP seem to play an important role. A simplified diagram of the processes involved in LTP is presented in Fig. (2), and highlights the presumed role of cAMP and cGMP. Generally, it is postulated that increased levels of cAMP and cGMP would enhance the processes that maintain LTP and thereby augment synaptic plasticity [61-64]. This is the basic principle for the possible mechanism for the use of PDEs in treating memory dysfunctions [see 65]. Based on the electrophysiological properties of LTP, at least two types of LTP have been described: early phase LTP (E-LTP), induced by relative weak electrical stimulation, and late phase LTP (L-LTP), induced by high electrical stimulation. [62, 64, 66, 67]. Below, we will describe the separate contributions of cAMP and cGMP to these types of LTP. However, it is beyond the scope of this review to discuss in detail the pre- and postsynaptic changes resulting in the expression of E- and L-LTP [for discussion, see 14, 68] Postsynaptic, cAMP/protein kinase A (PKA) signaling is not required for the expression of E-LTP [68], but the presynaptic cGMP/protein kinase G (PKG) pathway is involved in E-LTP in the CA1 stratum radiatum [69-71]. The duration of E-LTP is less than 3 h and E-LTP is not dependent on gene expression and protein synthesis. The time-window of E-LTP corresponds with the duration of short-term memory (STM) as defined by some researchers, i.e., as a form of memory which does not require gene expression and protein synthesis [42].
Improving Memory
Frontiers in Medicinal Chemistry, 2010, Vol. 5
63
Post-synaptic
Pre-synaptic Glutamate Ca2+
cGMP sGC
NOS
cAMP cGMP sGC
CaM
Protein synthesis
NO
Fig. (2). Simplified diagram of molecules involved in long-term potentiation (LTP). After the release of glutamate from the presynaptic neuron, it binds to AMPA and NMDA receptors. If the signal is strong enough, calcium (Ca2+) will enter the post-synaptic neuron through the NMDA receptor and activates calmodulin (CaM) which in turn stimulates adenylate cyclase (AC). Subsequently, cAMP is synthesized. Besides activation of CaM, Ca2+ activates constitutive nitric oxide synthase (NOS). After activation of NOS the gaseous molecule nitric oxide (NO) is formed, and can have a dual action. First, NO can diffuse back to the pre-synaptic region and activate soluble guanylate cyclase (sGC). cGC increases cGMP levels which in turn can potentiate the release of glutamate. A second action of NO is the activation of sGC postsynaptically. This can also lead to protein synthesis. These phenomena, including other molecular events, are generally assumed to underlie LTP. PDEs break down cGMP and camp. Selective PDE inhibitors can therefore increase cGMP levels pre-synaptically and/or increase cAMP and cGMP levels post-synaptically.
In the CA1 stratum radiatum, a postsynaptic cAMP/ PKA/cAMP responsive element binding protein (CREB) pathway, a postsynaptic cGMP/PKG pathway, and a postsynaptic cGMP/PKG/CREB pathway are involved in L-LTP [61, 72, 73]. In contrast to E-LTP, LLTP lasts longer than 3 h and may therefore be a candidate for long-term memory (LTM) processes. Taken together, although there is some debate with regard to the exact localization of signaling pathways for both types of LTP in hippocampal neurons, it is assumed that the molecular pathways underlying E-LTP processes are located pre-synaptically. Inspection of Fig. (2) shows that the retrograde NO signal that activates sGC/cGMP presynaptically is likely to underlie E-LTP. Conversely, the postsynaptic cAMP/protein kinase A (PKA) signaling pathway is more likely to be involved in L-LTP. Since E-LTP and L-LTP may represent non-structural and structural changes in neuronal connections, respectively, it is tempting to relate E-LTP to short-term/working memory and L-LTP to long-term memory. Finally, some evidence supports a role for cGMP in L-LTP via a postsynaptic cGMP/PKG/CREB pathway [74]. However, it is beyond the scope of this review to discuss these dual effects of cGMP (see Fig. (2) for pathways). PDEs and Memory The family of cyclic nucleotide PDEs is large, and eleven different isozymes have been identified at present [75, 76]. An overview of these PDEs and some of their characteristics are listed in Table 1. PDE6 and PDE11 appear not relevant targets for memory functions since these enzymes are not present in the brain. Conversely, inhibitors of the other PDEs are expected to increase cAMP and/or cGMP levels in neurons and hence might improve
64 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Blokland et al.
memory. Since the hippocampus is the main structure where LTP and memory are closely linked, localization of PDEs in this region is consistent with a potential role in processes of learning and memory. It should be mentioned that LTP is classically related to hippocampal synaptic plasticity, but LTP (and Long-Term Depression, LTD) has also been recorded in other brain regions, including cortical areas [77, 78]. Therefore, relative specificity of the localization of PDE enzymes in hippocampus and/or cortex could be considered as a criterion for selecting a PDE as a drug target. Table 1.
Type
Overview and Properties of Known Enzymes of the Cyclic Nucleotide Phosphodiesterases
Number of
Localization
Description
Substrate
Genes PDE1
3
Selective Inhibitors
brain, heart, smooth
Ca2+ -CaM
muscle
stimulated
cAMP/cGMP
IBMX, calimidazolium, phenethiazines, vinpocetine, SCH51866
PDE2
PDE3
1
2
brain, heart, adrenal
cGMP
cortex
stimulated
brain, heart, smooth
cGMP inhibited
cAMP/cGMP
aptosyn cAMP
muscle, adipose platelets PDE4
4
ubiquitous
EHNA, Bay 60-7550,
cilostamide, milrinone, SK&F 95654
cAMP specific
cAMP
rolipram, rofluminast, Ariflo, HT0712, ibudilast, mesembrine
PDE5
1
brain, lung, platelets,
cGMP specific
cGMP
smooth muscle
zaprinast, sildenafil, vardenafil, tadelafil, SK&F 96231, udenafil, avanafil, SK&F 96231
PDE6
4
rod and cones photo
Photoreceptor
cGMP
(sildenafil)
brain, skeletal muscle,
cAMP high
cAMP
BRL 50481
kidney, T-cells,
affinity
cAMP
?
cGMP
SCH 81566, BAY 73-6691
receptor PDE7
2
liver, testis PDE8
2
brain, liver, testis, ovary
cAMP high affinity
PDE9
1
brain, kidney
cGMP high affinity
PDE10
1
PDE11
1
brain, testis
cAMP-inhibited
cGMP
Papaverine, TP-10, PQ10
skeletal muscle, kidney,
Dual substrate
cAMP/cGMP
(tadelafil)
liver, pituitary Note that the list of tissues in the localization column is not exhaustive.
Improving Memory
Frontiers in Medicinal Chemistry, 2010, Vol. 5
65
As depicted in Tables 1 and 2, PDE1-PDE5 and PDE7-PDE10 enzymes are located in the brain. Inhibition of these enzymes could therefore be considered as a means for improving brain functions. As mentioned above, the hippocampus and the cortex are considered to be the most relevant sites involved in cognitive functions. In Table 2, an overview is given of the localization of different PDEs, and their splice variants, in different brain regions. For a possible target for cognition, high expression in other organs, or high expression in many other brain areas is not preferable. At present a number of studies showed effects of selective PDE inhibitors on memory performance. These include inhibitors of PDE2, PDE4, PDE5 and PDE9. Table 2.
Localization of Different Types of PDEs (Including their Isoforms) in Cortex, Hippocampus and Other Brain Regions. Note that this Table does not Provide Information with Respect to the Level of Expression of the Different PDEs in the Brain
PDE
Cortex
Hippocampus
PDE1
+
+
Rest of Brain thalamus, cerebellum, olfactory bulb, nucleus accumbens, striatum
Species
Reference
rat
[122-124]
mouse human
PDE1B
+
+
olfactory bulb, striatum
mouse
[125]
PDE1B1
-
-
striatum
mouse
[126]
PDE1C
+
+
cerebellum, amygdala
mouse
[127]
PDE2
+
+
forebrain, midbrain, amygdala
rat
[128-131]
PDE3
+
+
throughout brain
rat
[95, 131]
PDE4
+
+
throughout brain
rat
[131, 132]
mouse PDE4A
+
+
olfactory bulb
mouse
[132]
PDE4B
+
+
striatum, hypothalamus, midbrain, cerebellum
mouse
[132]
PDE4D
+
+
hypothalamus, midbrain, cerebellum
mouse
[132]
PDE5
+
+
cerebellum
rat
[129]
mouse PDE7A
+
+
olfactory bulb, cerebellum
PDE7B
-
+
striatum, midbrain
rat
[134]
PDE8B
+
+
olfactory bulb, midbrain
rat
[135]
PDE9A
+
+
rat
[129, 136]
striatum, cerebellum, olfactory bulb, amygdala, midbrain
PDE10
+
+
striatum, cerebellum, substantia nigra
[133]
mouse rat
[137]
66 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Blokland et al.
These PDEs differ in their substrate (see Table 1). The specific substrate for PDE4 is cAMP. The substrates for PDE5 and PDE9 inhibitors appear to be cGMP. Finally, both cAMP and cGMP are substrates for PDE2. Studies with cAMP and cGMP analogs support a role for these cyclic nucleotides in memory formation (see below). ROLE OF CAMP AND CGMP IN MEMORY cAMP The effects of direct manipulations of brain cAMP levels have only sporadically been investigated, i.e. to our knowledge there are only few one-trial learning studies with intrahippocampal injections of cAMP analogues. With respect to STM/WM it seems that cAMP/PKA signaling is probably not involved as demonstrated with manipulations downstream of cAMP, i.e. affecting the PKA/CREB pathway, did not impair STM [42], but this appears to be dependent on the memory performance tested [79]. In the passive avoidance task, post-training bilateral intrahippocampal injections of 8bromo-cAMP (1.25 μg/side) enhanced retention performance of rats 24 h after training when given 3 h after training, but not immediately after training [80, 81]. The latter was also found in the object recognition task [82]. Furthermore, rats submitted to the passive avoidance task showed an increase in the amount of cAMP in the hippocampus at 3 h after training, but not immediately after training [80, 81]. Thus, it can be argued that hippocampal cAMP is only involved in late consolidation processes of LTM. cGMP Studies on the injections of cGMP or its analogues into the brain and its effect on memory are also scarce. In rats, bilateral cGMP (10 μg/side) or 8-bromo-cGMP (1.25 μg/side) injection into the hippocampus immediately after training improved passive avoidance retention 24 h later [80, 83]. Likewise, when 8-bromo-cGMP (10 μg/side) was bilaterally injected into the hippocampus immediately after object recognition training, it improved retention performance 24 h later [82]. However, bilateral intrahippocampal injections of 8-bromo-cGMP (1.25 μg/side) had no effect on the retention of passive avoidance performance 24 h after training when given 3 h after training [80]. Furthermore, rats tested in a passive avoidance task showed an increase in the amount of cGMP in the hippocampus only at 0 and 30 min after training [80, 81]. Thus, it appears that cGMP in the hippocampus is involved in early consolidation processes of object and shock information into LTM. Conversely, late consolidation processes appear to be independent of cGMP. EFFECTS OF SPECIFIC PDE INHIBITORS ON MEMORY PDE2 Inhibitors PDE2 hydrolyzes both cAMP and cGMP. At present, only a few studies have been published in which PDE2 inhibitors have been tested in behavioral assays. This is primarily related to lack of specific PDE2 inhibitors. Some studies have investigated the effects of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) on behavior. For example, in one study EHNA was injected intracerebroventricularly and the effects on avoidance learning in rats was measured [84]. The results suggested that the performance of these rats was impaired after EHNA treatment. Although this finding does not support the notion that PDE2 inhibition should be able to improve memory performance, it should be noted that EHNA is also a potent adenosine deaminase inhibitor [e.g. 85]. Consequently, the use of EHNA may not be suitable to test the specific effects of PDE2 inhibition.
Improving Memory
Frontiers in Medicinal Chemistry, 2010, Vol. 5
67
To our knowledge, Bay 60-7550 is the only selective PDE2 inhibitor which has been tested in learning and memory models [86-88]. In vitro experiments showed that this compound increases both cAMP and cGMP levels in cortical neurons and hippocampal fibers (especially in the perforant path), and improved the memory performance of rats in different memory tests [86]. These findings were replicated in further studies and showed that PDE inhibition improved both early- and late-phase consolidation [87, 88]. Effects on STM/WM and LTM Different behavioral tests were used to characterize the effects of Bay 60-7550 on memory performance [86]. At a dose of 3 mg/kg (p.o.) Bay 60-7550 reversed the spatial WM deficit in a T-maze induced by the NMDA antagonist dizocilpine (MK-801) (0.04 mg/kg, i.p.). When given immediately after training in tasks of object or social recognition, Bay 60-7550 improved object recognition in both rats (1 and 3 mg/kg, p.o.) and mice (0.3 and 1 mg/kg, p.o). Likewise, social recognition was improved in rats (1 and 3 mg/kg, p.o.) as well as mice (0.6, 2 and 6 mg/kg, p.o.). These effects of BAY 60-7550 on consolidation processes may be mainly mediated by cGMP and not cAMP, since cGMP, but not cAMP, injections into the hippocampus immediately after training improved LTM in tasks of object recognition and passive avoidance learning. PDE4 Inhibitors Ample evidence supports a role for the cAMP/PKA/CREB pathway in learning and memory processes [89, 90]. PDE4 inhibitors specifically increase cAMP levels and the underlying mechanism for their cognitive-enhancing effects may involve modulation of activity within the cAMP/PKA/CREB pathway [91, 92]. The prototypical PDE4 inhibitor most widely used in cognition studies is rolipram (Table 3). It possesses good brain penetration and a half-life of 1-3 h [93] and in vitro studies showed that cAMP levels increased in hippocampal slices treated with rolipram [94, 95]. One of the perceived liabilities of rolipram is emesis, and second generation PDE4 inhibitors such as cilomilast (Ariflo) and roflumilast are thought to be less emetic. But these newer PDE4 inhibitors have been developed for peripheral indications, such as respiratory disorders, and so far no data have been published regarding their activity in cognition models. Herein, we review the cognition literature with PDE4 inhibitors and what aspects of memory systems are predominantly modulated (Table 3). Effects on STM/WM Rolipram and HT0712, both given before the training trial, had no effect on STM performance of mice in the object recognition task and contextual fear conditioning [94, 96]. The latter is in agreement with the assumption that cAMP is generally not involved in STM (see previous sections), although it must be realized that it is generally difficult to improve STM/WM in unimpaired animals due to a high level of baseline performance (‘ceiling effect’). Indeed, employing a cholinergic deficiency model in rodents treated with the muscarinic antagonist scopolamine, rolipram attenuated deficits in spatial and non-spatial STM and WM in several behavioral tasks [52, 53, 91]. Rolipram reversed the disruption in reference memory and/or working memory by the glutamate antagonist MK-801 in a radial-arm maze, and reversed the effects of MK-801 in a passive avoidance task [97]. The underlying mechanisms for these effects on STM/WM are not well understood. However, several neurotransmitters involved in learning and STM/WM processes use cAMP as a second
68 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Table 3.
Blokland et al.
Effects of PDE4 Inhibitors on Learning and Memory Processes
Task
Model
(Memory Process)
(Species)
Treatment
Results
Reference
Object recognition (episodic-like memory,
Scopolamine and time-
Rolipram (0.01-0.1 mg/kg in
MED in scopolamine
[138]
dependent deficit (rat)
time dependent forgetting;
model: 0.1 mg/kg
hippocampus and
0.03-0.3 mg/kg in
MED in time-dependent
rhinal cortex dependent
scopolamine model)
forgetting: 0.03 mg/kg
Rolipram (0.01-0.1 mg/kg)
MED 0.1 mg/kg
[139]
Time dependent
Rolipram (0.03 mg/kg), 0, 1,
Rolipram effective when
[87]
forgetting
3, 6 h after first trial
given 3 h after first trial
Object-Place recogni-
Time dependent
Rolipram (0.03 mg/kg) 3 h
Rolipram effective when
tion (episodic-spatial
forgetting
after first trial
given 3 h after first trial
Morris water maze
Microsphere embolism-
Rolipram 3 mg/kg, ip, 10
Rolipram attenuates
(spatial, hippocampus-
induced cerebral
days, after embolism
acquisition deficit
dependent)
ischaemia
Actute tryptophan depletion (5-HT deficit) (rat)
[88]
memory, hippocampus dependent) [92]
measured at days 7-9
(rat) Normal forgetting
L-454,560 (0.1-1 mg/kg)
MED 0.3 mg/kg
[140]
Radial arm water maze
APP-PS1 Alzheimer
Rolipram 0.1 uM/kg for 3
Improvement when
[101]
(spatial, hippocampus
(mouse)
weeks
tested at 2 months after
Delayed-matching to position in water maze (spatial, hippocampusdependent)
dependent)
3-week treatment
Barnes circular maze
Age-deficit
Rolipram 0.016 mg/kg, ip,
More mice acquire the
(Spatial, hippocampus-
(18 months old mouse)
40 min before training
task and number of
dependent)
[141]
errors is reduced
Radial arm maze
Scopolamine
Rolipram 0.01 – 1 mg/kg, ip,
MED: 0.1 (working
(working & reference
0.5/1.0mg/kg, ip,
45 min before test
memory) and >0.1
memory, hippocampus-
30 min before test
mg/kg (reference
dependent)
(rat)
memory)
Scopolamine 0.5 mg/kg
(±)-Rolipram
MED (working
ip, 30 min before test
0.01 – 1 mg/kg, po
memory):
(rat)
(-)-rolipram
(±)-rolipram 0.02 mg/kg
0.005-1mg/kg, po
(-)-rolipram 0.01 and 0.2
(+)-rolipram
mg/kg (biphasic)
(0.1-50 mg/kg, po)
(+)-rolipram 20/50 mg/kg
[53]
[52]
Improving Memory
Frontiers in Medicinal Chemistry, 2010, Vol. 5
69
Table 3. contd….
Task
Model
(Memory Process)
(Species)
Treatment
Results
Reference
Dizocilpine 0.l mg/kg,
Rolipram 0.01 – 0.1 mg/kg,
MED: 0.05 (working
[99]
ip, 60 min before test
ip, 30 min before test
memory) and 0.1 mg/kg
(rat)
(reference memory)
MEK inhibitor UO126,
Rolipram, 0.05, 0.1, mg/kg,
MED: 0.1 mg/kg
8ug/rat into
ip, 30 min before test
(reference memory)
[142]
hippocampus, given twice: 60 and 30 min before test Passive avoidance
Scopolamine, 3 mg/kg
Given 60 min before
MED:
(inhibitory avoidance
ip, 30 min before
retention test.
(±)-rolipram 0.02 mg/kg
learning, hippocampus
retention test
(±)-rolipram 0.01 – 0.1
(-)-rolipram 0.01 mg/kg
and amygdala
(rat)
mg/kg, po
(+)-rolipram 2 mg/kg;
(-)-rolipram 0.005-0.02
no effect at 10 mg/kg
dependent)
[52]
mg/kg, po (+)-rolipram 0.3-10 mg/kg, po Scopolamine, 1.5
rolipram 10 and 30 mg/kg,
mg/kg, ip, immediately
po, 30 min before training
MED: 30 mg/kg
[143]
MED: 10 mg/kg
[91]
MED: 0.1 mg/kg
[99]
[142]
after training (mouse) Scopolamine, 1 mg/kg,
Rolipram, 1-30 mg/kg, ip,
ip 30 min before
30 min before acquisition
acquisition (mouse) Dizocilpine 0.l mg/kg,
Rolipram 0.1 mg/kg, ip, 30
ip, 60 min before test
min before test
(rat) MEK inhibitor UO126,
Rolipram, 0.1, mg/kg, ip, 30
Reversal retention deficit
8ug/rat into hippocam-
min before test or 30 ug/rat
48-h post training
pus, given twice: 60
into hippocampus, 20 min
and 30 min before test
before test
3-panel runway task
Scopolamine, 0.56
Rolipram, 0.032, 0.1 mg/kg,
MED: 0.1 mg/kg for
(working memory,
mg/kg, ip, 15 min
ip, 30 min before first trial
decrease errors
hippocampus- prefron-
before first trial
tal cortex dependent)
(rat) Cerebral ischemia by
Rolipram, 0.032, 0.1 mg/kg,
MED: 0.1 mg/kg for
four-vessel occlusion
ip, 30 min before first
decrease errors
(rat)
trial (immediately after reperfusion)
[91]
[91]
70 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Blokland et al.
Table 3. contd….
Task
Model
(Memory Process)
(Species)
Treatment
Results
Reference
ECS immediately after
Rolipram, 0.1 , 0.32 mg/kg,
MED: 0.32 mg/kg for
[91]
training
ip, just before ECS
decrease errors
(rat) Inhibitory avoidance
1. Protein synthesis
Rolipram 3, 10 mg/kg, ip,
MED 10 mg/kg, given
(hippocampus and
inhibitor anisomycin,
immediately after training or
immediately after
amygdala dependent)
150 mg/kg, sc, 30 min
3 hours after training
training (1 + 2)
[144]
before training 2. Low baseline (mouse) Contextual
Unimpaired
Rolipram 0.03 mg/kg, sc,
Improved retention 24 h
fear-conditioning
(mice)
30 min before training
after training
Impaired TG2576
Rolipram 30 min prior to
Improvement in mutants
Alzheimer mice
training at 0.1 mg/kg ip
and wild type
APP-PS Alzheimer
Rolipram 0.1 uM/kg for 3
Improvement when
mice
weeks
tested 2 months
[94]
(hippocampus and amygdala dependent) [100]
[101]
following 3-week treatment Heterozygous CBP
Rolipram 0.1 mg/kg, ip;
MED: 0.1 mg/kg for
mutants
HT0712 0.001 – 0.5 mg/kg,
both drugs. Improved
(mice)
ip 20 min before training
object recognition at 24
[96]
hours Object retrieval
Increase in complexity
Rolipram (0.003-0.03
(frontal cortex)
(cynomolgus
mg/kg)
MED 0.01 mg/kg
[145]
[103]
macaques) Delayed responding
unimpaired and
rolipram 0.01-100 ug/kg, im
At 0.1 ug/kg, trend for
(prefrontal cortex
age-deficit
1 hour before testing
improvement in young
dependent, working
(rhesus monkeys)
memory)
Aged subjects impaired by 10 ug/kg.
messenger, and an increase in cAMP by rolipram may modulate the activity of these transmitters and their effects on cAMP, subsequently leading to an improvement in STM/WM. For example, cAMP facilitates the release of noradrenaline, dopamine, and serotonin from rat brain slices [98] and potentiates cholinergic activity as it increased tremors induced by the cholinergic agonist oxotremorine in mice [52]. Thus, PDE4 inhibition may lead elevated activity of cholinergic neurons which could explain the effects of rolipram in the scopolamine model. Furthermore, rolipram facilitated the NMDA-induced elevation in cAMP, and it has been suggested that PDE4 is an integral component of the NMDA receptor-mediated transduction pathway involved in memory processes [99]. Such a
Improving Memory
Frontiers in Medicinal Chemistry, 2010, Vol. 5
71
transduction pathway involved in memory processes [99]. Such a mechanism may underlie the reversal of the cognition-impairing effect of dizocilpine by PDE4 inhibitors. Effects on LTM Rolipram or HT0712 treatment of mice 20 min before training in the object recognition task improved retention performance 24 h later [96]. Likewise, the retention performance 24 h after contextual fear learning was improved in mice treated with rolipram 30 min before training [94]. Similar results were obtained with rodents in spatial and non spatial tasks in unimpaired and impaired animals (see Table 3). A preliminary finding of special interest is that rolipram improved memory performance in transgenic mouse models for Alzheimer’s disease [100], even when tested two months after drug treatment [101]. Such persistence of memory is consistent with the hypothesis that activation of the cAMP/PKA/CREB pathway leads to transcription of CREB-dependent genes, synthesis of proteins such as BDNF, and synaptic re-modeling [89, 90] and that such changes provide the ‘wiring’ for memory storage. The finding that PDE4 inhibition can reverse memory performance in different mouse disease models [96, 100, 101] provides strong support that this treatment approach may be effective in Alzheimer's disease. This notion is supported by a recent study showing that A inhibits the PKA/CREB pathway and this inhibition can be reversed by drugs that enhance cAMP levels [102]. Temporal Features So far, no studies have been reported which specifically address the effects of PDE4 inhibitors on the early stages of information processing such as attention. There has also been a lack of a systematic and profound evaluation of the effects of PDE4 inhibition on acquisition, consolidation and retrieval in tasks of STM/WM or LTM. Rolipram has a short half-life and has typically been given shortly before training or testing (see Table 3), suggesting that PDE4 inhibition improves acquisition and/or consolidation processes involved in LTM. However, some recent studies suggest that rolipram may especially exerts its effects via late phase LTP processes. This was shown in a study in which rolipram showed clear effects when administered 3 h after the acquisition of new information [87, 88]. However, other mechanisms of rolipram cannot be excluded (see above). The activity of rolipram reported across a range of different models and experimental conditions in rodents is remarkable and suggests that PDE4 inhibitors possess robust cognitive-enhancing properties. PDE4 inhibitors can improve STM/WM, likely via modulation of neurotransmitter activity, which might be such that it also improves LTM. On the other hand, consolidation of LTM might also be influenced, presumably via a camp/PKA/CREB pathway. Notwithstanding these intriguing findings in rodents, PDE4 is a clinically invalidated target for the treatment of cognitive disorders and the rationale would be strengthened if more data in higher species such as nonhuman primates became available. In a first study, a trend was found for rolipram to improve delayed responding performance in young – but not old - rhesus monkeys [103]. Clearly further studies in non human primates are needed to address the potential of PDE4 inhibitors as novel cognition enhancers. PDE5 Inhibitors In 1997 it was first described that PDE5 inhibition improves memory processes [104]. Zaprinast was used to inhibit PDE5 and when given immediately after training at a dose of 10 mg/kg (i.p.) it improved the LTM performance of rats in the object recognition task
72 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Blokland et al.
[104]. However, we now know that zaprinast also inhibits PDE1, 9, 10 and 11. Since then, more selective PDE5 inhibitors have been developed, except for the pharmacological treatment of erectile dysfunction. Currently, three PDE5 inhibitors are approved for use in several countries; sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis). In vitro experiments demonstrated that sildenafil or vardenafil increased NO-mediated cGMP accumulation in the hippocampus [95, 105, 106]. Both sildenafil and vardenafil have already been tested in LTM models as is discussed below. Effects on LTM Sildenafil treatment immediately after training in the object recognition task improved the retention performance of rats 24 h later with a lowest effective dose of 3 mg/kg (p.o.) [106]. Compared with sildenafil, vardenafil appeared to be even more potent in this respect since it already produced a high discrimination performance at a dose of 0.3 mg/kg (p.o.) [106]. When sildenafil was given 30 min before the first trial it also clearly improved the memory performance [107]. However, the lowest effective dose was increased from 3 mg/kg to 10 mg/kg when changing the administration of sildenafil from after to 30 min before the first trial. In male rats the elimination half-life of sildenafil is about 0.4 h and as a result sildenafil levels quickly decrease as a result of its metabolic clearance by the liver [108]. Thus, 30 min after its administration the 10 mg/kg dose may be close to the level of the 3 mg/kg dose and, consequently, improves consolidation processes of object information. Sildenafil has also been tested in mice. When administered immediately after the training trial of passive avoidance learning, sildenafil improved the retention performance 48 h later with a MED of 3 mg/kg (i.p.) [109]. Zaprinast and vardenafil were also tested in spatial LTM tasks at doses which were effective in object LTM tasks. Zaprinast (10 mg/kg, i.p.) was given immediately after daily learning in the Morris water escape task. Vardenafil (3 mg/kg, i.p.) was tested in a spatial recognition task (Y-maze) and given immediately after training [14]. However, both drugs did not affect consolidation processes of spatial information. A more recent study showed that vardenafil was especially effective when given immediately after the acquisition trial in an object recognition paradigm [87]. This finding suggests that PDE5 inhibition may be especially effective in improving early phase LTP. Effects in Humans The effects of sildenafil (100 mg) on early information processing and memory processes in humans have only sporadically been studied. Thus far, no clear effect on the behavioral measures of attention and verbal recognition memory have been reported [110]. However, there are some methodological considerations since only STM was measured at an already optimal performance allowing a minimal window for treatment effects. Yet, in the same study, attention-related, event-related brain potential (ERP) measures were enhanced by sildenafil. In addition, another study reported that the simple choice reaction time was faster in sildenafil-treated subjects [111]. Thus, early information processing in humans can be influenced by PDE5 inhibition, but these processes as well as memory-related processes clearly need more investigation. Taken together, animal studies indicate that PDE5 inhibitors have the potential to improve early consolidation processes of LTM, although this may be excluded for spatial information. This memory improvement might be mediated by elevations in central cGMP
Improving Memory
Frontiers in Medicinal Chemistry, 2010, Vol. 5
73
levels. Sildenafil treatment in humans suggests that information processing may be improved. CONCLUSIONS Reviewing the existing literature on the effects of PDE inhibitors on memory performance there is a large body of evidence indicating that these drugs can improve the memory performance in animals. This may not be unexpected since the mechanism of action of these drugs can be related to neurochemical processes that are assumed to underlie neuronal plasticity (LTP). There seems good evidence that PDE5 inhibition improves processes of early consolidation [14], which may involve a cGMP/PKG/CREB pathway. cAMP is assumed to be involved in late consolidation [80, 81] and PDE4 inhibition should improve this phase of memory formation. Studies with rolipram suggest that PDE4 inhibition can improve both acquisition and consolidation and it is proposed that the former may predominantly involve cAMP-mediated changes in the activity of acetylcholine, glutamate, and other neurotransmitters. Conversely, consolidation may predominantly involve changes in the cAMP/PKA/ CREB pathway, although it is not clear whether it is early or late consolidation. Along similar lines, since cAMP and cGMP are involved in different pathways underlying different types of LTP, it is likely that each PDE is involved in specific memory processes [65]. Clearly, more studies are needed to demonstrate such a specific effect on memory for PDE4 and PDE5 inhibitors. At present these data have been mostly obtained in animal studies, and only sporadic evidence is available that PDE5 inhibitors appear to affect central processes in man. Human studies, designed to test the memory enhancing effects of PDE inhibitors, are needed to demonstrate a proof of principle for this class of drugs as a possible tool for improving memory in man. It is also important to anticipate on possible on possible side effects of treatment with PDE inhibitors. Since PDEs are widely distributed throughout the body, this is an important point to consider. At present not much information is available since there are no clinical relevant drugs except for rolipram and selective PDE5 inhibitors. With respect to rolipram, some side effects have been reported [eg. headache, nausea, gastric hyper secretion and emesis, see 112]. On the other hand, rolipram has anti-inflammatory activity via suppression of proinflammatory cytokines and other mediators of inflammation [112]. This can be considered as a positive effect. Sildenafil has been reported not to affect cerebral blood flow but does seem to induce headache in healthy control subjects [113]. However, a recent study suggest that the effects of PDE4 or PDE5 inhibition on memory performance are independent on cerebral blood flow and glucose metabolism [88]. Also, there have been various anecdotal reports that sildenafil induces various types of neurological and affective effects [eg. loss of consciousness, anxiety, aggression, see 114]. Interestingly, a recent study indicated that chronic PDE5A inhibition has a positive effect as it prevented and reversed cardiac hypertrophy [115]. Although no clear and consistent negative side effect profile of rolipram and sildenafil are apparent, it is clear that more data are needed to evaluate side effect profile of selective PDE inhibitors. The field of PDEs is still highly novel and new aspects of these PDEs will emerge in the near future. One of these features is the existence of isoforms of PDEs. For example, the PDE4B and PDE4D enzymes seem to have a different distribution in the brain (see Table 2), and may therefore underlie different functions. In a recent study in which PDE4D knock out (-/-), heterozygote (+/-) and wild type mice were tested in models of depression, the PDE4D (-/-) mice showed clear anti-depressive like behavior and these mice were insensitive to rol-
74 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Blokland et al.
ipram. [116]. Comparative studies with PDE4B and PDE4A knock out mice will help to address if splice variants of PDE can subserve different behavioral functions. In line with this notion, preliminary data suggest that PDE4D (-/-) mice perform better in several learning tasks [117]. However, recent studies provide no clear interpretations with respect to a specific involvement of these suptypes [118, 119] As stated by Houslay and Adams [120]: “PDE4 genes code for 16 isoforms which play a pivotal role in controlling functionally and spatially distinct pools of cAMP by virtue of their unique intracellular targeting”. Therefore even subtle differences between compounds in their inhibition of PDE4 subtypes may result in a differential pattern of action across cognition models. Evidently, much more research is needed to delineate the specific role of these isoforms and to develop molecules that specifically inhibit these enzymes. In this paper we only reviewed drugs that have been tested in animal models of learning and memory. This is merely based on the availability of specific PDE inhibitors and the rational to test these drugs in these models. Based on the localization of the PDE enzymes in the brain and their distribution in the body, we suggest that PDE2, PDE4 and PDE5 are relevant targets for improving memory functions. Other PDEs, except PDE6 and PDE11, could also be relevant because they are all expressed in areas that are directly or indirectly related to learning and memory. A recent study showed that PDE9 may also be considered as a relevant target [121]. The selective PDE9 inhibitor BAY 73-6691 showed clear memory enhancing effects in different animal models. It should be noted that presently there are no PDEs that are exclusively located in the hippocampus and/or cortex (see Table 2). Nevertheless, animal studies have shown remarkable effects of PDE inhibitors on memory performance thus far. The development of selective PDE inhibitors and specific localization studies of PDEs are needed to evaluate the potential of PDE inhibitors for the development of memory dysfunctions. REFERENCES [1] [2]
[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13]
[14]
Horton, D.L.; Mills, C.B. Human learning and memory. Ann. Rev. Psychol., 1984, 35, 361-394. Alkon, D.L.; Amaral, D.G.; Bear, M.F.; Black, J.; Carew, T.J.; Cohen, N.J.; Disterhoft, J.F.; Eichenbaum, H.; Golski, S.; Gorman, L.K.; Lynch, G.; McNaughton, B.L.; Mishkin, M.; Moyer, J.R.; Olds, J.L.; Olton, D.S.; Otto, T.; Squire, L.R.; Staubli, U.; Thompson, L.T.; Wible, C. Learning and memory. Brain Res. Rev., 1991, 16, 193-220. Cahill, L.; Prins, B.; Weber, M.; McGaugh, J.L. -Adrenergic activation and memory for emotional events. Nature, 1994, 371, 702-704. Davis, H.P.; Squire, L.R. Protein synthesis and memory: a review. Psychol. Bull., 1984, 96, 518-559. DeZazzo, J.; Tully, T. Dissection of memory formation: from behavioral pharmacology to molecular genetics. Trends Neurosci., 1995, 18, 212-218. McGaugh, J.L. Dissociating learning and performance: drug and hormone enhancement of memory storage. Brain Res. Bull., 1989, 23, 339-345. Messier, C. Glucose improvement of memory: a review. Eur. J. Pharmacol., 2004, 490, 33-57. Izquierdo, I.; Barros, D.M.; Mello e Souza, T.; de Souza, M.M.; Izquierdo, L.A.; Medina, J.H. Mechanisms for memory types differ. Nature, 1998, 393, 635-636. Geyer, M.A.; Tamminga, C.A. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology, 2004, 174, 1-2. Blaney, P.H. Affect and memory: a review. Psychol. Bull.,1986, 99, 229-246. Squire, L.R.; Knowlton, B.J.; Musen, G. The structure and organization of memory. Ann. Rev. Psychol., 1993, 44, 453-495. Baddeley, A. Working memory: looking back and looking forward. Nat. Rev. Neurosci., 2003, 4, 829-839. Ng, K.T.; Gibbs, M.E.; Crowe, S.F.; Sedman, G.L.; Hua, F.; Zhao, W.; O'Dowd, B.; Rickard, N.; Gibbs, C.L.; Sykova, E.; Svoboda, J, Jendelova, P. Molecular mechanisms of memory formation. Mol. Neurobiol., 1991, 5, 333-350. Prickaerts, J.; Sik, A.; van Staveren, W.C.; Koopmans, G.; Steinbusch, H.W.; van der Staay, F.J.; de Vente, J.; Blokland, A. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem. Int., 2004, 45, 915-928.
Improving Memory [15] [16] [17]
[18] [19] [20]
[21] [22] [23] [24]
[25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38]
[39] [40] [41] [42]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
75
Ebert, U.; Kirch, W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur. J. Clin. Invest., 1998, 28, 944-949. Izquierdo, I.: Mechanism of action of scopolamine as an amnestic. Trends Pharmacol. Sci., 1989, 10, 175177. Riedel, W.J.; Klaassen, T.; Deutz, N.E.; van Someren, A.; van Praag, H.M.Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology, 1999, 141, 362-369. Park, S.B.; Coull, J.T.; McShane, R.H.; Young, A.H.; Sahakian, B.J.; Robbins, T.W.; Cowen, P.J. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology, 1994, 33, 575-588. Ellison, G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Rev., 1995, 20, 250-267. Lieben, C.K.; van Oorsouw, K.; Deutz, N.E.; Blokland, A. Acute tryptophan depletion induced by a gelatin-based protein-carbohydrate mixture impairs object memory but not affective behavior and spatial learning in the rat. Behav. Brain Res., 2004, 151, 53-64. Newcomer, J.W.; Farber, N.B.; Jevtovic-Todorovic, V.; Selke, G.; Melson, A.K.; Hershey, T.; Craft, S.; Olney, J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology, 1999, 20, 106-118. Rossner, S. Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease. Int. J. Dev. Neurosci., 1997, 15, 835-850. Eisenstein, E.M. Selecting a model system for neurobiological studies of learning and memory. Behav. Brain Res., 1997, 82, 121-132. Ingram, D.K.; Spangler, E.L.; Iijima, S.; Ikari, H.; Kuo, H.; Greig, N.H.; London, E.D. Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. Life Sci., 1994, 55, 2037-2049. Myhrer, T. Animal models of Alzheimer's disease glutamatergic denervation as an alternative approach to cholinergic denervation. Neurosci. Biobehav. Rev., 1993, 17, 195-202. Dodart, J.C.; Mathis, C.; Bales, K.R.; Paul, S.M. Does my mouse have Alzheimer's disease? Genes Brain Behav., 2002, 1, 142-155. Takeda, T. Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol. Aging, 1999, 20, 105-110. Davis, S.; Laroche, S. What can rodent models tell us about cognitive decline in Alzheimer's disease? Mol. Neurobiol., 2003, 27, 249-276. Riekkinen, P., Jr.; Schmidt, B.H.; van der Staay, F.J. Animal models in the development of symptomatic and preventive drug therapies for Alzheimer's disease. Ann. Med., 1998, 30, 566-576. Decker, M.W. Animal models of cognitive function. Crit. Rev. Neurobiol., 1995, 9, 321-343. Bartus, R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol., 2000, 163, 495-529. Bartus, R.T.; Dean, R.L.; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217, 408-417. Mesulam, M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn. Mem., 2004, 11, 43-9. Palmer, A.M. Cholinergic therapies for Alzheimer's disease: progress and prospects. Curr. Opin. Investig. Drugs, 2003, 4, 820-825. Levin, E.D.; Rezvani, A.H. Nicotinic treatment for cognitive dysfunction. Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 423-431. Rezvani, A.H.; Levin, E.D. Cognitive effects of nicotine. Biol. Psychiatry, 2001, 49, 258-267. Levin, E.D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol., 2002, 53, 633-640. Meyer, E.M.; Tay, E.T.; Papke, R.L.; Meyers, C.; Huang, G.L.; de Fiebre, C.M. 3-[2,4Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res., 1997, 768, 49-56. Levin, E.D.; Bettegowda, C.; Blosser, J.; Gordon, J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol., 1999, 10, 675-680. Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology, 2004, 172, 375-383. Blokland, A.: Acetylcholine: a neurotransmitter for learning and memory? Brain Res. Rev., 1995, 21, 285300. Izquierdo, L.A.; Barros, D.M.; Vianna, M.R.; Coitinho, A.; deDavid e Silva, T.; Choi, H.; Moletta, B.; Medina, J.H.; Izquierdo, I. Molecular pharmacological dissection of short- and long-term memory. Cell. Mol. Neurobiol., 2002, 22, 269-287.
76 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [43] [44] [45] [46] [47] [48] [49] [50] [51] [52]
[53] [54] [55] [56] [57] [58] [59] [60] [61]
[62] [63]
[64] [65] [66] [67] [68] [69] [70] [71]
Blokland et al.
Cahill, L.; McGaugh, J.L. Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci., 1998, 21, 294. Hock, F.J. Therapeutic approches for memory impairments. Behav. Brain Res., 1995, 66, 143-150. Cahill, L.; McGaugh, J.L. Modulation of memory storage. Curr. Opin. Neurobiol., 1996, 6, 237-242. Nehlig, A.; Daval, J.L.; Debry, G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Rev., 1992, 17, 139-170. McGaugh, J.L.; Roozendaal, B. Role of adrenal stress hormones in forming lasting memories in the brain. Curr. Opin. Neurobiol., 2002, 12, 205-210. Prickaerts, J.; Steckler, T. In Handbook of Stress and the Brain, Steckler, T.; Kalin, N.; Reul, J.M.H.M.; Eds.; Elsevier: Amsterdam, 2005; vol. 15, pp. 359-386. Sherwin, B.B. Steroid hormones and cognitive functioning in aging men: a mini-review. J. Mol. Neurosci., 2003, 20, 385-393. Gertz, H.J.; Kiefer, M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr. Pharm. Des., 2004, 10, 261-264. Fedele, E.; Raiteri, M. In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Prog. Neurobiol., 1999, 58, 89-120. Egawa, T.; Mishima, K.; Matsumoto, Y.; Iwasaki, K.; Fujiwara, M. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn. J. Pharmacol., 1997, 75, 275-281. Zhang, H.T.; O'Donnell, J.M. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology, 2000, 150, 311-316. Son, H.; Lu, Y.F.; Zhuo, M.; Arancio, O.; Kandel, E.R.; Hawkins, R.D. The specific role of cGMP in hippocampal LTP. Learn. Mem., 1998, 5, 231-245. Bailey, C.H.; Bartsch, D.; Kandel, E.R. Toward a molecular definition of long-term memory storage. Proc. Natl. Acad. Sci. USA, 1996, 93, 13445-13452. Chien, W.L.; Liang, K.C.; Teng, C.M.; Kuo, S.C.; Lee, F.Y.; Fu, W.M. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol. Pharmacol., 2003, 63, 1322-1328. Bliss, T.V.P.; Collingridge, G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 1993, 361, 31-39. Malenka, R.C.; Bear, M.F. LTP and LTD: an embarrassment of riches. Neuron, 2004, 44, 5-21. Lynch, M.A.: Long-term potentiation and memory. Physiol. Rev., 2004, 84, 87-136. Eichenbaum, H. Learning from LTP: a comment on recent attempts to identify cellular and molecular mechanisms of memory. Learn. Mem., 1996, 3, 61-73. Impey, S.; Mark, M.; Villacres, E.C.; Poser, S.; Chavkin, C.; Storm, D.R. Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron, 1996, 16, 973-982. Frey, U.; Huang, Y.; Kandel, E.R. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science, 1993, 260, 1661-1664. Monfort, P.; Munoz, M.D.; Kosenko, E.; Llansola, M.; Sanchez-Perez, A.; Cauli, O.; Felipo, V. Sequential activation of soluble guanylate cyclase, protein kinase G and cGMP-degrading phosphodiesterase is necessary for proper induction of long-term potentiation in CA1 of hippocampus. Alterations in hyperammonemia. Neurochem. Int., 2004, 45, 895-901. Bon, C.L.; Garthwaite, J. On the role of nitric oxide in hippocampal long-term potentiation. J. Neurosci., 2003, 23, 1941-1948. Blokland, A.; Boess, F. Use of behavioral and LTP models in the development of memory-improving drugs. Expert Opin. Drug Discov., 2008, 3, 1067-1080. Huang, Y.Y.; Li, X.C.; Kandel, E.R. cAMP contributes to mossy fiber LTP by initiating both a covalently mediated early phase and macromolecular synthesis-dependent late phase. Cell, 1994, 79, 69-79. O'Dell, T.J.; Hawkins, R.D.; Kandel, E.R.; Arancio, O. Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc. Nat. Acad. Sci. USA, 1991, 88, 11285-11289. Nguyen, P.V.; Woo, N.H.: Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases. Prog. Neurobiol., 2003, 71, 401-437. Zhuo, M.; Hu, Y.; Schultz, C.; Kandel, E.R.; Hawkins, R.D. Role of guanylyl cyclase and cGMPdependent protein kinase in long-term potentiation. Nature, 1994, 368, 635-639. Arancio, O.; Kandel, E.R.; Hawkins, R.D. Activity-dependent long-term enhancement of transmitter release by presynaptic 3',5'-cyclic GMP in cultured hippocampal neurons. Nature, 1995, 376, 74-80. Arancio, O.; Antonova, I.; Gambaryan, S.; Lohmann, S.M.; Wood, J.S.; Lawrence, D.S.; Hawkins, R.D. Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation. J. Neurosci., 2001, 21, 143-9.
Improving Memory [72] [73]
[74] [75] [76] [77] [78] [79] [80]
[81] [82]
[83] [84]
[85] [86]
[87] [88]
[89] [90] [91] [92]
[93] [94] [95]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
77
Boulton, C.L.; Southam, E.; Garthwaite, J. Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience, 1995, 69, 699-703. Monfort, P.; Munoz, M.D.; Kosenko, E.; Felipo, V. Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase. J. Neurosci., 2002, 22, 10116-10122. Lu, Y.F.; Hawkins, R.D. Ryanodine receptors contribute to cGMP-induced late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurophysiol., 2002, 88, 1270-1278. Francis, S.H.; Turko, I.V.; Corbin, J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol., 2001, 65, 1-52. Beavo, J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 1995, 75, 725-748. Bear, M.F.; Kirkwood, A.: Neocortical long-term potentiation. Curr. Opin. Neurobiol., 1993, 3, 197-202. Otani, S.; Daniel, H.; Roisin, M.P.; Crepel, F. Dopaminergic modulation of long-term synaptic plasticity in rat prefrontal neurons. Cereb. Cortex, 2003, 13, 1251-1256. Ahi, J.; Radulovic, J.; Spiess, J. The role of hippocampal signaling cascades in consolidation of fear memory. Behav. Brain Res., 2004, 149, 17-31. Bernabeu, R.; Schmitz, P.; Faillace, M.P.; Izquierdo, I.; Medina, J.H. Hippocampal cGMP and cAMP are differently involved in memory processing of inhibitory avoidance learning. Neuroreport, 1996, 7, 585588. Bernabeu, R.; Schroder, N.; Quevedo.J.; Cammarota, M.; Izquierdo, I.; Medina, J.H. Further evidence for the involvement of a hippocampal cGMP/cGMP-dependent protein kinase cascade in memory consolidation. Neuroreport, 1997, 8, 2221-2224. Prickaerts, J.; de Vente, J.; Honig, W.; Steinbusch, H.W.; Blokland, A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur. J. Pharmacol., 2002, 436, 8387. Rubin, M.A.; Jurach, A.; da Costa, E.M., Jr.; Lima, T.T.F.; Jiménez-Bernal, R.E.; Begnini, J.; Souza, D.O.; de Mello, C.F. GMP reverses the facilitory effect of glutamate on inhibitory avoidance task in rats. Neuroreport, 1996, 7, 2078-2080. Woodson, J.C.; Minor, T.R.; Job, R.F. Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3nonyl)adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats. Behav. Neurosci., 1998, 112, 399-409. Bessodes, M.; Bastian, G.; Abushanab, E.; Panzica, R.P.; Berman, S.F.; Marcaccio, E.J., Jr.; Chen, S.F.; Stoeckler, J.D.; Parks, R.E., Jr. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Biochem. Pharmacol., 1982, 31, 879-882. Boess, F.G.; Hendrix, M.; Van der Staay, F.J.; Erb, C.; Schreiber, R.; Van Staveren, W.; De Vente, J.; Prickaerts, J.; Blokland, A.; Koenig, G. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology, 2004, 47, 1081-1092. Rutten, K.; Prickaerts, J.; Hendrix, M.; van der Staay, F.J.; Sik, A.; Blokland, A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: Studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur. J. Pharmacol., 2007, 558, 107-112. Rutten, K.; Van Donkelaar, E.L.; Ferrington, L.; Blokland, A.; Bollen, E.; Steinbusch, H.W.; Kelly, P.A.; Prickaerts, J.H. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats. 2009, 34, 1914-1925. Barco, A.; Pittenger, C.; Kandel, E.R. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert. Opin. Ther. Targets, 2003, 7, 101-114. Tully, T.; Bourtchouladze, R.; Scott, R.; Tallman, J. Targeting the CREB pathway for memory enhancers. Nat. Rev. Drug Discov., 2003, 2, 267-277. Imanishi, T.; Sawa, A.; Ichimaru, Y.; Miyashiro, M.; Kato, S.; Yamamoto, T.; Ueki, S. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur. J. Pharmacol., 1997, 321, 273-278. Nagakura, A.; Niimura, M.; Takeo, S. Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats. Br. J. Pharmacol., 2002, 135, 1783-1793. Krause, W.; Kuhne, G. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica, 1988, 18, 561-571. Barad, M.; Bourtchouladze, R.; Winder, D.G.; Golan, H.; Kandel, E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. USA, 1998, 95, 15020-15025. van Staveren, W.C.; Markerink-van Ittersum, M.; Steinbusch, H.W.; de Vente, J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res., 2001, 888, 275-286.
78 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [96]
[97] [98]
[99] [100]
[101]
[102] [103]
[104] [105]
[106]
[107]
[108] [109] [110]
[111] [112] [113] [114] [115] [116]
Blokland et al.
Bourtchouladze, R.; Lidge, R.; Catapano, R.; Stanley, J.; Gossweiler, S.; Romashko, D.; Scott, R.; Tully, T. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl. Acad. Sci. USA, 2003, 100, 10518-10522. Zhang, H.T.; Huang, Y.; Suvarna, N.U.; Crissman, A.M.; Hopper, A.T.; De Vivo, M.; Rose, G.M.; O'Donnell, J.M. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 in models of memory and antidepressant sensitivity. Soc. Neurosci. Abstr., 2002, 684,12. Schoffelmeer, A.N.; Wardeh, G.; Mulder, A.H. Cyclic AMP facilitates the electrically evoked release of radiolabelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices. Naunyn Schmiedebergs Arch. Pharmacol., 1985, 330, 74-76. Zhang, H.T.; Crissman, A.M.; Dorairaj, N.R.; Chandler, L.J.; O'Donnell, J.M. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology, 2000, 23, 198-204. Comery, T.A.; Aschmies, S.; Atchison, K.P.; Borusovic, K.; Diamantidis, G.; Gong, X.; Mayer, S.C.; Zhou, H.; Martone, R.L.; Sonnenberg-Reine, J.; Kreft, A.F.; Jacobsen, J.S.; Marquis, K.L.: Acute secretase inhibition improves cognition in the TG2576 mouse model of Alzheimer's disease. Soc. Neurosci. Abstr., 2003, 525, 21. Gong, B.; Vitolo, O.; Trinchese, F.; Liu, S.; Shelanski, M.L.; Arancio, O. Long-lasting reversal of deficits in long-term potentiation and memory by the phosphodiesterase inhibitor rolipram in a mouse model of Alzheimer disease. Soc. Neurosci. Abstr., 2003, 201, 20. Vitolo, O.V.; Sant'Angelo, A.; Costanzo, V.; Battaglia, F.; Arancio, O.; Shelanski, M. Amyloid beta peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. USA, 2002, 99, 13217-13221. Ramos, B.P.; Birnbaum, S.G.; Lindenmayer, I.; Newton, S.S.; Duman, R.S.; Arnsten, A.F. Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron, 2003, 40, 835-845. Prickaerts, J.; Steinbusch, H.W.M.; Smits, J.F.M.; De Vente, J. Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast. Eur. J. Pharmacol., 1997, 337, 125-136. De Vente, J.; Hopkins, D.A.; Markerink-van Ittersum, M.; Steinbusch, H.W.M. Effects of the 3',5'phosphodiesterase inhibitors isobutylmethylxanthine and zaprinast on NO-mediated cGMP accumulation in the hippocampus slice preparation: an immunocytochemical study. J. Chem. Neuroanat., 1996, 10, 241248. Prickaerts, J.; van Staveren, W.C.; Sik, A.; Markerink-van Ittersum, M.; Niewohner, U.; van der Staay, F.J.; Blokland, A.; de Vente, J. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience, 2002, 113, 351-361. Prickaerts, J.; Sik, A.; Van Der Staay, F.J.; De Vente, J.; Blokland, A. Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation. Psychopharmacology, 2005, 177, 381-390. Walker, D.K.; Ackland, M.J.; James, G.C.; Muirhead, G.J.; Rance, D.J.; Wastall, P.; Wright, P.A. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica, 1999, 29, 297310. Baratti, C.M.; Kopf, S.R. A nitric oxide synthase inhibitor impairs memory storage in mice. Neurobiol. Learn. Mem., 1996, 65, 197-201. Schultheiss, D.; Muller, S.V.; Nager, W.; Stief, C.G.; Schlote, N.; Jonas, U.; Asvestis, C.; Johannes, S.; Munte, T.F. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J. Urol., 2001, 19, 46-50. Grass, H.; Klotz, T.; Fathian-Sabet, B.; Berghaus, G.; Engelmann, U.; Kaferstein, H. Sildenafil (Viagra): is there an influence on psychological performance? Int. Urol. Nephrol., 2001, 32, 409-412. Zhu, J.; Mix, E.; Winblad, B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev., 2001, 7, 387-398. Kruuse, C.; Thomsen, L.L.; Birk, S.; Olesen, J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain, 2003, 126, 241-247. Milman, H.A.; Arnold, S.B.: Neurologic, psychological, and aggressive disturbances with sildenafil. Ann. Pharmacother., 2002, 36, 1129-1134. Takimoto, E.; Champion, H.C.; Li, M.; Belardi, D.; Ren, S.; Rodriguez, E.R.; Bedja, D.; Gabrielson, K.L.; Wang, Y.; Kass, D.A. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med., 2005, 11, 214-222. Zhang, H.T.; Huang, Y.; Jin, S.L.; Frith, S.A.; Suvarna, N.; Conti, M.; O'Donnell, J.M. Antidepressantlike profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology, 2002, 27, 587-595.
Improving Memory [117]
[118] [119]
[120] [121]
[122] [123] [124] [125] [126] [127]
[128] [129] [130]
[131] [132] [133] [134] [135]
[136] [137]
[138] [139]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
79
Zhang, H.T.; Huang, Y.; Jin, C.S.L.; Frith, S.A.; Zhao, Y.; Suvarna, N.U.; Conti, M.; Steketee, J.D.; O'Donnell, J.M. Cyclic AMP-specific phosphodiesterase 4 (PDE4): memory, emotion, and drug abuse. Soc. Neurosci. Abstr., 2003, 874,9. Rutten, K.; Misner, D.L.; Works, M.; Blokland, A.; Novak, T.J.; Santarelli, L.; Wallace, T.L. Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. Eur. J. Neurosci., 2008, 28, 625-632. Siuciak, J.A.; McCarthy, S.A.; Chapin, D.S.; Martin, A.N. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology, 2008, 197, 115126. Houslay, M.D.; Adams, D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J., 2003, 370, 1-18. van der Staay, F.J.; Rutten, K.; Barfacker, L.; Devry, J.; Erb, C.; Heckroth, H.; Karthaus, D.; Tersteegen, A.; van Kampen, M.; Blokland, A.; Prickaerts, J.; Reymann, K.G.; Schroder, U.H.; Hendrix, M. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology, 2008, 55, 908-918. Yan, C.; Bentley, J.K.; Sonnenburg, W.K.; Beavo, J.A. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J. Neurosci., 1994, 14, 973-984. Billingsley, M.L.; Polli, J.W.; Balaban, C.D.; Kincaid, R.L. Developmental expression of calmodulindependent cyclic nucleotide phosphodiesterase in rat brain. Dev. Brain Res., 1990, 53, 253-263. Lal, S.; Sharma, R.K.; McGregor, C.; Macaulay, R.J. Immunohistochemical localization of calmodulindependent cyclic phosphodiesterase in the human brain. Neurochem. Res., 1999, 24, 43-49. Reed, T.M.; Browning, J.E.; Blough, R.I.; Vorhees, C.V.; Repaske, D.R. Genomic structure and chromosome location of the murine PDE1B phosphodiesterase gene. Mamm. Genome, 1998, 9, 571-576. Polli, J.W.; Kincaid, R.L. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J. Neurosci., 1994, 14, 12511261. Yan, C.; Zhao, A.Z.; Bentley, J.K.; Beavo, J.A. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J. Biol. Chem., 1996, 271, 25699-25706. Repaske, D.R.; Corbin, J.G.; Conti, M.; Goy, M.F. A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain. Neuroscience, 1993, 56, 673-686. Van Staveren, W.C.; Steinbusch, H.W.; Markerink-Van Ittersum, M.; Repaske, D.R.; Goy, M.F.; Kotera, J.; Omori, K.; Beavo, J.A.; De Vente, J. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol., 2003, 467, 566-580. Sonnenburg, W.K.; Mullaney, P.J.; Beavo, J.A. Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants. J. Biol. Chem., 1991, 266, 17655-17661. Bolger, G.B.; Rodgers, L.; Riggs, M. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene, 1994, 149, 237-244. Cherry, J.A.; Davis, R.L.: Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol., 1999, 407, 287-301. Miro, X.; Perez-Torres, S.; Palacios, J.M.; Puigdomenech, P.; Mengod, G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse, 2001, 40, 201214. Sasaki, T.; Kotera, J.; Omori, K. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem. J., 2002, 361, 211-220. Kobayashi, T.; Gamanuma, M.; Sasaki, T.; Yamashita, Y.; Yuasa, K.; Kotera, J.; Omori, K. Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain. Gene, 2003, 319, 21-31. van Staveren, W.C.; Glick, J.; Markerink-van Ittersum, M.; Shimizu, M.; Beavo, J.A.; Steinbusch, H.W.; de Vente, J. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J. Neurocytol., 2002, 31, 729-741. Seeger, T.F.; Bartlett, B.; Coskran, T.M.; Culp, J.S.; James, L.C.; Krull, D.L.; Lanfear, J.; Ryan, A.M.; Schmidt, C.J.; Strick, C.A.; Varghese, A.H.; Williams, R.D.; Wylie, P.G.; Menniti, F.S. Immunohistochemical localization of PDE10A in the rat brain. Brain Res., 2003, 985, 113-126. Rutten, K.; Prickaerts, J.; Blokland, A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol. Learn. Mem., 2006, 85, 132-138. Rutten, K.; Lieben, C.; Smits, L.; Blokland, A. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology, 2007, 192, 275-282.
80 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [140]
[141]
[142]
[143] [144] [145]
Blokland et al.
Huang, Z.; Dias, R.; Jones, T.; Liu, S.; Styhler, A.; Claveau, D.; Otu, F.; Ng, K.; Laliberte, F.; Zhang, L.; Goetghebeur, P.; Abraham, W.M.; Macdonald, D.; Dube, D.; Gallant, M.; Lacombe, P.; Girard, Y.; Young, R.N.; Turner, M.J.; Nicholson, D.W.; Mancini, J.A. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. Biochem. Pharmacol., 2007, 73, 1971-1981. Bach, M.E.; Barad, M.; Son, H.; Zhuo, M.; Lu, Y.F.; Shih, R.; Mansuy, I.; Hawkins, R.D.; Kandel, E.R. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal longterm potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc. Natl. Acad. Sci. USA, 1999, 96, 5280-5285. Zhang, H.T.; Zhao, Y.; Huang, Y.; Dorairaj, N.R.; Chandler, L.J.; O'Donnell, J.M. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology, 2004, 29, 1432-1439. Ghelardini, C.; Galeotti, N.; Gualtieri, F.; Romanelli, M.N.; Bucherelli, C.; Baldi, E.; Bartolini, A. DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer. Naunyn Schmiedebergs Arch. Pharmacol., 2002, 365, 419-426. Randt, C.T.; Judge, M.E.; Bonnet, K.A.; Quartermain, D. Brain cyclic AMP and memory in mice. Pharmacol. Biochem. Behav., 1982, 17, 677-680. Rutten, K.; Basile, J.L.; Prickaerts, J.; Blokland, A.; Vivian, J.A.: Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology, 2008, 196, 643-648.
Frontiers in Medicinal Chemistry, 2010, 5, 81-97
81
Progress in Current Non-Viral Carriers for Gene Delivery Yoko Shoji-Moskowitz1,2,*, Daisuke Asai1,3,4, Kota Kodama1,5, Yoshiki Katayama1,6 and Hideki Nakashima1,3 1
CREST, JAPAN; 2FOLIGO Therapeutics, Inc. USA; 3Department of Microbiology, St. Marianna University School of Medicine, Japan; 4Department of Biomedical Engineering, Duke University, USA; 5Creative Research Institution, Hokkaido University, Japan; 6Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Japan Abstract: Since the viral vector for gene therapy has serious problems, including oncogenesity and other adverse effects, non-viral carriers have attracted a great deal of attention. However, the most critical issue of gene delivery by non-viral carriers is the low-expression efficiencies of the desired gene. In order to apply non-viral carriers for gene therapy in practical clinical usage, the improvement of transfection efficiency is a prerequisite. We will summarize the current progress of non-viral delivery systems for gene therapy. Especially, we will address the applications of cationic lipids (lipoplex) and cationic polymers (polyplex) in vivo. Furthermore, there have been reported a disease-site-specific delivery system which responds to highly activated cellular signals, which is called a drug delivery system based on responses cellular signal (D-RECS). We will also introduce the current progress of D-RECS gene delivery which is activated by HIV protease in only HIV-infected cells.
Keywords: Non-viral carrier, polyplex, lipoplex. 1. INTRODUCTION The progress of post-genomic research has provided further understanding of the genetic background of intractable diseases. Based on these findings, gene-based medicine is now in use. However, the biggest hurdle for gene-based medicine to overcome is the development of non-toxic and efficient delivery systems [1]. Currently, the intramuscularly administration of a naked plasmid DNA allows us to obtain a local transient transgene expression [2]. However, the intravenous injection of the naked DNA has resulted in low levels of gene expression in all major organs [3]. Therefore, the development of efficient delivery systems is urgently needed to treat metastatic diseases. According to data published in the Journal of Gene Medicine, over 1340 clinical trials for gene therapy had been approved worldwide by 2007 [4]. Approximately only 20% of these trials use non-viral vectors. Viral vectors are more efficient in terms of transfection efficiency, yet are plagued by safety concerns [5]. *Corresponding author: Tel: + 1-301-770-0099; Fax: + 1-301-881-7640; E-mail:
[email protected] Allen B. Reitz / Atta-ur-Rahman / M. Iqbal Choudhary (Eds.) All rights reserved – © 2010 Bentham Science Publishers.
82 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shoji-Moskowitz et al.
The first gene medicine, type 5 adenoviruses bearing the human wild-type p53 gene (Ad-p53) for the treatment of head and neck cancer, was approved by the State Food and Drug Administration (SFDA) of China. It has been on the market as Gendicine since October 2003. In 2005, SFDA approved Oncolin, adenoviruses with a defective E1B-55 kDa molecule for head and neck cancer, which has been on the market since 2006 [6]. In the past years, however, the safety issues surrounding the viral vectors were brought sharply into focus by the sudden death of an 18-year-old patient in a gene therapy trial [7]. Retrovirus is also used as a vector as well as adenovirus for gene therapy. Despite the successful gene therapy for correcting X-linked severe combined immunodeficiency, 2 out of 10 cases developed leukemia [8, 9]. There is a major concern that the randomness of the integration of retrovirus vectors on chromosomes may lead to activating oncogene, which causes cancer. Therefore, despite their comparatively low efficiency, non-viral vectors have been enthusiastically and vigorously investigated due to their advantageous safety profile. In addition to the safety issue, a recent report on the comparative activity of retroviral and non-viral (liposomal) gene transfer in a mouse model demonstrated that viral vectors have no advantage over the survival period [10]. Several clinical trials of non-viral carriers [11-13] have been evaluated, resulting in encouraging the research of non-viral carriers. The other promising non-viral carrier is a delivery system that responds to cellular signals [14-18]. As shown in Fig. (1), the system, the so-called drug or drug delivery system, which responded to cellular signals (D-RECS), includes a peptide substrate, which can be cleaved by the target enzyme in disease cells. For example, protein kinase C (PKC) alpha is excessively activated in most tumor cells. D-RECS containing cationic peptide substrate, which is phosphorylated by PKC-alpha, coupled with cationic copolymers comprising hydrophilic and neutral polymers in main chain. Under the presence of PKC-alpha, pDNA was released from cationic copolymer with DNA complex in tumor cells [15, 17]. Another example is D-RECS activated by caspase [16]. These reports successfully showed DNA release from D-RECS and DNA complex in the presence of corresponding a peptide substrate that was cleavable only in tumor cells. As a result, the desired DNA expression could gain only in tumor cells, not in normal cells. Recently, D-RECS containing peptide substrate for HIV protease demonstrated a specific transgene expression in HIV-infected cells by responding to HIV protease [19, 20]. This review will address the current progress of non-viral gene delivery systems including D-RECS. 2. NAKED DNA The administration of naked DNA is the most straightforward strategy for gene therapy. The direct administration of plasmid DNA to skeletal muscle cells results in efficient gene expression, which was contrary to expected results [3]. Therefore, the naked DNA has been administered intramuscularly for the purposes of vaccination, where antigen-encoding DNA is administered to produce a protective immune response to the transgene antigenic product [22, 22]. It was thought that this method would not be suitable for prolonged transgene expression. Efficient transfection levels, however, have been obtained on the direct injection of the naked DNA to the liver [23, 24], to solid tumors [25], and to the epidermis and hair follicles [26]. The introduction of bolus injection of a large amount of DNA via an artery improved enough to gain the high level of gene expression [27].
Non-Viral Carriers for Gene Delivery
Frontiers in Medicinal Chemistry, 2010, Vol. 5
83
Normal cells general transcription factors not accessible inhibit transcription
polymer/DNA complex
HIV infection
HIV protease expression
side chain peptide cleavage by HIV protease Infected cells disintegration of polymer/DNA complex permit transcription
Fig. (1). Schematic model of D-RECS responds to HIV protease.
Intriguingly, the direct administration of transgenes using non-viral carriers such as cationic liposomes does not enhance the transfection efficiency [28, 29]. And actually these carriers hinder gene expression [30]. The failure in the enhancement of transfection efficiency by carriers is observed even when DNA tissue clearance is inhibited by the use of cationic liposomes [28]. The deleterious effects of cationic lipids such as N- [1-(2,3dioleoyloxy) propyl]-N,N,N-trimethylammonium methylsulphate (DOTAP) to cells such as erythrocytes [31] and macrophages [32] may be responsible for the lack of transfection efficiency. The molecular mechanism of DNA uptake has remained unknown. Early studies suggested that DNA binding proteins on the cell surface could promote uptake of DNA. They have not been confirmed, however. Recently, it was suggested that DNA is taken up via proteoglycan dependent macropinocytosis [33]. Although DNA transporting proteins in various tissues should be further investigated, this finding would give insights into the better understanding of DNA internalization. The direct injection of DNA without any carriers is the simplest way to administer it, but this method would not be appropriate for metastasized diseases and in anatomically inaccessible sites.
84 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shoji-Moskowitz et al.
3. LIPOPLEX AND POLYPLEX The approaches using non-viral carriers involve the combination of nucleic acids with cationic lipids (lipoplexes) and/or cationic polymers (polyplexes). Several major obstacles need to be overcome for the development of non-viral gene delivery systems for clinical use in humans. These obstacles include: transfection efficiency, toxicity, manufacturing process, formulation and bio-physiological stability, and extracellular/intracellular barriers. Recent progress on the development of lipoplex and polyplex is introduced here. 4. LIPOPLEX The first gene delivery cationic liposome with a polar head group (protonated at physiological pH), was introduced in 1987 [34]. Since then, a variety of commercial cationic lipids as in vitro gene delivery reagents, e.g. lipofectin (N- [1-(2,3-di-olyloxy) propyl]-N,N,Ntrimethyl-ammonium chloride, 1,2-dioleoyl- phosphatidylethanolamine-DOPE, 1:1) have been developed. Furthermore, the liposomal gene delivery method has been applied in clinical trials [35, 36]. A large number of cationic lipids have been synthesized and studied as non-viral carriers for gene delivery. The structure-activity relationship studies have shown that increasing the number of amine groups, which is necessity for the transfection competence, per molecule [37], and the distance between the amine groups and the hydrophobic units [38], is advantageous to gene delivery. This arrangement of atoms allows an intimate level of DNA binding in the lipoplex (by increasing contact sites) as well as a dissociation of the bound DNA from the cohesive interaction of the hydrophobic units. Lipoplexes range from 50 nm to just over a micrometer in size. The influence of lipoplex size on the transfection efficacy is contrary to what would be expected. Actually, the larger lipoplexes have been reported as improving the transfection efficiency in vitro. A positive charge of lipoplex is essential for the cell binding prior to the internalization by endocytosis [39]. Some neutral lipids, such as DOPE [40] and cholesterol [41-43], have been incorporated into the cationic lipid bilayer with DOPE to improve in vitro transfection of some cell lines by facilitating endosormal escape [40]. The role of cholesterol, however, is unclear [42, 44]. The use of cationic liposomes to deliver genes increases the level of protein expression obtained on intravenous injection [45, 46]. The complexation of DNA with cationic liposomes also prevents DNA degradation in the plasma [47]. Polyethylene glycol (PEG) lipids into the lipoplexes can contribute to diverting lipoplex from the lung. PEG coating successfully prolongs the circulation time of the lipoplexes and allows the production of the desired protein in the distal tumors [48, 49]. This strategy is reminiscent of that used to divert drug-carrying liposomes from the liver and spleen [50]. In vitro, however, a PEG coating decreases the uptake and gene transfer [51]. Cationic liposomes may also be administered directly to the target site in order to avoid the targeting difficulties that are encountered in the case of intravenous administration. Access to the alveolar epithelium has been achieved via the intratracheal route, resulting in expression of the -1-antitrypsin [52], the -galactosidase reporter [53] genes and a reduction in the size of pulmonary tumors on the administration of the p53 apoptosisinducing gene [54]. However, intratracheal administration is not routinely applicable in the clinical usage. The application of aerosols [55] made it possible to access the alveolar epithelium. Lipoplexes were effective in preventing degradation of DNA during aerosolisation [56]. Successful gene delivery to the eye will have an enormous impact on the treatment of genetic eye diseases. It has been reported that the efficient transfection to the retinal gan-
Non-Viral Carriers for Gene Delivery
Frontiers in Medicinal Chemistry, 2010, Vol. 5
85
glion cells has been observed on the instillation of lipoplex eye drops with no inflammation [57]. Since cell toxicity of cationic liposomes has been reported, research to reduce the toxicity of these carriers is required. In addition to improving the biological properties of lipidic gene carriers, some studies have focused on improving the stability of lipoplexes employing lyophilisation with the aid of monosaccharide, disaccharide or PEG lipid [28] cryoprotectants. Allovectin is a mixture of plasmid DNA encoding the genes HLA-B7 and 2-microglobulin complexed with a cationic lipid mixture, DMRIE/DOPE (1,2-dimyristyloxypropyl3-dimethyl-hydroxyethyl ammonium bromide/dioleoyl-phosphatidyl-ethanolamine) [58-60]. Allovectin was intratumorally injected to treat Stage III or IV melanoma patients, and showed minor adverse effects. These effects included ecchymosis and pruritis, which were not serious [58]. The cationic liposome showed no severe cytotoxicity. Tumor regression at the injection site was observed in 18% of patients [58]. The mechanism of Allovectin is still not completely defined, however, it is thought that it stimulates the immune system to recognize and destroy cancerous cells. This DNA-based immunotherapy is also encouraging for the clinical usage of cationic liposomes. Currently, phase III clinical trial of Allovectin has been conducted. Most cationic liposomes and DNA complexes form a multilayered structure with DNA sandwiched between cationic lipids. The membrane charge density of the cationic liposomes is one of the parameters to gain transfection efficiency [61]. Further understanding of the supermolecular structure of lipoplex may lead to the design of better non-viral carriers in terms of delivery efficiency. 5. POLYPLEX Polyplex, which has protonated polymer-bearing groups at physiological pH, has been employed as a gene carrier. The electrostatic attraction between the cationic charge on the polymers and the negatively charged DNA results in a particulate complex–the polyplex, which is the transfecting unit. 5.1. Poly-Lysine Based Polymers The first polycation for gene delivery was poly-L-lysine (PLL) conjugated with asialoorosomucoid for hepatocellular gene targeting [62]. Unlike cationic liposomes, many of the early works involving the use of polyplexes utilized ligands to facilitate cellular uptake, e.g. asialoorosomucoid, transferrin [63-65], folate [66], monoclonal antibodies [67-69] and basic fibroblast growth factor [70]. The gene transfer activity of PLL polyplexes without the use of receptor-mediated strategies is poor [71] unless endosomolytic or lysosomotropic agents (e.g. chloroquine) are added [72, 73]. This is an important difference in the biological activity of the amphiphilic cationic lipids and the soluble polymer PLL. Cellular uptake of gene transfer by polyplexes in the absence [73] or presence [74] of targeting ligands is, however, still dependant on the presence of a positively charged polyplex [74]. Various other PLL copolymers have also been shown to transfer genes into mammalian cells such as those incorporating –tryptophan [72], and graft poly-histidine [76]. The conjugation of histidine to lysine residues of PLL [76] resulted in a transfecting polyplex, which was more efficient than a PLL-chloroquine mixture. This graft copolymer showed an enhancement in activity in the absence of chloroquine because of the additional endosormal buffering capacity
86 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shoji-Moskowitz et al.
ity offered by histidine, which is protonated below pH 6. In a similar strategy, gluconylated polyhistidine has also been used to transfer genes to mammalian cells and does not require chloroquine [77]. Hence, the use of histidine residues seems to facilitate an endosormal escape. Although PLL polyplexes prevent the degradation of DNA by the serum nucleases [78] in a similar manner to liposomes [46]; on the intravenous injection, these polyplexes are bound to the plasma proteins and rapidly cleared from the plasma [79] that is similar to cationic liposomes. Polyplex opsonisation by the plasma proteins may be suppressed by coating the polyplexes with a hydrophilic polymer such as hydroxypropyl methacrylic acid. The cellular uptake of the polyplexes may be promoted by the conjugation of targeting ligands such as transferrin [80] or fibroblast growth factor [81] to the surface of the coated polyplexes. To improve the transfection efficiency, reducible linear L-lysine modified copolymer was used instead of high molecular weight PLL. The molecular weight of the copolymer was about 3.2kD. The transfection efficiency of this polyplex was much higher compared to the optimal PLL control [82]. Mannose receptors are abundant on dendritic cells (DCs) and macrophages. To facilitate mannose receptor for DNA internalization, oxidized mannan or reduced mannan conjugated with PLL (mannan-PLL) as a carrier was applied for DNA vaccination [83]. The injection of DNA encoding ovalbumin (OA) complexed with mannan-PLL in tumor-bearing C57BL/6 mice showed sufficient antibody production leading to the inhibition of OVA tumor growth and induced CD4 and CD8 T-cell responses. This method provides efficient internalization via a mannose receptor, which was better than the PLL delivery system alone [83]. 5.2. Polyethylenimine Recently both branched [84, 85] and linear [86] polyethylenimine (PEI) have been introduced as cationic polymers for gene delivery. Unlike PLL, this polymer shows efficient gene transfer without the need for endosomolytic or lysosomotropic agents or any agents facilitating receptor-mediated uptake. PEI is endocytosed by cells and also facilitates endosormal escape [87]. As with all the other non-viral gene delivery systems mentioned above, it has a positive charge for the internalization [84]. Although PEI is quite an efficient gene transfer agent [88], the addition of targeting ligands to this polymer enhances its activity in some cell lines [89-92]. Recently hydrophobised PEI, which has been incorporated within DOPE, egg phosphatidylcholine and dipalmitoyl phosphatidylcholine liposomes, produced an efficient gene transfection, although the activity of this soluble amphiphilic polymer was diminished when it was administered without the liposomal lipids [93]. Unfortunately, PEI, like some of the cationic lipids, has also been reported to be toxic to cells. Ovarian cancer is the most deadly gynecological cancer and most patients are found at a late stage with a lack of effective treatments. PEI containing polyplex conjugated with interleukin-12 (IL-12) plasmid was tested to enhance local and systemic immune responses against ovarian cancer [94]. The intraperitoneal administration of polyplex with IL-12 plasmid increased murine IL-12 and interferon-gamma in ascites fluid, although serum levels remained unchanged. They observed the delay of onset of ascite tumors. Followed by successful animal tests, a phase 1 clinical trial of PEI-gene complex in ovarian cancer showed promising results [13]. Synthetic polyethyleneglycol-PEI-cholesterol conjugated with IL-12 plasmid was administered to women with chemotherapy-resistant recurrent ovarian cancer to enhance immune responses against ovarian cancer. This gene delivery system proved safe
Non-Viral Carriers for Gene Delivery
Frontiers in Medicinal Chemistry, 2010, Vol. 5
87
and demonstrated the reduction of serum CA-125 levels in some patients [13]. Some patients remained at a steady condition. Thus, this system would open a new door to treat chemotherapy-resistant, metastasized, and recurrent cancers. 5.3. Other polymers A transfecting peptide has been prepared from the N-terminal of the human adenovirus fiber protein, which promotes the transport of DNA to the nucleus and improves transfection rates. The cationic liposomes prepared from DOTAP [95], copolymer including PEG and poly (aminoethyl methacrylate) and poly (dimethylamino) ehytlmethacrylate [96], poly (Nethyl-4-vinylpyridinium) polymers [97], poly-histidine [76] polyglycolide (PLG) and chitosan [98] have also been used for gene delivery. Both chitosan [99] and PLG [16] nanoparticles appeared to control the release of DNA and prolong its action both in vitro [99] an in vivo [30]. The use of PLG is a peculiar example of the efficacy of a polymer. It is not protonated and hence not cationic at physiological pH, so that PLG particles actually possess a negative surface charge [30]. Chitosan has also been used via oral administration to achieve an immune response against a peanut allergen [100], which is the first report of an orally active gene delivery system. Cyclodextrin (CD) has been used as the modification of existent therapeutic reagents to protect physical, enzymatic degradation and to improve delivery efficiency [101]. The properties of CD and its toxicology have been well characterized clinically. Thus, CD is an ideal carrier for clinical usage. A cationic CD has a great ability to bind polyanionic polymer such as oligonucleotides and DNA. The conjugation of mannose with dendrimer has been also applied for integration CD showing promising transfection efficiency [102]. Recently, a film containing DNA drew great interest for gene delivery such as a patch vaccination [103]. The multilayered film consisting of poly L-glutamic acid (PLGA) and PLL containing DNA in the presence of the cationic CD demonstrated efficient gene delivery as a carrier. The cationic CD acts as an enhancer of cellular permeability in this system. The cationic CD also preserves DNA activity well and shows no significant DNA release from the film for 6 days. This type of film promotes not only the absorption but also the interfacial delivery of DNA into cells [103]. 5.4. Dendrimers Dendrimers are spherical nanostructures that can encapsulate therapeutic drugs in their interior or attach to the surface. The dendrimer diameter increases linearly per generation, whereas the number of surface groups increases geometrically. Dendrimers consist of core nanoparticles and interior branching, which connect the core to surface groups such as cationic, anionic, neutral, either hydrophobic moiety. Among all, polyamidoamine (PAMAM) dendrimer has been commonly studied. A range of polyamidoamine- [104-108] and phosphorous-containing dendrimers has been studied as gene delivery systems. Terminal amino groups bind to DNA by electrostatic force [106]. Positively charged complexes are advantageous for gene delivery [109]. An increase in the level of terminal amino groups appeared to enhance gene delivery [110]. Dendrimer-gene complexes are presumably internalized by endocytosis and there are also advantages associated with the star shape of the polymer as DNA appears to interact with the surface-primary amines only, leaving the internal tertiary amines available for the neutralization of the acid pH [111] within the endosomal/lysosomal compartment. Following the internalization, the release of polyamidoamine-gene complexes from the endosome has been attributed to the protonation of the internal tertiary nitrogens by endosormal protons, which then results in a swelling of the endosome and the release of the DNA to the cytoplasm [112]. The hydrolytic degradation of polyamidoamine dendrimer
88 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shoji-Moskowitz et al.
amide bonds in water or ethanol increased transfection efficacy up to 50-fold, which the authors attribute to the increased flexibility of the polymer on heat degradation [112,113]. This increased flexibility is crucial to the swelling of the endosome [112]. Partially hydrolyzed polyamidoamine dendrimers were found to be more effective as gene transfer agents than branched PEI in the in vivo transfection of the carotid artery of rabbits [113]. Cytotoxicity is a pivotal issue to overcome. Primi et al. investigated the internalization process of PAMAM dendrimers. They provided insights that 500-700nM was effective in cell internalization without significant cytotoxicity [114]. Systemic administration of polypropylemimine dendrimer showed remarkable tumor regression [115]. The polypropylemimine dendrimer was conjugated with transferin which were over-expressed in tumors. Transferrin-bearing polypropylemimine dendrimer resulted in high gene expression, mainly in the tumors. Therapeutic DNA conjugated with transferring-bearing polypropylemimine dendrimer showed significant tumor regression without apparent signs of toxicity. 6. CELLULAR SIGNAL RESPONSE DRUG DELIVERY SYSTEM (D-RECS) The aforementioned targeting strategies often utilize a molecular marker on the cellular surface to promote the efficient transfection of genes to the target cells. However, this socalled active targeting strategy is not always successful because the effective molecular markers are not always available. It is inevitable that genes are delivered to the unwanted sites and it is difficult to control the gene expression itself in the target cells. A novel strategy that can discriminate normal cells and target cells in gene therapy by focusing on differences in intracellular signals such as PKC alpha, I-B kinase, caspase 3, HIV protease has been reported [14-20, 116-118]. Aberrant activation of certain intracellular signals is often seen in many diseases [119-126]. Thus, if such unusual intracellular signals could be utilized to activate the delivered gene, the cell-selective control of the delivered gene expression could be achieved. Fig. (1) shows a schematic model of D-RECS containing peptide side chains that are cleavable by HIV protease. D-RECS consists of polymer which has cationic peptide chains and responsible DNA. Because of cationic peptide side chains, the polymer conjugate can form a stable polyplex with DNA. Thus, the transcription of DNA is suppressed in the nonactivated condition (normal cells). On the other hand, the cationic peptide is connected to the polymer backbone via a sequence that is specifically cleaved by the target protease, HIV protease. When the conjugate encounters the target protease, the cationic peptide side chain is cleaved by the target protease and the polymer loses the electrostatic interaction with the DNA. As a result, the DNA is released in the target cell and is transcribed (Fig. 1). Thus, DRECS acts as a gene regulator only in cells containing the target protease. Recently, protein kinase C (PKC) was used as a trigger to activate the transgene expression to prove the applicability of D-RECS as a gene carrier [118]. We also apply the strategy of D-RECS in HIV infectious disease [19, 20]. This peptide side chain consists of the consensus substrate sequence for HIV protease, and protein transduction domain sequence of HIV-Tat protein (CPCHIVtat). First of all, we studied whether the peptide substrate is specifically cleaved by HIV protease in cell-free system. DNA was released from CPCHIVtat -DNA complex and was activated under the presence of HIV protease [19]. On the contrary, DNA was not released without HIV protease, which suggested that peptide substrate is cleaved by HIV protease [19]. However, HIV infected cells contain various hydrolytic enzymes. We also confirmed that the substrate peptide used in CPCHIVtat was not digested at all by other potential intracellular proteases, including
Non-Viral Carriers for Gene Delivery
Frontiers in Medicinal Chemistry, 2010, Vol. 5
89
caspase-8 and caspoase-3, using MALDI-TOF-MS and/or reversed-phase HPLC (data not shown). In the cell-free assay system, many factors, such as charged protein and high concentration of salts in the reticulocyte lysate, may influence the stability of the polyplex. Thus, under such conditions, it is likely that a larger C/A charge would be required to suppress the transgene expression. Furthermore, HIV-1 protease-induced transgene expression from CPCHIVtat polyplex in this cell-free system was inhibited by protease inhibitors such as indinavir, saquinavir, and ritnavir [20]. Next, we studied whether this strategy works in HIV-infected cells. Various human T lymphocyte cell lines have been used for HIV infection experiments, including MT-4, CEM, MOLT-4, and Jurkat cells, and all of them are able to work as HIV producer cells. We chose a Jurkat human T lymphocyte cell line because Jurkat cells are not killed by HIV infection, i.e., they can be persistently infected with HIV, like CEM and MOLT-4 cells. Also their transfection efficiency is rather high compared with other human T lymphocyte cell lines. We confirmed that the titer of HIV in the supernatant of the Jurkat cell culture medium was high enough compared with that of MOLT-4 cell, and the concentration of p24 protein was similar in both cell lines (Fig. 2). Fig. (3) showed that CPCHIVtat-DNA was transfected in HIV-infected cells under fluorescent microscopy. As shown in Fig. (4), DNA was released from CPCHIVtat-DNA in HIV infected cells while negative control didn’t reveal transgene expression. Thus, CPCHIVtat-DNA reveals transgene expression responding to HIV-1 protease in HIV infected cells. These results indicated D-RECS can facilitate HIV protease signals in HIV-infected cells to switch on the target gene in only HIV-infected cells. p24 protein (pg/mL)
500 400 300 200 100 0 Jurkat
MOLT-4 Cells
Fig. (2). Cells were infected with HIV at a multiplicity of infection (MOI) of 0.01. HIV-infected cells (3.0 x 105 cells/ml) were placed into 96-well microtiter plates and incubated. After 5 days of culture at 37˚C in a CO2 incubator, the culture supernatant was collected, and the HIV-1 p24 antigen was detected and quantified by the HIV-1 p24 Antigen ELISA (ZeptoMetrix Corp., Buffalo, NY, USA).
7. CONCLUSION The success of gene therapy in China has inspired the medical arena, which had been awaiting it [6]. Unfortunately, non-Chinese researchers are unaware of the progress of gene therapy in China because most of these clinical trials of gene therapy have been reported only in Chinese. Furthermore, it is difficult to access such information and to get relevant comparisons of their clinical data to Western standardized clinical data. Also, the adenovirus receptors are often down-regulated in tumors resulting in insufficient therapeutic efficiency [127]. Another concern of gene therapy using adenovirus vector is that the presence of an adenovirus neutralizing antibody, which would hamper the therapeutic efficacy. It is thought that about 60% of adults have adenovirus neutralizing antibody before treatment. Further-
90 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Shoji-Moskowitz et al.
more, weakened viruses would alter and gain pathogenesity in the body. Also, patients may develop immune responses to the viruses and quickly eliminate the viral-DNA complex. Such events cause the inefficiency of activating therapeutic DNA. CP(DVP)tat
CPCHIVtat Fluorescein
Marged
(fluorescein and phase contrast)
Fluorescein
Marged
(fluorescein and phase contrast)
(-) HIV (naive)
(+) HIV (HIV-infected)
Fig. (3). Cells were incubated with the polyplexes at a C/A ratio of 1.0 in OptiMEM I medium for 4 h at 37˚C. After washing with PBS, DNA labeled was observed by fluorescence microscopy.
Luciferase activity (RLU/mg protein)
4.0E+08
- HIV + HIV
3.0E+08 2.0E+08 1.0E+08 0.0E+00
charge ratio Polymor
(-) none
+ 1.0
+ 2.0
CPCHIVtat
+ 1.0 CP(DVP)tat
+ 1.0 CPCCVtat
+ 2.0 PLL
Fig. (4). Transgene expression in HIV-infected Jurkat cells following transfection with various polymers. pMetLuc-control condensed with indicated polymers at a charge ratio of +1.0 and/or +2.0 was added and the cells were cultured for two days. None indicates plasmid DNA only. The light unit values represent specific luciferase activity (RLU/mg protein) standardized against total cellular protein content of cell lysates. Data shown are the mean ± SD of duplicate samples and are representative of at least two independent experiments.
As well as viral vectors, non-viral carriers for gene therapy have improved transfection efficiency, which prove that enough transgene expression can be introduced to the target
Non-Viral Carriers for Gene Delivery
Frontiers in Medicinal Chemistry, 2010, Vol. 5
91
site. In this article, we summarize the recent progress of lipoplexes and polyplexes as nonviral carriers for gene delivery. Mostly, non-viral carriers possess a positive charge to facilitate good transfection efficiency. It seems to be advantageous for gene delivery in increasing the number of amine groups and the distance between the amine groups and the hydrophobic units. A positive charge is advantageous to bind to the DNA and to facilitate endosomal escape. Other promising carriers for gene delivery are polyplexes, such as PEI, chitosan, and dendrimers. Major concerns about the toxicity of non-viral carriers have been drastically improved. Recently, PEI with tolerable low toxicity for clinical usage has reported, which is promising. D-RECS is a smart new strategy that can achieve the gene expression only in the desired sites. By using this system, the gene does not express in the normal cell even though the gene is delivered to the normal cell. Cellular signals only in the aberrant cell (e.g. caspase, HIV protease) cleave the carriers as shown in Fig. (1) and release DNA. For clinical usage, the toxicity of the polymer used in this study has to be improved. However, D-RECS can provide the specific targeting that other non-viral carriers do not. As other virus proteaseresponsive D-RECS, coxsackievirus (CV) 2A protease was applied and showed a similar result as HIV infection, which proved D-RECS is applicable for other virus infections [19]. Thus, D-RECS strategy can be useful to establish the universal concept of drug design for virus-infected cell-specific attacks or other cancer treatments. Recently, non-viral gene delivery has become more promising because several clinical trials have been conducted with encouraging results. Moreover, non-viral carriers can be repeatedly injected into the body, which viral vectors often cannot. In the last decade, the development of non-viral carriers for gene therapy has steadily progressed from the bench to clinical trials. If this progress continues at current rates, the coming decade will be bright for gene therapy. ACKNOWLEDGEMENTS This study was partially funded by a grant CREST of Japan Science and Technology Agency, Japan. The authors would like to express their thanks to Mr. Ken Moskowitz for editing this manuscript. REFERENCES [1] [2] [3] [4] [5] [6]
[7] [8]
[9]
Anderson, W.F. Human gene therapy. Nature, 1998, 392, 25. Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science, 1990, 190247, 1465. Liu, Y. Liggitt, D.; Zhong, W.; Tu, G.; Gaensler, K.; Debs, R. Cationic liposome-mediated intravenous gene delivery. J. Biol. Chem., 1995, 270, 24864. Edelstein, M.L.; Abedi, M.R.; Wixon, J. Gene therapy clinical trials worldwide to 2007—an update. J. Gene Med., 2007, 9, 833. Verma, I.M.; Somia, N.: Gene therapy — promises, problems and prospects. Nature, 1997, 389, 239. Ma, G.; Shimada, H.; Hiroshima K.; Tada, Y.; Suzuki, N.; Tagawa M. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des. Devel. Ther., 2008, 2, 115. Marshall. E. Gene therapy death prompts review of adenovirus vector. Science, 1999, 286, 2244. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffaat, N.; Mclntyre, E.; Radford, I.; Villeval, J.L.; Fraser, C.C.; Cavazzana-Calvo, M.; Fischer, A. A serious event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003, 348, 255. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Legoulch, P.; Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E.; Sorensen, R.; Forster, A.; Fraser, P.; Cohen, J.I.; de Saint Basile, G.; Alexander, I.; Wintergerst, U.; Frebourg, T.; Aurias, A.; Stoppa-Lyonneet, D.; Romana, S.; Radford-Weiss, I.; Gross, F.; Valensi, F.; Delabesse, E.; Macintyre, E.; Sigaux, F.; Soulier, J.; Leiva, L.E.;
92 Frontiers in Medicinal Chemistry, 2010, Vol. 5
[10]
[11]
[12] [13] [14] [15]
[16]
[17] [18]
[19]
[20]
[21]
[22]
[23]
[24]
[25] [26] [27] [28]
[29] [30]
Shoji-Moskowitz et al.
Wissler, M.; Prinz, C.; Rabbitts, T.H.; Le Deist, F.; Fuscher, A.; Cavazzana-Calvo, M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415. Princen, F.; Lechanteur, C.; Lopez, M.; Gielen, J.; Bours, V.; Merville, M.P. Similar efficiency of DNAliposome complexes and retrovirus-producing cells for HSV-tk suicidal gene therapy of peritoneal carcinoma. J. Drug Target, 2000, 8, 79. Hyde, S.C.; Southern, K.W.; Gileadi, U.; Fitzjohn, E.M.; Mofford, K.A.; Waddell, B.E.; Gooi, H.C.; Goddard, C.A.; Hannavy, K.; Smyth, S. E.; Egan, J.J.; Sorgi, F.L.; Huang, L.; Cuthbert, A.W.; Evans, M.J.; Colledge, W.H.; Higgins, C.F.; Webb, A.K.; Gill, D.R. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther., 2000, 7,1156. Pringle, I.A.; Hyde, S.C.; Gill, D.R. Non-viral vectors in cystic fibrosis gene therapy: recent development and future prospects. Expert Opin. Biol. Ther., 2009, 9, 991. Anwerk, K.; Barnes, M.N.; Fewell, J.; Lewis, D.H.; Alvarez, R.D. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther., 2009 [E-pub] Kang, J.H.; Asai, D.; Kim, J.H.; Mori, T.; Toita, R.; Tomiyama, T.; Asami, Y.; Oishi, J.; Sato, Y.T.; Niidome, T.; Jun, B.; Nakashima, H.; Katayama, Y. J. Am. Chem. Soc., 2008, 130, 14906. Toita, R.; Kang, J.H.; Kim, J.H.; Tomiyama, T.; Mori, T.; Niidome, T.; Jun, B.; Katayama, Y. Protein kinase C alpha-specific peptide substrate graft-type copolymer for cancer cell-specific gene regulation system. J. Control Release, 2009, 139, 133. Kawamura, K.; Kuramoto, M.; Mori, T.; Toita, R.; Oishi, J.; Sato, Y.; Kang, J.H.; Asai, D.; Niidome, T.; Katayama, Y. Molecular mechanism of caspase-d-induced gene expression of polyplexes formed from polycations grafted with cationic substrate peptide. J. Biomater. Sci. Polym. Ed., 2009, 20, 967. Tomiyama, T.; Kang, J.H.; Toita, R.; Niidome, T.; Katayama, T. Protein kinase C alpha-responsive polymeric carrier: its application for gene delivery into human cancers. Cancer Sci., 2009, 100, 1532. Kang, J.H.; Toita, R.; Tomiyama, T.; Oishi, J.; Asai, D.; Niidome, T.; Katayama, Y. Cellular signalspecific peptide substrate is essential for the gene delivery system responding to cellular signals. Bioorg Med. Chem. Lett., 2009, 19, 6082. Asai, D.; Kodama, B.K., Shoji, Y., Nakashima, H., Kawamura, K., Oishi, J., Kuramoto, M., Niidome, T., Katayama, Y. Drug delivery system based on responses to an HIV infectious signal. Med. Chem., 2008, 4, 386. Asai D.; Kuramoto, M.; Shoji, Y.; Kang, J.H.; Kodama, K.B.; Kawamura, K.; Mori, T., Miyoshi, H.; Niidome, T.; Nakashima, H.; Katayama, Y. Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator. J. Control Release, 2010, 141, 52. Smith, B.F.; Baker, H.J.; Curiel, D.T.; Jiang, W.; Conry, R.M. Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen. Gene Ther., 1998, 5, 865. Velaz-Fiarcloth, M.; Cobb, A.J.; Horstman, A.L.; Henry, S.C.; Frothingham, R. Protection against mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein. Infect. Immun., 1999, 67, 4243. Hickman, M.A.; Malone, R.W.; Lehmann-Bruinsma, K.; Sih, T.R.; Knoell, D.; Szoka, F.C.; Walzem, R.; Carlson, D.M.; Powell, J.S. Jr. Gene expression following direct injection of DNA into liver. Hum. Gene Ther., 1994, 5, 1477. Zhang, G.; Vargo, D.; Budker, V.; Armstrong, N.; Knechtle, S.; Wolff, JA. Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum. Gene Ther., 1997, 8, 1763. Yang, J.P.; Huang, L. Direct gene transfer to mouse melanoma by intratumor injection of free DNA. Gene Ther., 1996, 3, 542. Yu, W.H.; Kashani-Sabet, M.; Liggitt, D.; Moore, D.; Heath, T.D.; Debs, R.J. Topical gene delivery to murine skin. J. Invest. Dermatol., 1999, 112, 370. Budker, V.; Zhang, G.; Danko, I.; Williams, P.; Wolff, J. The efficient expression of intravascularly delivered DNA in rat muscle. Gene Ther., 1998, 5, 272. Meyer, K.B.; Thompson, M.M.; Levy, M.Y.; Barren, L.G., Szoka, F.C. Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics. Gene Ther., 1995, 2, 450. Balasubramanian, R.P.; Bennet, M.J.; Aberle, A.M.; Malone, J.G.; Nantz, M.H.; Malone, R.W. Structural functional analysis of cationic transfection lipids: the hydrophobic domain. Gene Ther., 1996, 3, 163. Cohen, H.; Levy, R.J.; Gao, J.; Fishbein, I.; Kousaev, V.; Sosnowski, S.; Slomkowski, S.; Golomb, G.. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther., 2000, 7, 1896.
Non-Viral Carriers for Gene Delivery [31] [32] [33]
[34]
[35]
[36]
[37]
[38] [39]
[40] [41] [42]
[43] [44] [45]
[46] [47]
[48]
[49] [50] [51] [52]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
93
Uchegbu, I.F.; Schätzlein, A.G.; Tetley, L.; Gray, A.I.; Sludden, J.; Siddique S.; Mosha, E. Polymeric chitosan-based vesicles for drug delivery. J. Pharm. Pharmacol., 1998, 50, 453. Filion, M.C.; Phillips, N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipid toward immune effector cell. Biochim. Biophys. Acta, 1998, 162, 159. Wittrup, A.; Sandgren, S.; Lilja, J.; Bratt, C.; Gustavsson, N.; Mörgelin, M.; Belting, M. Identification of proteins released by mammalian cells that mediate DNA internalization through proteoglycan-dependent macropinocytosis. J. Chem. Biol., 2007, 282, 27897. Felgner, P.L.; Gadek, T.R.; Holm, M.; Roman, R.; Chan, H.W.; Wenz, M.; Northrop, J.P.; Ringold, G.M.; Danielsen, M. Lipofectin: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 7413. Porteous, D.J.; Dorin, J.R.; McLachlan, G.; DavidsonSmith, H.; Davidson, H.; Stevenson, B.J.; Carothers, A.D.; Wallace, W.A.H.; Moralee, S.; Hoenes, C.; Kallmeyer, G.; Michaelis, U.; Naujoks, K.; Ho, L.P.; Samways, J.M.; Imrie, M.; Greening, A.P.; Innes, J.A. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther., 1997, 4, 210. Laitinen, M.; Hartikainen, J.; Hiltunen, M.O.; Eranen, J.; Kiviniemi, M.; Narvanen, O.; Makinen, K.; Manninen, H.; Syvanne, M.; Martin, J.F.; Laakso, M.; Yla-Herttuala, S. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther., 2000, 11, 263-270. Wheeler, C.J.; Sukhu, L.; Yang, G.; Tsai, Y.; Bustamente, C.; Felgner, P.; Norman, J.; Manthorpe, M. Converting an alcohol to an amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes. Biochim. Biophys. Acta., 1996, 1280, 1. Remy, J.S.; Sirlin, C.; Vierling, P.; Behr, J.P. Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjug. Chem., 1994, 5, 647. da Cruz, M.T.; Simoes, S.; Pires, P.P.; Nir, S.; de Lima, M.C. Kinetic analysis of the initial steps involved in lipoplex—cell interactions: effect of various factors that influence transfection activity. Biochim. Biophys. Acta., 2001, 1510, 136. Farhood, H.; Serbina, N.; Huang, L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta, 1995, 1235, 289. Semple, S.C.; Chonn, A.; Cullis, P.R. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry, 1996, 35, 2521. Hong, K.; Zheng, W.; Baker, A.; Papahadjopoulos, D. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett., 1997, 400, 233. Liu, Y.; Liggitt, D.; Zhong, W.; Tu, G.; Gaensler, K.; Debs, R. Cationic liposome-mediated intravenous gene delivery. J. Biol. Chem., 1995, 270, 24864. Song, Y.K.; Liu, D. Free liposomes enhance the transfection activity of DNA/lipid complexes in vivo by intravenous administration. Biochim. Biophys. Acta, 1998, 1372, 141. Barron, L.G.; Uyechi, L.; Szoka, F.J. Jr. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Ther., 1999, 6, 1179. Barron, L.G.; Gagne, L.; Szoka, F.C. Jr. Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration. Hum. Gene Ther., 1999, 10, 1683. Monck, M.A.; Mori, A.; Lee, D.; Tam, P.; Wheeler, J.J.; Cullis, P.R.; Scherrer, P. Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J. Drug Target., 2000, 7, 439. Anwer, K.; Kao, G.; Proctor, B.; Anscombe, I.; Florack, V.; Earls, R.; Wilson, E.; McCreery, T.; Unger, E.; Rolland, A.; Sullivan, S.M. Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration. Gene Ther., 2000, 7, 1833. Anwer, K.; Kao, G.; Proctor, B.; Rolland, A.; Sullivan, S. Optimization of cationic lipid/DNA complexes for systemic gene transfer to tumor lesions. J. Drug Target, 2000, 8, 125. Blume, G.; Cevc, G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta, 1990, 1029, 91. Harvie, P.; Wong, F.M.; Bally, M.B. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J. Pharm. Sci., 2000, 89, 652. Canonico, A.E.; Conary, J.T.; Meyrick, B.O.; Brigham, K.L. Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits. Am. J. Resp. Cell Mol. Biol., 1994, 10, 24.
94 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [53]
[54] [55] [56]
[57]
[58]
[59] [60] [61] [62] [63]
[64] [65]
[66] [67] [68] [69] [70] [71]
[72] [73]
[74] [75]
[76]
Shoji-Moskowitz et al.
Griesenbach, U.; Chonn, A.; Cassady, R.; Hannam, V.; Ackerley, C.; Post, M., Tanswell, A.K.; Olek, K.; O'Brodovich, H.; Tsui, L.C. Comparison between intratracheal and intravenous administration of liposome-DNA complexes for cystic fibrosis lung gene therapy. Gene Ther., 1998, 5, 181. Zhou, X.H.; Klibanov, A.L.; Huang, L. Lipophylic polylysines mediate efficient DNA transfection in mammalian cells. Biochim. Biophys. Acta, 1991, 1065, 8. Stribling, R.; Brunette, E.; Liggit, D.; Gaensler, K.; Debs, R. Aerosol gene delivery in vivo. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 11277. Crook, K.; McLachlan, G.; Stevenson, B.J.; Porteous, D.J. Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation. Gene Ther., 1996, 3, 834. Allison, S.D.; Molina, M.C.; Anchordoquy, T.J. Stabilization of lipid/DNA complexes during the freezing step of the lyophilization process: the particle isolation hypothesis. Biochim. Biophys. Acta, 2000, 1468, 127. Stopeck, A.T.; Jones, A.; Hersh, E.M.; Thompson J.A.; Finucane, D.M.; Gutheil, J.C.; Bonzalez R. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNAliposome complex, in patients with metastatic melanoma. Clin. Cancer Res., 2001, 7, 2285. Gonzalez, R.; Hutchins, L.; Nemunaitis, J.; Atkins, M.; Schwarzenberger, P.O. Phase 2 trial of allovectin-7 in advanced metastatic melanoma. Melanoma Res., 2006, 16, 521. Bedikian, A.Y.; Del Vecchio, M. Allovectin-7 therapy in metastatic melanoma. Expert Opin. Biol. Ther., 2008, 8, 839. Ewert, K.; Evans, H.M.; Ahmad, A.; Slack, N.L.; Lin, A.J., Martin-Herrnaz, A.; Safinya, C.R. Lipoplex structures and their distinct cellular pathways. Adv. Genet., 2005, 53, 119. Wu, G.Y.; Wu, C.H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem., 1987, 262, 4429. Cotton, M.; Langle-Rouault, F.; Kirlappos, H.; Wagner, E.; Mechtler, K.; Zenke, H.; Beug, M.; Birnstiel, M.L. Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferring receptor levels. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 4033. Wagner, E.; Zenke, M.; Cotton, M.; Beug, H.; Birnstiel, M.L. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 3410. Curiel, D.T.; Birnstiel, M.L.; Cotton, M.; Wagner, E.; Zatloukal, K.; Plank, C.; Oberhauser, B.; Schmidt, W.G.M. Composition for introducing nucleic acid complexes into higher eukaryotic cells. 1996. USA Pat. 5, 547,932. Mislick, K.A.; Baldeschwieler, J.D.; Kayyem, J.F.; Meade, T.J. Transfection of folate-polylysine DNA complexes: evidence for lysosomal delivery. Bioconjug. Chem., 1995, 6, 512. Chen, J.; Gamou, S.; Takayanagi, A., Shimizu, N. A novel gene delivery system using EGF receptormediated endocytosis. FEBS Lett., 1994, 338, 167. Schachtschabel, U.; Pavlinkova, G.; Lou, D.; Köhler, H. Antibody-mediated gene delivery for B-cell lymphoma in vitro. Cancer Gene Ther., 1996, 3, 365. Shimizu, N.; Chen, J.B.; Gamou, S.; Takayanagi, A. Immunogene approach toward cancer therapy using erythrocyte growth factor receptor-mediated gene delivery. Cancer Gene Ther., 1996, 3, 113. Sosnowski, B.A.; Gonzalez, A.M.; Chandler, L.A.; Buechler, Y.J.; Pierce, G.F.; Baird, A. Targeting DNA to cells with basic fibroblast growth factor (FGF2). J. Biol. Chem., 1996, 271, 33647. Brown, M.D.; Schätzlein, A.; Brownlie, A.; Jack, V.; Wang, W.; Tetley, L.; Gray, A.I.; Uchegbu, I.F. Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents. Bioconjug. Chem., 2000, 11, 880. Wadhwa, M.S.; Collard, W.T.; Adami, R.C.; McKenzie, D.L.; Rice, K.G. Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjug. Chem., 1997, 8, 81. Pouton, C.W.; Lucas, P.; Thomas, B.J.; Uduehi, A.N.; Milroy, D.A.; Moss, S.H. Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J. Control. Release, 1998, 53, 289. Schaffer, D.V.; Lauffenburger, D.A. Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery. J. Biol. Chem., 1998, 273, 28004. Benns, J.M.; Choi, J.S.; Mahato, R.I.; Park, J.S.; Kim, S.W. pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly (L-histidine)-graft-poly-(L-lysine) comb shaped polymer. Bioconjug. Chem., 2000, 11, 637. Midoux, P.; Monsigny, M. Efficient gene transfer by histidylated polylysine/DNA complexes. Bioconjug. Chem., 1999, 10, 406.
Non-Viral Carriers for Gene Delivery [77] [78]
[79] [80]
[81]
[82] [83]
[84]
[85] [86]
[87] [88] [89] [90] [91] [92] [93]
[94]
[95] [96] [97]
[98]
[99] [100]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
95
Pack, D.W.; Putnam, D.; Langer, R. Design of imidazole-containing endosomolytic biopolymers for gene delivery. Biotechnol. Bioeng., 2000, 67, 217. Chiou, H.C.; Tangco, M.V.; Levine, S.M.; Robertson, D.; Kormis, K.; Wu, C.H.; Wu, G.Y. Enhanced resistance to nuclear degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. Nucleic Acids Res., 1994, 2, 5349. Dash, P.R.; Read, M.L.; Barrett, L.B.; Wolfert, M.A.; Seymour, L.W. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther., 1999, 6, 643. Dash, P.R.; Read, M.L.; Fisher, K.D.; Howard, K.A.; Wolfert, M.; Oupicky, D., Subr, V.; Strohalm, J.; Ulbrich, K.; Seymour, L.W. Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferring. J. Biol. Chem., 2000, 275, 3793. Fisher, K.D.; Ulbrich, K.; Subr, V.; Ward, C.M.; Mautner, V.; Blakey, D.; Seymour, L.W. A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression. Gene Ther., 2000, 7, 1337. Nounou, M.I.; Emmanouil, K.; Chung, S.; Pham, T.; Lu, Z.; Bikram, M. Movel reducible linear L-lysinemodified copolymers as efficient nonviral vectors. J. Control Release, 2010, [Epub ahead of print]. Tang, C.K.; Lodding, J.; Minigo, G.; Pouniotis, D.S.; Plebanski, M.; Scholzen, A.; McKenzie, I.F.C.; Pietersz, G.A.; Apostolopoulos, V. Mannan-mediated gene delivery for cancer immunotherapy. Immunology, 2007, 120, 325. Boussif, O.; Lezoualc’h, F.; Zanta, M.A.; Mergny, M.D.; Scherman, D.; Demeneix, B.; Behr, J.P. A versatile vector for gene and oligonucleotides transfer into cells in culture and in vivo: polyethylamine. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 7297. Boussif, O.; Zanta, M.A.; Behr, J.P. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther., 1996, 3, 1074. Chemin, I.; Moradpour, D.; Wieland, S.; Offensperger, W.B.; Walter, E.; Behr, J.P.; Blum, H.E. Liver-directed gene transfer; a linear Polyethylenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo. J. Viral. Hepat., 1998, 5, 369. Klemm, A.R.; Young, D.; Lloyd, J.B. Effects of polyethyleneimine on endocytosis and lysosome stability. Biochem. Pharmacol., 1998, 56, 41. Ferrari, S.; Moro, E.; Pettenazzo, A.; Behr, J.P.; Zacchello, F.; Scarpa, M. ExGene 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther., 1997, 4, 1100. Kircheis, R.; Kichler, A.; Wallner, G.; Kursa, M.; Ogris, M.; Felzmann, T.; Buchberger, M.; Wagner, E. Coupling of cell-binding ligands to polyethylenimine for target gene delivery. Gene Ther., 1997, 4, 409. Zanta, M.A.; Boussif, O.; Adib, A.; Behr, J.P. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug. Chem., 1997, 8, 839. Li, B.; Li, S.; Tan, Y.D.; Stolz, D.B.; Watkins, S.C.; Block, L.H.; Huang, L. Lyophilization of cationic lipid-protamine-DNA (LPD) complexes. J. Pharm. Sci., 2000, 89, 355. Li, S.; Tan, Y.; Viroonchatapan, E.; Pitt, B.R.; Huang, L. Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. Am. J. Physiol. Lung Cell Mol. Physiol., 2000, 278, L504. Yamazaki, Y.; Nango, M.; Matsura, M.; Hasegawa, Y.; Hasegawa, M.; Oku, N. Polycation liposomes, a novel nonviral gene transfer system, constructed from cetylated polyethylenimine. Gene Ther., 2000, 7, 1148. Fewell, J.G.; Matar, M..; Rice, J.S.; Brunhoeber, E., Slobodkin, G.; Pence, C.; Worker, M.; Lewis, D.H.; Anwer, K. Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J. Gene Med., 2009, 11,78. Zhang, F.; Andreassen, P.; Fender, P.; Geissler, E.; Hernandez, J.F.; Chroboczek, J. A transfecting peptide derived from adenovirus fiber protein. Gene Ther., 1999, 6, 171. Dufresne, M.H.; Elasabahy, M.; Leroux, J.C. Characeterization of polyion complex micelles designed to address the challenges of oligonucleotides delivery. Pharm. Res., 2008, 25, 2083 . Kabanov, A.V.; Astafieva, I.V.; Maksimova, I.V.; Lukanidin, E.M.; Georgiev, G.P.; Kabanov, V.A. Efficient transformation of mammalian cells using DNA interpolyelectrolyte complexes with carbon chain polycations. Bioconjug. Chem., 1993, 4, 448. Murata, J.; Nagae, H.; Ohya, Y.; Ouchi, T. Design of macromolecular biological response modifier by immobilizing of D-glucose of muramyl dipeptide on carboxymethyl-dextran having mannose branches. J. Biomater. Sci. Polym. Ed., 1997, 8, 931. Erbacher, P.; Zou, S.; Bettinger, T.; Steffan, A.M.; Remy, J.S. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm. Res., 1998, 15, 1332. Roy, K.; Mao, H.Q.; Huang, S.K.; Leong, K.W. Oral gene delivery with chitosan—DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med., 1999, 5, 387.
96 Frontiers in Medicinal Chemistry, 2010, Vol. 5 [101] [102]
[103]
[104]
[105]
[106] [107]
[108] [109] [110] [111] [112] [113]
[114] [115]
[116]
[117]
[118]
[119]
[120] [121]
[122]
Shoji-Moskowitz et al.
Kilsdonk, E.P,; Yancey, P.G.; Stoudt, G.W.; Bangerter, F.W.; Johnson, W.J.; Phillips, M.C., Rothblat, G.H. Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem., 1995, 270, 17250. Wada, K.; Arima, H.; Tsutsumi, T.; Chihara, Y.; Hattori, K.; Hirayama, F.; Uekama, K. Improvement of gene delivery mediated by mannosylated dendrimer/alpha-cyclodextrin conjugates. J. Control Release, 2005, 104, 397. Jessel, N.; Oulad-Abdelghani, M.; Meyer, F.; Lavalle, P.; Haikel, Y.; Schaaf, P.; Voegel, J.C. Multiple and time-scheduled in situ DNA delivery mediated by beta-cyclodextrin embedded in a polyelectrolyte multilayer. Prot, Natl. Acad. Sci. USA., 2006, 103, 8618. Bielinska, A.U.; KukowskaLatallo, J.F.; Baker, J.R. Jr. The interaction of plasmid DNA with polyamidoamine dendrimers: mechanism of complex formation and analysis of alteration induced in nuclease sensitivity and transcriptional activity of the complexed DNA. Biochim. Biophys. Acta, 1997, 1353, 180. Kukowska-Latallo, J.F.; Bielinska, A.U.; Johnson, J.; Spindler, R.; Tomalia, D.A.; Baker, J.R. Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 4897. Bielinska, A.U.; Chen, C.L.; Johnson, J.; Baker, J.R. Jr. DNA complexing with polyamidoamine dendrimers: implications for transfection. Bioconjug. Chem., 1999, 10, 843. Bielinska, A.U.; Yen, A.; Wu, H.L.; Zahos, K.M.; Sun, R.; Weiner, N.D.; Baker, J.R. Jr., Roessler, B.J. Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo. Biomaterials, 2000, 21, 877. Mamoun, C.B., Truong, R.; Gluzman, I., Akopyants, N.S.; Oksman, A.; Goldberg, D.E. Transfer of genes into plasmodium falciparum by polyamidoamine dendrimers. Mol. Biochem. Parasitol., 1999, 103, 117. Shah, D.S.; Sakthivel, T.; Toth, I.; Florence, A.T.; Wilderspin, A.F. DNA transfection and transfected cell viability using amophipathic asymmetric dendrimers. Int. J. Pharm., 2000, 208, 41. Toth, I.; Sakthivel, T.; Wilderspin, A.F.; Bayele, H.; Odonnell, M.; Perry, D.J.; Pasi, C.A.; Lee, K.J.; Florence, A.T. STP. Pharm. Sci., 1999, 9, 93. Lee, R.J.; Wang, S.; Low, P.S. Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim. Biophys. Acta, 1996, 1312, 237. Tang, M.X.; Redemann, C.T.; Szoka, F.C. Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug. Chem., 1996, 7, 703. Hudde, T.; Rayner, S.A.; Comer, R.M.; Weber, M.; Isaacs, J.D.; Waldmann, H.; Larkin, D.F.; George, A.J. Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium. Gene Ther., 1999, 6, 939. Parimi, S.; Barnes, T.J.; Callen, D.F.; Prestidge, C.A. Mechanistic insight into cell growth, internalization, and cytotoxicity of PAMAM dendrimers. Biomacromolecules, 2010, 11, 382. Koppu, S.; Oh, Y.J.; Edrada-Ebel, R.; Blatchford, D. R.; Tetley, L.; Tate, R.J.; Dufes, C. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J. Control Release. 2010, 143(2), 167. Kawamura, K.; Oishi, J.; Kang, J.H.; Kodama, K.; Sonoda, T.; Murata, M.; Niidome t.; Katayama, Y. Intracellular signal-responsive gene carrier for cell-specific gene expression. Biomacromolecules, 2005, 6, 908. Kang, J.H.; Toita, R.; Tomiyama, T.; Oishi, J.; Asai, D.; Mori, T.; Niidome, T.; Katayama, Y. Polar 3alkylidene-5-pivaloyloxymethyl-5’-hydroxymethyl-gamma-lactones as protein kinase C ligands and antitumor agents. Bioorg. Med. Chem. Lett., 2009, 19, 6082. Asai, D.; Tsuchiya, A.; Kang, J.H.; Kawamura, K.; Oishi, J.; Mori, T.; Niidome, T.: Shoji, Y; Nakashima, H.; Katayama, Y. J. Inflammatory cell-specific transgene expression system responding to Ikappa-B kinase beta activation. Gene Med., 2009, 11, 624. Hartmann, A.; Hunot, S.; Michel, P.P.; Muriel, M.P.; Vyas, S.; Faucheux, B.A.; Mouatt-Prigent, A.; Turmel, H.; Srinivasan, A.; Ruberg, M.; Evan, G.I.; Agid, Y.; Hirsch, E.C. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 2875. Gopalakrishna, R.; Jaken, S. Protein kinase C signaling and oxidative stress. Free Radic. Biol. Med., 2000, 28, 1349. Graff, J.R.; Konicek, B.W.; McNulty, A.M.; Wang, Z.; Houck, K.; Allen, S.; Paul, J.D.; Hbaiu, A.; Goode, R.G.; Sandusky, G.E.; Vessella R.L.; Neubauer, B.L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip 1 expression. J. Biol. Chem., 2000, 275, 24500. Page, C.; Huang, M.; Jin, X.; Cho, K.; Lilja, J.; Reynolds, R.K.; Lin, J. Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int. J. Oncol., 2000, 17, 23.
Non-Viral Carriers for Gene Delivery [123] [124] [125] [126]
[127]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
97
Kim, S.H.; Forman, A.P.; Mathews, M.B.; Gunnery, S. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene, 2000, 19, 3086. Price, D.T.; Della Rocca, G.; Guo, C.; Ballo, M.S.; Schwinn, D.A.; Luttrell, L.M. Activation of extracellular signal-regulated kinase in human prostate cancer. J. Urol., 1999, 162, 1537. Nemoto, T.; Ohashi, K.; Akashi, T.; Johnson, J.D.; Hirokawa, K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology, 1997, 65, 195. Shimizu, T.; Usuda, N.; Sugenoya, A.; Masuda, H.; Hagiwara, M.; Hidaka, H.; Nagata, T.; Iida, F. Immunohistochemical evidence for the overexpression of protein kinase C in proliferative diseases of human thyroid. Cell Mol. Biol., 1991, 37, 813. Zeimet, A.G.; Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol., 2003, 4, 415.
98
Frontiers in Medicinal Chemistry, 2010, 5, 98-126
Protein Transduction: Cell Penetrating Peptides and Their Therapeutic Applications Kylie M. Wagstaff 1 and David A. Jans2,* 1
Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia; 2ARC Centre of Excellence for Biotechnology and Development, Australia Abstract: Cell penetrating proteins or peptides (CPPs) have the ability to cross the plasma membranes of mammalian cells in an apparently energy- and receptorindependent fashion. Although there is much debate over the mechanism by which this “protein transduction” occurs, the ability of CPPs to translocate rapidly into cells is being exploited to deliver a broad range of therapeutics including proteins, DNA, antibodies, oligonucleotides, imaging agents and liposomes in a variety of situations and biological systems. The current review looks at the delivery of many such molecules by various CPPs, and their potential therapeutic application in a wide range of areas. CPP ability to deliver different cargoes in a relatively efficient and non-invasive manner has implications as far reaching as drug delivery, gene transfer, DNA vaccination and beyond. Although many questions remain to be answered and limitations on the use of CPPs exist, it is clear that this emerging technology has much to offer in a clinical setting.
Keywords: Cell penetrating protein or peptide, CPP, protein transduction. 1. INTRODUCTION A large proportion of current therapeutics require the intracellular delivery of biologically active compounds to mediate effects in the cytoplasm, nucleus and other organelles. The greatest barrier to this process is the plasma membrane itself. Although numerous strategies to overcome this in vitro have been devised, including microinjection and electroporation, they have extremely limited in vivo applications. Furthermore, large molecules usually enter cells through receptor-mediated endocytosis, which, due to subsequent fusion with the cellular lysosomal compartment, results in their degradation. Thus, methods to increase the bioavailability of compounds in vivo, especially those that can facilitate cell entry without the requirement for endocytosis, are particularly sought after. In recent years, numerous proteins and peptides have been found to enter intact cells in an apparently energy- and receptor-independent fashion [1, 2]. This process of translocation across plasma membranes, also termed protein transduction or “cellular internalisation”, has already been utilised to deliver numerous cargoes to a large number of cell types and tissues, both in vitro and in vivo.
*Corresponding author: Tel: +613 99029341; Fax: # + 613 99029500; E-mail:
[email protected] Allen B. Reitz / Atta-ur-Rahman / M. Iqbal Choudhary (Eds.) All rights reserved – © 2010 Bentham Science Publishers.
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
99
Molecules that can undergo protein transduction are known as Cell Penetrating Proteins or Peptides (CPPs), an exponentially expanding class of molecules [3]. The first CPP was discovered independently by two laboratories, which found that the trans-activating transcriptional activator (Tat) from Human Immunodeficiency Virus 1 (HIV-1) could be efficiently taken up from the surrounding media by numerous cell types in culture [4, 5]. Since then, translocational ability has been established for the Homeodomain of Antennapedia (Antp, a transcription factor from Drosophila) [6, 7], Herpes Simplex Virus 1 protein 22 (VP22) [8], Flock house Virus coat protein (FHVC) [9], the core histones [10, 11] and a multitude of others. Numerous peptides, either derived from these, or generated synthetically such as Transportan [12], have also shown strong protein transduction ability. More specifically, distinct short domains, typically less than 20-30 amino acids, which are highly rich in basic residues, mediate protein transduction [1]. Such domains are known as Protein Transduction Domains (PTDs), but their mechanism of action is still poorly understood. The present review seeks to outline the nature of some of the better-understood CPPs and their potential mechanisms of cellular entry. The main focus is the application of CPPs to mediate the cellular delivery of a wide range of therapeutic molecules and the various advantages of this system, such as the ability to deliver efficiently to a broad range of cell types and tissues. It is clear that CPPs represent an exciting new prospect for drug delivery, in a range of clinical contexts. 2. SPECIFIC CELL-PENETRATING PROTEINS It has been proposed that PTDs have evolved specifically to facilitate the translocation into cells of certain proteins and peptides with intracellular bioactivity [13], where they may play a role in host response to intracellular infections, or in infection itself in diseases such as the PrP related disorder Creutzfeldt-Jacob [14], where the cellular uptake mechanism of the infectious protein particle is unknown. In favour of the former idea, various naturally occurring antimicrobial peptides (eg, magainin or buforin) are known to penetrate plasma membranes rapidly [15], resulting in subsequent killing of the infecting organism either through cell lysis or inhibition of functions through binding to DNA and/or RNA targets. This implies that membrane translocation of specialised proteins may be an important mechanism to protect against infectious agents. In terms of pathogens, VP22 (see Section 2.3), shown to mediate intercellular trafficking between neighbouring cells, both in vitro and in vivo, plays an important role in HSV-1 infection [8, 16]. As more CPPs are discovered it has become clear that there are at least two distinct classes of PTD, as highlighted in Table (1). One class consists of Arginine (Arg) rich peptides such as Antp and Tat, whilst the other is composed of amphipathic helical peptides, such as Transportan and model amphipathic peptide, in which Lysine (Lys) is the predominant positively charged residue. The next sections describe some of the more commonly studied and most interesting CPPs, most of which will then be discussed in detail in the subsequent sections with respect to their mechanisms of action and potential therapeutic applications. 2.1. Trans-activating Transcriptional Activator (Tat) HIV-1 Tat is an 86 amino acid transcription activating protein. It has numerous domains, including a highly basic region (residues 49-57, containing 6 Arg and 2 Lys residues), which is important for nuclear localisation and RNA binding [17]. The original Tat peptide used to mediate the cellular entry of proteins (Tatp) was Tat (residues 37-72) [18], including the basic domain as well as an amphipathic -helical region (residues 38-49) [19]. The -helix
100 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Table 1.
Wagstaff and Jans
Examples of CPP/PTD Sequences
CPP
Sequence*
Length (Residues)
Reference
11
[22]
16
[6]
8
[50]
A) Arginine Rich Peptides Tatp
YGRKKRRQRRR57
Antp (Penetratin)
RQIKIWFQNRRMKWKK
Arg8
RRRRRRRR
pVEC
58#
18
[42]
50
17
[9]
MAP
KLALKLALKALKAALKLA
18
[44]
Transportan
GWTLNSAGYLLGKINLKALAALAKKIL
27
[12]
Transportan-10
AGYLLGKINLKALAALAKKIL
21
[30]
KALA
WEAKLAKALAKALAKHLAKALAKALKACEA
30
[65]
ppTG1
GLFKALLKLLKSLWKLLLKA
20
[61]
27
[98]
HIV Rev
LLIILRRRIRKQAHAHSK
635
TRQARRNRRRRWRERQR
B) Amphipathic Helical Peptides (Lysine Rich)
C) Non-basic Chimeric Peptide MPG
GALFLGFLGAAGSTMGAWSQPKSKRKV
*
Single letter amino acid code Residue 58 of the homeodomiain; corresponds to residue 356 of the full length Antennapedia protein. Abbreviations: CPP, Cell Penetrating Peptide; PTD, Protein Transduction Domain; Tat, Trans-acting transcriptional activator; Antp, pAntennapedia; pVEC, VE-cadherin-derived cell-penetrating peptide; HIV, Human Immunodeficiency Virus; MAP; Model Amphipathic peptide.
#
forming domain was originally presumed to be critical for Tat protein transduction, because shorter peptides, such as Tat (37-58) or (47-58), possessed weaker translocating ability [18]. Subsequently, however, structure-activity relationship studies of peptides derived from Tatp demonstrated the involvement of the complete basic domain (Tat (48-60)) [20]. Since any deletion within residues 49-57 led to a reduced uptake [21], the generally accepted Tat PTD peptide is now regarded as residues 47-57 [22]. This is supported by mutational studies, whereby deletion or substitution of the three C-terminal Arg residues [23], or Ala substitution of any of the cationic residues between residues 48-57, results in dramatic decreases in cellular uptake [24]. 2.2. Homeodomain of Antennapedia (Antp)/Penetratin Derived from the third helix of the Antennapedia protein homeodomain from Drosophila, Antp [6, 7] is one of the most widely studied and best-understood CPPs. Homeodomains are regions of a specific sequence of 60 amino acids, found in the homeoprotein class of transcription factors that are responsible for binding to DNA [25]. The homeodomain is structured into 3 -helices, and although the entire 60-amino acid domain is capable of
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
101
translocation, this is mediated entirely by amino acids in the third helix [6]. Specifically, the Antp PTD, also commonly known as Penetratin, consists of residues 43-58 of the homeodomain [13, 26] (see Table 1). 2.3. Herpes Simplex Virus Type 1 (HSV-1) protein 22 (VP22) VP22, one of the major structural components of HSV-1, has the ability to transport between cells [8]. In cells expressing VP22, the protein is found predominantly in the cytoplasm, where it colocalises with microtubules [27]. From here, it is exported from the cell and then taken up by surrounding cells, where it can accumulate in the nucleus [8, 16]. Within the HSV-1 virus life cycle, VP22 has many different functions and, by utilising a series of Green Fluorescent Protein (GFP)-tagged deletion constructs, these functions have been mapped to specific regions of the polypeptide as follows: intercellular transport, amino acids 81-195; binding and reorganisation/stabilisation of the cytoskeleton, amino acids 159267; inhibition of cytoskeleton collapse, amino acids 81-121; and nuclear targeting and facilitation of intercellular transport, amino acids 267-301 [27, 28]. 2.4. Transportan The 27 amino acid long Transportan is a chimeric CPP containing 12 functional amino acids from the N-terminus of galanin (a neuropeptide), bound to the membrane interacting wasp venom peptide, Mastoporan, via a Lys residue [12]. Transportan predominantly resides in membranous structures inside cells [29], but it can be taken into the nucleus where it appears to concentrate in the nucleoli [12]. Deletion analogues of Transportan, such as Transportan-10 which lacks the first 6 amino acid residues, have also been generated and retain much of the translocational ability [30] (see Table 1). 2.5. Model Amphipathic Peptide (MAP) The 18 amino acid model amphipathic peptide (MAP) is -helical in structure and displays extensive uptake into several cell types [31]. This peptide has been shown to translocate across plasma membranes in both energy-dependent and energy-independent fashion (see Section 3). In kinetic studies comparing the cellular uptake and cargo delivery of several CPPs, MAP showed both the fastest uptake and the highest cargo delivery efficiency, followed by Transportan, Tat (48-60) and then Antp (43-58) [32]. By examining the influence of various CPPs on cellular 2-((3)H)deoxyglucose-6-phosphate leakage, they also demonstrated that the membrane-disturbing potential of the peptides correlated with their hydrophobic moment. 2.6. Histones One of the most recent additions to the CPP family are the core histone proteins [33]. The primary unit of DNA compaction in eukaryotic cells is the nucleosome core particle, where 146 bp of DNA are wrapped twice around a protein core, consisting of two of each of the four core histones; H2A, H2B, H3 and H4 [34]. The DNA is electrostatically bound to this histone octamer [35] and the intervening DNA between each nucleosome condensed further through the action of a fifth histone, H1 [36]. Due to their DNA binding and packaging ability histones have been examined as potential gene therapy vectors [37, 38], under the assumption that they enter cells via classical endocytotic mechanisms (see Section 3.1 below). Recently, however, it was shown that histone proteins are capable of direct translocation across plasma membranes [33]. H2A and H4 posses the strongest translocational ability, with H3 not far behind, while H2B demonstrated the lowest amount of cell-penetrating
102 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Wagstaff and Jans
potential, both in whole cells and in uni- and multi-lamellar liposomes [10, 33]. Interestingly, core histones were also shown to penetrate the plasma membrane of petunia protoplasts, the first demonstration of the activity of CPPs in plant cells [11]. Importantly, histones of the linker variety (histone H1 and its homologues) have also been investigated for their CPP activity [39, 40], with one recent report demonstrating that nuclear delivery of proteins mediated by protein transduction through Histone-H1o could be significantly enhanced by the inclusion of a dynein-association sequence, resulting in enhanced binding to the microtubule network [41], suggesting that traffic through the cytoplasm is also an important factor in nuclear delivery of CPP cargo. 2.7. Other Cell Penetrating Proteins/Peptides Apart from those mentioned above, many other CPPs have been discovered or designed. These include; pVEC, an 18 amino acid peptide derived from the murine cell adhesion molecule vascular endothelial cadherin (amino acids 613-635), shown to be efficiently taken up by cells and accumulated predominantly in the nucleus [42]; and the PreS2-domain of the hepatitis B virus surface antigens, which translocate into cells through energy-dependent mechanisms, and subsequently localise diffusely throughout the cytoplasm [43]. Interestingly, the 26 amino acid peptide VT5, exhibits extensive cellular internalisation even though it forms a water soluble, amphipathic -sheet conformation [44], whilst D-substituted analogues with no propensity to form -sheets, show only ~5% translocation ability compared to VT5 itself. This is in stark contrast to the “classical” -helical amphipathic CPPs (see Table 1B), but the authors suggest that VT5 internalisation may not follow the same precise pathway, as its uptake is temperature-, energy- and pH-dependent (see Section 3). Importantly, the N-terminal portion of the mouse prion protein (PrP), which has a strong tendency towards aggregation and forms -sheets in the presence of phospholipids, has also been shown to act as a CPP [14]. 3. MECHANISMS OF MEMBRANE TRANSLOCATION 3.1. Conventional Cellular Entry Mechanisms There are many ways in which a molecule can gain entry into a cell, some of which result in degradation of the ingested substance. The cellular uptake pathways, summarised in Table 2, include receptor-mediated endocytosis, pinocytosis, macropinocytosis and potocytosis (for a review see [45]). Since the pathways involve very different uptake mechanisms, the effects of inhibitors vary greatly (see Table 2), with their actions used extensively to define the pathways. Receptor-mediated endocytosis (see Table 2A) involves the recognition of a ligand by a cell surface receptor. Cellular uptake is then mediated through invagination of the plasma membrane to form a vacuole. This invagination is energy-dependent and relies upon clathrin, which lines the membrane ‘pits’ that are central to the process and mediates the invagination process and also involves microtubules and actin filaments. Pinocytosis (see Table 2B) is the mechanism through which a cell samples its extracellular environment by the budding of small vesicles from the cell membrane into the cytoplasm. This mechanism allows the cell to gain a representative sample of the molecules and ions in the extracellular fluid, or to replenish nutrients that may be in short supply. Only small molecules are engulfed by pinocytosis, which occurs continuously in almost all cell types.
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
103
Macropinocytosis (see Table 2C), on the other hand, allows cells to engulf much larger molecules. In this regard, it is similar to receptor-mediated endocytosis, but is not reliant on a specific receptor. Instead, the formation of the endocytotic vesicles occurs in response to stimulation of a cell-signalling cascade involving RhoGTPases, resulting in the closure of lamellipodia at the sites of membrane ruffling to form large, irregular vesicles. The membrane ruffling in this process is primarily actin-driven and does not require clathrin. Macropinosomes have been known to undergo acidification and enter the endosomal pathway, although this is not always the case. Potocytosis (see Table 2D), also known as caveolae-mediated uptake, is a mechanism by which both small and large molecules can be sequestered and transported by caveolae, flaskshaped specialised regions of the plasma membrane which are characterised by the filamentous coat of caveolins that line their inner surface. They differ from endosomes in that they are not associated with clathrin and can deliver the internalised molecule to four different parts of the cell, bypassing the lysosome. There is some evidence to suggest that potocytosis is temperature independent [46]. 3.2. Receptor-independent Uptake The uptake of CPPs (see Table 2E) does not appear to require specific cell-surface receptors [13]; rather the overall charge of the peptide appears to be important. Indeed, structural studies of the Tat PTD have demonstrated the general importance of Arg residues in mediating translocation [47] (see Section 2.1). Added to this, the retro and inverso forms of Tatp, synthesised with either a reversed linear orientation or containing D-amino acids respectively, show translocational ability comparable to wild type peptide [9, 24], implying that the very specific conformational/steric constraints typical of ligand-receptor interactions do not apply to Tat. Similarly, D-enantiomers of Antp and pVEC show no decrease in internalisation, with the D-enantiomer of (Arg)8 actually showing enhanced uptake [24, 42, 48]. 3.3. Energy-dependent or Energy-independent Uptake Originally, the uptake of Tat, Antp and others was believed to occur in non-saturable, dose-dependent fashion. Protein translocation was initially viewed as non-endocytotic in light of the fact that no decrease in uptake efficiency is seen at 4ºC, when compared to 37ºC, implying an energy-independent translocation mechanism (see Table 2E) [20, 49]. Low temperature was thought to inhibit all forms of cell entry, but potocytosis has also been proposed to be a temperature insensitive uptake mechanism, although there is little direct evidence to support this [46]. In favour of a non-endocytotic mechanism of uptake are reports that showed no effect on CPP uptake in the presence of inhibitors of endocytosis [33, 50], including the microtubule disrupting agents nocodazole, taxol and colchicine; the filament disrupting agent cytochalasin D; brefeldin A, an inhibitor of trans-Golgi transport; the phosphatidylinositol-3 kinase inhibitor Wortmanin; the caveolae formation inhibitor nystatin; and chloroquine, an inhibitor of the acidification of endocytotic vesicles [33, 50-52] (see Table 2). Translocation also occurred in ATP-depleted cells and in cells incubated with 0.5 M sucrose, conditions that block endocytosis/pinocytosis [33]. Recently however, the energy-independence of CPP uptake has come into question. Some studies have applied a trypsin digestion step after application of the peptide, prior to visualisation of CPP localisation, the idea being that trypsin will remove any extracellular proteins that may interfere with the peptide, as well as removing any residual surface-bound
104 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Table 2.
Wagstaff and Jans
Summary of Conventional Cell Entry Pathways Compared to Protein Transduction Name
A Receptor-mediated endocytosis
eg. Ligands such as Transferrin, Epidermal Growth Factor (EGF).
B Pinocytosis
eg. Molecules such as Low Density Lipoproteins (LDLs), Iron.
C Macropinocytosis
eg. Fibroblast Growth Factor (FGF)
Description
Characteristics
Ingestion of ligands after interaction with specific cell surface receptors into intracellular endosomes. These undergo acidification and eventually fuse with lysosomes to degrade the internalised material
Dependent upon:
Small molecules, usually liquids are ingested from the extracellular fluid through vesicles budding intracellularly from the plasma membrane.
Dependent upon:
Also important for membrane recycling
Caveolin
Engulfment of large macromolecule by invagination of the membrane through actin-driven ruffling
Inhibited by
Cell Surface Receptor Clathrin
Brefeldin A (Clathrin inhibitor).
Kinases
Wortmanin (PI-3K* inhibitor)
Acidic Compartment
Chloroquine (prevents
Energy
acidification of endosomes)
Temperature
Sodium azide, sodium fluoride
Cytoskeleton
(metabolic inhibitors) 4ºC
Independent of: Caveolin
Energy
Nocodazole, taxol, colchicine and cytochalasin D (target the cytoskeleton)
Temperature
Sodium azide, sodium fluoride (metabolic inhibitors)
Tubulin
4ºC Colchicine (targets tubulin)
Independent of: Cell-Surface Receptors
Others
Clathrin
Bacitracin and monensin (antibiotics that inhibit pinocytosis, thought to be related to Ca+/Mg+ binding ability)
Acidic Compartment Kinases
Yeast mannans and phosphorylated sugars (inhibit pinocytosis possibly through competition)
Dependent on: Actin
Cytochalasin D (targets actin)
RhoGTPases
RhoGTPase inhibitors, such as C. difficile toxin B.
Energy Temperature
Sodium azide, sodium fluoride (metabolic inhibitors) 4ºC
Independent of: Cell Surface Receptors Clathrin Caveolin
Others ethylisopropylamiloride (EIPA) and dimethylamiloride (DMA) (inhibit the formation of macropinosomes)
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
105
Table 2. contd….
Name D Potocytosis
eg. Retinol Binding Protein, Simian Virus 40 (SV40)
Description Transport of small and large molecules into cells, bypassing the lysosome. Delivery to four internal cellular destinations
Characteristics
Inhibited by
Dependent upon: Caveolae
V-type proton ATPases Lipid Rafts Energy
Independent of: Temperature (?)
Sterol-binding agents such as nystatin, filipin and digitonin (disassemble caveolae) Activators of protein kinase C such as PMA* (inhibit caveolae internalization) Bafilomycin A1, (inhibits vacuolar ATPases)
Sodium azide, sodium fluoride (metabolic inhibitors)
Cell Surface Receptors Clathrin Actin E Protein Transduction
eg. Transportan, Histones
Direct translocation through cell membrane. Precise mechanism unknown
Dependent upon%
Unknown
Basic residues Amphipathic -helices Heparin Sulfate
Independent of: Energy Temperature# Cell Surface Receptors Clathrin Caveolin
%
See Section 3 See however [48, 51] *Abbreviations: PI-3K, Phosphotidinositol-3-Kinase; PMA phorbol-12-myristate-13-acetate
#
peptide not displaced by washing [52]. Using this protocol, a strong reduction in Tatp uptake was observed, as measured by Fluorescence Assisted Cell Sorting (FACS) [53]. This indicates that previous FACS measurement of the internalisation of CPPs may have overestimated the extent of translocation by including surface-bound peptides in the analysis [52]. Further to this, low temperature incubation followed by trypsin treatment showed little to no cellular internalisation of CPPs. This implies that the previously reported temperatureinsensitivity of CPP uptake may in fact be an artefact, due to extracellular binding of peptide, rather than membrane translocation [53]. Studies using the trypsin approach demonstrated that the kinetics of Tat uptake fits with those of cell entry of molecules that are nor-
106 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Wagstaff and Jans
mally taken up by endocytosis. In accordance with this, one study found that the delivery of Tat-oligonucleotide complexes was mediated by endocytosis, as it was inhibited at 4ºC, and in the presence of metabolic inhibitors such as sodium azide, sodium fluoride and antimycin A, as well as increased in the presence of chloroquine [54] (see Table (2)). Fluorescence microscopic examination observed temperature dependent localisation of either Tatp or Antp bound to oligonucleotides in perinuclear vesicles having the hallmarks of endosomes, indicative of endocytosis [55]. It is worth noting at this point that this study utilised trypsin to remove adherent cells prior to FACS, in a similar fashion to the above study. In general, the contribution of extracellular binding of peptide, classical endocytosis and true protein transduction mechanisms to the observed cellular uptake of CPPs is not entirely clear. Whether the afore-mentioned effects hold true for all of the diverse CPP family members remains to be seen. 3.4. Is Translocation Merely an Artefact of Fixation? Recently, it has been reported that both VP22 and Histone H1 can adhere to the cell membrane of living cells, with membrane disruption upon fixation allowing them to relocate to the cell cytoplasm and nucleus [14]. Such a change in localisation upon fixation was also seen for Tatp and Tat-mini-antigen fusion protein constructs [53, 56]. Even paraformaldehyde, which is a relatively mild means to fix cells, has been shown to result in an artefactually high level of translocation [53]. This suggests that the protein transduction observed in many cases may simply be an artefact of cell fixation, not reflecting the live cell situation. This does not explain the induction of biological effects after uptake of biologically active molecules fused to CPPs, however. An elegant example is experiments using a transducing, modified, apoptosis-promoting caspase-3 protein, Tat-Casp3, that has HIV proteolytic cleavage sites substituted for its endogenous ones [57]. Tat-Casp3 was shown to transduce nearly 100% of cells, but remains inactive in uninfected cells. In HIV-infected cells, however, Tat-Casp3 is processed into an active form by the HIV protease, resulting in efficient apoptosis of such cells, without affecting the uninfected cell population [57]. This is a clear demonstration of the intracellular functionality of a CPP-delivered protein, in the absence of cell fixation procedures. Furthermore, numerous reports have demonstrated the uptake of CPPs and/or the corresponding biological response in living cells by fluorescence microscopy and in vivo experiments [10, 33, 58, 59]. Nonetheless, it is clear that fixation should be avoided if at all possible when dealing with CPPs, and that demonstration of an expected biological outcome, such as the expression of a protein or downregulation of a gene, can be considered as the gold standard for confirming intracellular delivery of the attached cargo [60, 61]. 3.5. Important Features Required for Membrane Translocation When comparing the physico-chemical characteristics of the various CPPs, a consistent finding is the high content of basic amino acids and a resultant positive charge [61]. As discussed briefly above, cationic residues have been shown to be critical for protein transduction [62, 63], but positive charge alone is not enough. Using polyArg peptides of various lengths, Futaki et al. [9] demonstrated that there is an optimal number of residues (~8) for efficient translocation, with greater chain lengths not aiding, but rather hindering uptake, as shown for the (Arg)16 peptide, which shows no cellular uptake. It was therefore concluded that the guanidinium group of Arg was therefore important for translocation [24, 47], and further, that the distance between this group and the peptide backbone is critical [9, 24].
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
107
This of course, does not account for the strong translocating ability of Lys-rich peptides with little or no Arg content, such as MAP or Transportan [12, 44] (see Table 1B). Secondary structure is also important for translocation, with many CPPs adopting, or predicted to adopt, an -helical structure, including KALA and the Tatp [64, 65]. This does not, however, appear to be a critical requirement. Although the parental Antennapedia homeodomain adopts and maintains an -helical conformation, Antp has been shown to adopt a -sheet conformation in the presence of a charged lipid monolayer [66]. Similarly, an amphipathic -sheet peptide displayed potent PTD qualities, in that it remained in soluble form and was efficiently taken up into cells [44]. Consistent with reports that -helix conformations can be maintained and even promoted by the presence of SDS micelles [13, 67], Transportan has been observed to adopt a random coil conformation when in aqueous solutions, but becomes mainly -helical in the presence of SDS [68]. Similarly hCT(9-32), a CPP derived from human calcitonin is unstructured in aqueous solutions, but adopts two short helical stretches when bound to dodecylphosphocholine micelles [69]. Pep-1, a synthetic CPP with an -helical trytophan-rich N terminus, has been shown to interact with both micelles and protein cargo via its tryptophan-rich domain [70]; a C-terminal cysteamine group was found to offer additional anchorage to the membrane surface, leading to more efficient cellular translocation, a property also seen with hCT(9-32) mutants [69, 70]. Yet further studies maintain that Tat fusion proteins must first be unfolded in order to promote efficient uptake by cells [71, 72]; unfolding may favour access to the cell membrane to promote internalisation. 3.6. Proposed Models of Membrane Translocation Three models have been put forward to explain the mechanism of cellular uptake utilised by CPPs. The inverted micelle model (Fig. (1A)) was proposed from NMR studies on the interaction of Antp with phospholipid membranes [49]. The first step of translocation involves the positively charged CPP interacting with, or recruiting, the negatively charged heads of the membrane phospholipids into the membrane vicinity. A reorganisation of the lipid bilayer around the CPP then occurs, aided by interactions of the hydrophobic residues of the CPP with the membrane. This induces the formation of an inverted micelle, in which the hydrophilic centre pocket entraps the CPP. Intracellular release is then affected by an analogous set of reactions in reverse. Although this model may explain translocation of some CPPs, it is not sufficient for peptide/proteins that do not contain the hydrophobic amino acids necessary to mediate the lipid interactions of the translocation process (eg. polyArg) [13]. Moreover, the large size of some of the transported cargoes (eg. a 45 nm diameter ferromagnetic particle [73]) argues strongly against the formation of such particles. Also, intermediate membrane structures such as those shown in Fig. (1A) have never been observed microscopically [52]. There is some evidence, however, to suggest that the entry of Antp into liposomes involves a trans-membrane electrical potential, which may act in a similar fashion to the initial steps of this model [74], where it was shown that the positively charged peptide initially accumulated on the surface of the membrane. This asymmetrical distribution of the peptide between the outer and inner surfaces of the charged lipid bilayer led to a transmembrane electrical field, which presumably altered the lateral and curvature stresses acting within the membrane and resulted in an electroporation-like permeabilisation of the membrane. Further binding of the CPP caused the electrical field to reach a critical threshold value, ultimately inducing CPP uptake, presumably via the formation of inversely curved membrane structures, similar to those proposed in the inverted micelle model [75].
108 Frontiers in Medicinal Chemistry, 2010, Vol. 5
A
Wagstaff and Jans
B
CPP
C
(a) (b)
(a) CPP
CPP
(c) (b)
(c) CPP
CPP
(d)
(c) CPP
CPP
CPP
(d) CPP
(d)
CPP
(e)
Fig. (1). Proposed models of membrane translocation mechanisms: A is based on NMR studies, B and C are based on the membrane translocation of antimicrobial peptides [49, 74, 75]. A. Inverted micelle model: The positive charges present in the CPP interact with and recruit negatively charged phospholipids in the cell membrane (a). The hydrophobic part of the CPP then interacts with the membrane (b), generating an inverted micelle (c). The hydrophilic cavity can then accommodate the protein and allow release into the cytoplasm (d). B. ‘Carpet’ model: (a) The CPP first interacts through its positive charges with the negative charges of the phospholipids, causing a change in secondary structure as the basic residues turn themselves towards the membrane. (b) The CPP then rotates, allowing hydrophobic residues to interact with the hydrophobic core of the membrane. (c) A small disruption in the lipid membrane then permits the CPP to be internalised, presumably followed by membrane closure (d). C. Pore-formation model: The CPP first interacts with the membrane as per B (a/b). Amphipathic helices in the CPPs then form into bundles (c), thus creating a pore within the membrane (d), where the hydrophobic residues interact with the lipid membrane and the hydrophilic residues line the pore, allowing other peptides to pass through. (e) The pore formation is speculated to be transient.
The carpet model (Fig. (1B)) is based on the known translocation mechanism of some antimicrobial peptides [76], but has been proposed to apply to CPP translocation in the case of certain CPPs, based mainly on their toxicity at high concentrations [13, 76]. The CPP is proposed to interact initially with the negatively charged phospholipids; this causes a change in the CPP secondary structure as the basic residues turn towards the membrane surface. The CPP then rotates so that its hydrophobic residues can interact with the hydrophobic membrane core. Finally, a small disruption of the lipid membrane surface occurs, allowing the peptide to pass through and into the cytoplasm, leaving the membrane to presumably close behind it. Although this mechanism has been suggested for CPP entry, its reliance on hydrophobic residues seems to preclude its application to most CPPs, as they are predominantly basic (see Table 1). It has clear value as a mechanism by which antimicrobial peptides exert their toxicity, however [13, 76].
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
109
As for the carpet model, the pore formation model (Fig. (1C)), is based on one of mechanisms by which antimicrobial peptides appear to weaken bacterial membranes [77]. Amphipathic -helices within the CPPs are proposed to form bundles on the membrane surface. Following this, the outwardly facing hydrophobic residues interact with the lipid membrane, allowing the inwardly facing hydrophilic residues to form a pore through which other peptides can pass. Some amphipathic basic peptides such as mastoparan and magainin have been shown to form helical structures in the cell membrane and to assemble as complexes to form pores [50, 78-80]. This pore formation leads to a leakage of the intracellular contents and resultant high cytotoxicity. HIV Rev (34-50), which contains an Arg-rich basic domain similar to Tat, has been suggested to form helical structures in the membrane, much like mastoparan [9]. However, no significant membrane perturbation was seen when cells were treated with this, or a number of other Arg-rich peptides [50] and no significant cytotoxicity was associated with internalisation of these peptides. This indicates that if this mechanism is a means by which CPPs enter cells, then the pores must be transient and the membrane must repair itself afterwards. Although all three mechanisms potentially explain membrane translocation, none are satisfying in terms of explaining the translocation by all CPPs, and none of them are able to satisfactorily describe how these peptides can translocate cargoes 100-fold their own size [13]. Clearly, much further research is required to establish the mechanism of CPP translocation through membranes, and discount the very real possibility that CPPs use multiple different mechanisms (see above and below) and that they may behave differently when complexed with cargo molecules. To this end, evidence in favour of other mechanisms of uptake is beginning to mount. 3.7. Enhanced Endosomal Escape Overwhelming support for endocytotic uptake of CPPs has been generated recently, at least for Tatp and Antp. It was demonstrated that Tatp or Antp bound to oligonucleotides enter cells in a mechanism indistinguishable from endocytosis [55]. Similarly, plasmid DNA translocation into cells mediated by oligomers of Tatp, was found to occur by endocytosis [54]. Several reports have shown that Tatp demonstrated enhanced binding to the cell membrane, subsequently resulting in endocytosis and accumulation in endosomes [56, 61, 63]. Tat-fusion proteins also seem to enter the cell via an endosomal pathway, but circumvent degradation in the lysosome and are ultimately sequestered in the nuclear periphery [81]. In support of this, the synthetic CPP, ppTG1, has demonstrated extremely efficient membrane translocation in HeLa cells, which appeared to be due to endosomal uptake combined with enhanced liposomal escape as demonstrated by in vitro liposomal leakage assays [82]. These studies demonstrated that ppTG1 forms a random coil structure at neutral pH, but in acidic conditions, such as those found in late endosomes, it converts to an amphipathic helix and inserts into the liposomal membrane to cause membrane disruption and leakage of vesicle contents. Therefore, it seems possible that rather than follow the mechanisms illustrated in Fig. (1), the cationic residues of Tatp initially confer interaction with negative charged moieties at the membrane surface, such as phospholipids or extracellular proteins. Following this, Tatp is internalised through conventional endocytosis, subsequent to which it manages to circumvent lysosomal degradation and escapes into the cytoplasm [52]. Whether these endosomolytic properties, rather than protein transduction, hold true for other CPPs is yet to be shown.
110 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Wagstaff and Jans
3.8. Multiple Mechanisms of Membrane Translocation In contrast to the above, much evidence supports the idea that many CPPs do not enter the cell via endocytosis [33, 50], consistent with more than one mechanism being involved in the translocation of CPPs. It may be that the apparently conflicting endocytosis versus non-endocytosis reports are explicable in terms of the fact that both endocytotic and nonendocytotic mechanisms work in parallel, both contributing to translocation to differing extents, depending on the CPP [13, 60]. Alternatively, considering the vast physicochemical diversity among the different classes of CPPs, it is possible that distinct cellular uptake mechanisms operate for different CPPs [13]. For example, Tat-mediated intracellular delivery may proceed via energy-dependent macropinocytosis, with subsequent enhanced endosomal escape [83], whilst other CPPs seem to penetrate cells via charge interactions and hydrogen bonding, without an energy requirement [1, 84]. In all cases, it seems clear that direct contact between the CPP and the cell surface are essential for successful cellular uptake [1]. The role of cell surface proteoglycans such as heparin sulfate, in membrane translocation, and whether they may act like cell surface receptors for the endocytotic/ macropinocytotic uptake remains unclear [50, 85, 86]. 4. THERAPEUTIC APPLICATION OF CPPS Since the cell membrane represents a major barrier to the delivery of numerous pharmaceuticals, CPPs are very promising potential delivery vectors. They have already been utilised to deliver a wide range of cargoes into mammalian cells, both in vitro and in vivo [1]. CPPs often have many desirable features for cellular delivery, such as efficacy in vivo, nuclear targeting, applicability in a wide variety of cell types and no apparent cargo size restrictions or immunogenic, antigenic or inflammatory properties [13]. They also appear to be able to deliver cargo such as peptide nucleic acids into bacterial cells [87] and can efficiently translocate mycoplasma membranes [10]. These properties make CPPs ideal for use in a wide range of therapeutic applications, some of which are covered in the remaining sections. 4.1. Cargo Considerations 4.1.1. Cargo Size CPPs have been used to deliver numerous classes of cargo, including DNA, proteins, drugs and nanoparticles, most of which are many times larger than the CPP itself [1]. However, it has not yet been conclusively determined whether the coupling of a CPP to a cargo, particularly a sizeable one, interferes with the translocation mechanism [88]. Some studies suggest that the coupling of a CPP to a high-molecular weight cargo forces it into an endocytotic route of entry, regardless of whether this is the case for the CPP alone [54, 61, 85, 89]. In such a circumstance, the CPP would therefore appear to mediate mainly the binding of the CPP/cargo to the cell membrane [88]. 4.1.2. Coupling of CPP to Cargo An important consideration is the nature of the CPP-cargo attachment, some common examples of which are illustrated in Fig. (2). The link between the two is usually a covalent bond, with, in these cases, the orientation of the CPP and cargo major considerations [88]. A common approach is the use of suitable amino acid side chains such as the thiol group of Cys or the amino group of Lys [12, 90]. Of these, disulfide bonds are the most common and have the added benefit of being rapidly reduced in the intracellular environment, enabling
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
111
release of the cargo [12]. Other stable, covalent linkages that have been employed include amide, thioether, thiolmalmeide, thiazolidine, oxmine and hydrazine linkages, as well as bifunctional cross-linkers such as SMCC [88, 90-92]. If the cargo is a peptide/protein, then the two can be produced as a single chimeric protein in bacteria [92, 93].
Covalent Linkages Genetic Linkage
A
Non-Covalent Linkages
Side-chain Linkages
B
F H
CPP
CPP
Cargo
C
N
CPP Cargo
O
C
G CPP
S
S
Cargo
CPP
Cargo
D H S
CPP
N H
Cargo
E CPP
S
SMCC
Cargo
Fig. (2). Common methods of CPP cargo attachment; Covalent bonding techniques include: A. Generation of fusion proteins in bacteria B. Peptide bond formation (similar to A, but for synthetic peptide CPPs and cargo) C. Disulfide bridge formation D. Thiazoline ring formation E. Bifunctional linker molecules, such as SMCC (Succinimidyl 4-(N-maleimidomethyl)cyclohexane1-carboxylate). Non-covalent bonding techniques include: A. Electrostatic interactions between cargo (usually nucleic acid) and CPP B. “Piggy-back” attachment: Non-covalent attachment of a large cargo molecule to a smaller cargo (represented by the dark circle), that is covalently attached to the CPP.
Non-covalent attachments can also be employed, most commonly for nucleic acid delivery. In this case, an electrostatic interaction between the positively charged CPP and the negatively charged nucleotide-phosphate backbone effects complexation [1, 90]. Alternatively cargo and CPP can be cross-linked individually to biotin and streptavidin, and subsequent attachment conferred by the streptavidin-biotin interaction (Fig. (2G)) [94]. When utilising non-covalent bonding to deliver cargo by CPP, an important consideration is the stoichiometry of chemical complexation and physical formulation and how this may affect translocation into the cell [88]. 4.2. Application of CPPs in Gene Therapy To treat genetic disorders through introducing therapeutically active genes that overcome debilitating loss-of-function mutations has long been a goal for medical science. A major limitation, however, is the delivery of DNA across biological membranes, including both the plasma membrane and subsequently the nuclear membrane, whilst minimising toxicity to the cell. Although viral gene delivery vectors have been commonly used due to their efficient gene transfer capabilities, many safety considerations have hampered their use as
112 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Wagstaff and Jans
therapeutics, including pathogenicity, oncogenicity and stimulation of immunological responses in the host [95]. Non-viral vectors, on the other hand, are relatively safe to use, but their inefficiency is an ongoing problem. CPP-based delivery systems have emerged as strong possibilities to facilitate non-viral gene therapy; they have also been applied to the enhancement of viral gene therapy, with limited success [96]. 4.2.1. Synthetic CPPs for DNA delivery To overcome the inefficient gene transfer mediated by non-viral based vectors, synthetic CPP delivery systems have been developed. Synthetic CPPs have been designed which can both condense DNA and transport it across the lipid bilayer into the cell, either directly, in the case of amphipathic CPPs, or via endosomes, in which case the CPP mediates plasmid release by destabilising the endosomal lipid bilayer at low pH [97]. Some of these, such as the synthetic membrane destabilising KALA peptide [65] and (LARL)6 [98], have proved relatively successful in the transfection of different cell lines in vitro. However, the increased cytotoxicity of these peptides and their inability to mediate DNA transfer into primary cell lines has limited their use in vivo. New basic amphipathic CPPs have been designed, with gene delivery to animals being achieved using a single-component peptide vector, although this system most likely utilises endosomal uptake and endosomolytic activity for enhanced entry to the cell [82]. These peptides (designated ppTG1 and ppTG20) were found to be superior to KALA in cell culture experiments, leading to transfection efficiencies comparable to polyethylenimine (PEI) and Lipofectin, especially at low DNA doses. Structure-function studies suggest that the high gene transfer efficiency of these peptides correlates with their ability to form -helical conformations at low pH, which is largely influenced by the nature of the hydrophobic amino acids within the peptides [64, 65, 82]. This conformation enables the CPP to interact with the endosomal membrane, causing release of the plasmid into the cytoplasm [60, 82]. This is in agreement with earlier reports that demonstrate that cationic -helical peptides bound to DNA are internalised via the endocytotic pathway in vitro [98] (see also Section 3.7). As electrostatic interactions between the DNA and the CPP may interfere with the protein transduction process, synthetic peptides, designed as branching complexes were also investigated [99]. The 8-tat peptide, consisting of 8 arborising Tat moieties, was capable of transfecting both dividing and non-dividing endothelial cells, but unfortunately these levels, especially in non-dividing cells, were well below those obtained using the commercial transfection reagent LipofectAMINE. 4.2.2. Delivery of Oligonucleotides by CPP Much of the work in terms of nucleic acid delivery by CPPs has thus far focused on the delivery of oligonucleotides (ONs), and in particular antisense ONs for gene silencing [60]. Antisense therapies are based on ONs that can hybridise, in sequence-specific fashion, with complimentary mRNA strands in the cytoplasm, causing translational arrest or the recruitment of RNaseH [100]. The end result is the downregulation/silencing of gene expression. As the cellular uptake of ONs themselves is relatively poor, coupling to CPPs can significantly increase their efficiency [2, 97]; for a review on the preparation of ON-peptide conjugates, see [101]. Peptides are most commonly coupled to ONs via electrostatic binding interactions [65, 97], rather than hydrophobic or covalent bonding, although di-sulfide linkages have also been used [12, 58], and may in fact have advantages as the linkage can be readily reduced in the intracellular environment [12, 32]. ONs have been modified in may ways, with changes to the sequence, chemical group modification and the use of nucleotide analogues resulting in varying degrees of antisense
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
113
activity. Above all, it has been shown that modification of the sugar-phosphate backbone of the ON plays an important part, not only in the gene silencing, but also in efficient membrane translocation [62]. Improvements to ON modifications are constantly being developed [100], the use of ONs containing nucleotide analogues overcoming many of the degradation issues plaguing naturally occurring ONs. For example, morpholinos, which are modified ONs, have standard nucleic acid bases, but are bound to morpholine rings instead of deoxyribose rings and linked through phosphorodiamidate groups instead of phosphates [102]. This makes them completely resistant to nuclease degradation and prevents them from activating innate immune responses. Several CPPs, bound to ONs have been shown to be efficiently delivered into cultured mammalian cells [12, 97, 103, 104] with genes such as c-myc, bcl-2 and glyceraldehyde 3phosphate dehydrogenase (GAPDH) [105-107] having been targeted in this fashion. In an elegant study, VP22 (residues 159-301) was found to assemble with ONs into regular spherical particles, termed Vectosomes, that entered cells efficiently in 2-4 hours and were stable in the cell cytoplasm for several days [108]. Remarkably, when these cells were exposed to a bright light, the Vectosomes were disrupted and released the protein and ON into the nucleus and cytoplasm within seconds. This process was captured by time-lapse microscopy and was later demonstrated to be just as effective in vivo in the delivery of anti-c-Raf1 ONs to subcutaneous tumours implanted into nude mice [104]. One drawback to this process may be that VP22 can elicit an immune response in immunocompetent hosts, which may either neutralise the effect of repeated injections or prime an antitumoural effect favourable to tumour regression [104]. A sophisticated approach to examine the delivery of ONs for anti-sense therapy involves the blockade of an aberrant alternative splice site with an ON, thereby inducing the correct translation of a reporter gene, namely either GFP or firefly luciferase [55, 62, 109]. This technique has been utilised either in cultured mammalian cells, or in transgenic mice to examine ON delivery to organs in vivo [62]. In both cases, peptide-ON conjugates targeted to the aberrant splice site, but not mismatched controls, causing an increase in reporter gene expression, which is not observed with ON alone. The use of PNAs (Peptide Nucleic Acids) is common in CPP-mediated antisense delivery, possibly because the peptide backbone of the PNA allows the CPP-PNA construct to be synthesised as a single polypeptide [60, 101]. There is evidence to suggest, however, that synthesis of the peptide-PNA in this fashion may interfere either with the CPPs’ ability to translocate across membranes, or with the PNA-mRNA interaction [60]. Therefore, more often than not, PNAs are coupled to CPPs via a disulfide bridge [29, 110]. Both Transportan and Antp (43-58) were used in this way to deliver an antisense PNA complementary to the human galanin receptor type 1 mRNA in vitro and in vivo [12], resulting in significant suppression of the galanin receptor expression in cultured Bowes melanoma cells, as well as in the spinal cord of rats, leading to a modification of the pain response. This approach has also been extended such that the CPP is coupled to the antisense PNA via DOTA (a derivative of 1,4,7,10-tetraazacyclododecane-N,N’,N’,N’’-tetraacetic acid), which incorporates macrocyclic radiometal chelates into the conjugate, enabling it to be traced using radioimaging approaches [105]. CPPs conjugated via electrostatic interactions to short interfering RNA (siRNA) have also been used to promote robust down-regulation of target mRNAs [107]. 4.2.3. Suicide Gene Therapy Approaches Suicide gene therapy is a widely exploited approach for the treatment of cancers and other hyperproliferative disorders [1]. It involves the introduction into target cells of a gene
114 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Wagstaff and Jans
encoding an enzyme that converts a harmless prodrug into a potent cytotoxic agent [111]. Whilst various enzyme/prodrug combinations have been developed, the most widely used is the HSV-1 thymidine kinase (TK)/ganciclovir (GCV) combination [111, 112]. Despite its popularity, clinical successes have been hampered by the inefficiency of TK gene transfer and its limited effect on bystander cells [1]. Amplification of the cytotoxicity by co-transfer of the TK gene fused to a CPP has proved very successful. In cell culture, VP22-promoted spreading of TK resulted in killing of virtually all cells in cultures that only had a transfection efficiency of 27.5% [111]. This demonstrates that VP22 enhances both the intercellular trafficking and killing effect of TK, especially in the lower range of GCV concentrations. Similar results were seen using the Tat PTD [112], indicating that fusion to CPPs may constitute a viable approach in the optimisation of TK suicide gene therapy, towards its efficacious use in a clinical setting. 4.2.4. Plasmid Delivery by CPP The report that Tat PTD, when expressed as a fusion protein on the surface of recombinant -phage particles, can induce significant expression of marker genes, with no harmful effect on the cells [51], introduced the possibility of using PTDs for the in vivo delivery of therapeutic genes [1]. One recent study added polyLys residues to the Tat PTD (Tat-pK) to enhance gene delivery [113]. The resultant polypeptide possessed DNA binding ability and was able to mediate delivery of a reporter gene to cultured cells. Significantly, since delivery was enhanced in the presence of chloroquine or ammonium chloride, it appears clear that uptake of the plasmid DNA is via the endocytotic pathway (see Table 2A), rather than protein transduction. Previously, however, it was demonstrated that various viral derived peptides, including Tat (48-60) and FHV coat (35-49), were able to transfect Cos-7 cells as efficiently as polyLys or poly-Arg [9, 114]. Further, N-terminal stearylation of these peptides, including octoArg peptides, resulted in a 100-fold increase in transfection efficiency, that was not further enhanced by chloroquine [114]. This implies that CPPs modified to include this fatty acid group, can mediate cell entry of DNA via a pathway that is not endocytosis driven, although it should be stressed that it is not clear whether this modified CPP is taken up by the same mechanism as unmodified CPPs. Another study demonstrated that Tat (47-57) alone has DNA-binding ability sufficient to induce efficient transfection of plasmid DNA into cultured mammalian cells, which however appeared to be mediated by the endocytotic pathway [89]. Moreover, intravenous injection of the positively charged DNA-Tat complexes into C57BL/6 mice resulted in very low levels of gene expression in the liver. This was attributed to inactivation of the DNA-Tat complexes by serum proteins in vivo [89]. Finally, one group have generated a novel peptide-based delivery vector (MPG), derived from a chimera of the hydrophobic fusion peptide of HIV-1 gp41 and the hydrophilic nuclear localisation sequence of SV40 large tumour antigen (T-ag), that is non-cytotoxic, insensitive to serum, and importantly, able to deliver plasmids efficiently into several cell lines, in less than 1 hour [115]. MPG interacts strongly with nucleic acids, most likely forming a peptide cage around them, which can both stabilise and protect them from degradation in cell culture medium. Although this peptide has been studied quite extensively [97, 107, 115, 116], it has yet to be tested in whole animal experiments, which of course is essential to confirming its potential in therapeutic applications. As most of these studies were performed with either the Tatp or full length Tat protein and seemed to involve endocytotic-mediated uptake, further work in this area is required to
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
115
demonstrate conclusively that DNA can be efficiently delivered by protein transduction both in vitro and, more importantly, in vivo. It may be the case, that although CPPs can mediate the cellular uptake of smaller cargoes by protein transduction, coupling to plasmid DNA may result in complexes that can only enter the cell via endocytosis, or some other mechanism. VP22, however, has been utilised to increase the efficiency of myocardial gene therapy [1]. Based on the ability of VP22 to mediate intercellular trafficking of proteins to which it has been genetically linked [117, 118], DNA encoding a VP22-LacZ fusion protein, was injected into rat myocardium in vivo [16]. Histochemical staining showed expression of Gal in the cytoplasm of cardiomyocytes surrounding the site of injection in both LacZ and VP22-LacZ injected hearts. Interestingly, in VP22-LacZ samples only, cardiomyocytes surrounding this region showed -Gal staining in their nuclei, which was presumed to be due to secondary intercellular trafficking of VP22-LacZ into neighbouring cells and accumulation in the nucleus. Although this approach is not strictly VP22-mediated gene delivery, it highlights other potential uses of CPPs to enhance the gene therapy process. Targeting of fusion proteins specifically to the nucleus may be a limitation of this technique, but one can imagine it would be useful in enhancing the delivery of nuclear acting proteins, such as transcription factors [16]. Using this approach DNA encoding VP22 fused to the tumour suppressor gene p27 demonstrated significant spreading in cell culture, whilst intratumoural injection of the naked DNA resulted in significantly enhanced antitumour activity, compared to p27 alone-encoding plasmids [104]. This demonstrates that VP22 has important application in cancer gene therapy, as part of the encoded reporter gene product, in delivering the therapeutic gene product to bystander cells in the target tissue. Due to their CPP activity and also their ability to bind to and compact DNA, protecting it from degradation by nucleases, histones have been investigated by many as potential vectors for non-viral delivery of DNA [119]. In particular, histone H2A and H3 have been utilised for gene delivery to intact mammalian cells in culture [37, 120-122]. More recently, engineered histone H2B proteins, optimised for binding to the cellular nuclear import machinery, were demonstrated to deliver DNA to intact cells more efficiently than traditional liposomal techniques, either as monomers, or in a dimeric complex with histone H2A [123]; a process coined histone-mediated transduction (HMT). In similar fashion it has also been demonstrated that histone proteins engineered for efficient nuclear targeting can deliver DNA in reconstituted chromatin form, resulting in gene delivery to intact cells that is ~6fold more efficient than liposome-mediated transfection [124]. These reports highlight the importance of enhancing the nuclear delivery of DNA delivered by CPPs [119]. For an indepth review of the use of histone proteins in gene delivery see [119]. 4.2.5. Further Considerations for Gene Delivery 4.2.5.1. DNA compaction/Protection A major disadvantage with the use of non-viral gene delivery vectors is that the DNA is susceptible to degradation by nucleases, thereby greatly decreasing the likelihood that the therapeutic DNA will reach target cell nuclei in intact form [125]. DNA delivery by CPP does not appear to be immune from this issue, especially when the PTD is coupled to the nucleic acid through disulfide bonding [58], rather than complexed to it through either electrostatic or hydrophobic interactions. However, it has been demonstrated that oligomers of the Tat (47-57) peptide can compact DNA into nanometric particles and protect it against
116 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Wagstaff and Jans
nuclease degradation [54]. Compacting the DNA should have the added benefit of facilitating easier passage into the cell, but this may not always be the case. It has also been argued that electrostatic binding of the peptide to the DNA [65, 89] may lead to particles that are inappropriate for membrane penetration, i.e. particles that are simply too big [54]. 4.2.5.2. Transport to the Nucleus In order for therapeutic DNA to be expressed, it must first gain entry to the nucleus. Molecules > 45kDa in size such as DNA are excluded from the nucleus unless they possess a specific targeting signal, known as a nuclear localisation signal (NLS) [126, 127]. These NLSs mediate specific interactions with the nuclear import machinery, and in particular with members of the importin (Imp) protein superfamily [128-130]. NLSs are usually comprised of one or two short stretches of basic amino acids [131], also typically important in the process of protein transduction (see above; Table(1)) [1]. It is thus not surprising that many CPPs, including the Tat PTD [17] and Antp, also retain NLS function that may aid in the delivery of DNA to the nucleus. To this end, it has been shown that Tat (47-57), complexed to DNA, promoted 3-fold more efficient transfection in cell-cycle arrested cells, when compared to PEI transfection in proliferating cells [54]. This data, along with confocal images of the Tat-DNA complexes in cells, suggests that the Tat NLS is involved in the enhancement of gene transfer in this system. The use of NLSs to enhance non-viral gene therapy has been quite extensively investigated [125]. Linking the T-ag NLS via a PNA to plasmid DNA encoding GFP or LacZ led to an 8-fold increase in the uptake of the plasmid, when delivered by PEI [132]. Due to the high content of basic residues in the T-ag NLS (PKKKRKV132), it was suggested that the Tag NLS may itself function as a CPP [60], but the T-ag NLS-PNA has been shown not to be sufficient to mediate cellular uptake of the vector on its own [132]. Despite this, conjugation of efficient, optimised NLSs to CPPs is an exciting possibility to enhance the gene transfer mediated by these proteins. Indeed, the MPG peptide, which contains the T-ag NLS as part of its construction, enters the cell in endocytosis-independent fashion and effectively mediates interaction with Imps to effect nuclear targeting [107]. In contrast, a mutated non-functional version of this peptide, had significantly reduced nuclear import potential, but could still be utilised effectively in the delivery of siRNA to the cytoplasm of cultured mammalian cells. Fig. (3) depicts an optimised scheme for the efficient delivery of plasmid DNA into cell nuclei, incorporating both CPP and NLS activity, with the end result being increased transcription of the therapeutic gene due to elevated nuclear amounts of the DNA. A system similar to that depicted has been developed recently, with histone H2B serving as the DNA binding and compacting agent, as well as mediating the cellular entry, by including an optimised version of the T-ag NLS in the engineered histone, very efficient gene delivery was achieved [123, 124]. 4.2.5.3. Cell-type Specific CPPs A potentially major drawback in the use of CPPs in vivo is their lack of specificity, in that they are able to transduce almost every cell type tested in vitro and are distributed to multiple organs in vivo [59, 60]. Ideally pharmaceuticals should be delivered to specific target cells only, but thus far, there is little evidence for the cell specificity of CPP-mediated translocation. In the past, cell type specificity has been achieved by coupling cell-type specific ligands to the non-viral gene delivery vector [133, 134], but this of course results in entry of the vector into cells via endocytosis rather than translocation.
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
117
Plasmid DNA
1 Plasmid
DNA
CPP
2
Plasmid DNA
CPP
Extracellular
3
Cytoplasm Plasmid
Plasmid
DNA
DNA
CPP
4
CPP
Importin
Resistant to Degradation
5 Ran-GTP
CPP Plasmid DNA
Nucleus
6
Fig. (3). Scheme for CPP-mediated nuclear gene delivery. (1) The CPP binds to a therapeutic plasmid and condenses it. The CPP then binds to the plasma membrane (2) and mediates translocation through it into the cytoplasm (3). Once inside the cytosol, the plasmid is subjected to possible degradation by cytosolic nucleases, from which it is protected by its condensation. (4) Importin binding is mediated by the NLS moiety contained within the CPP or covalently bonded to it, followed by translocation into the nucleus. (5) Within the nucleus, Ran-GTP binding to the importin effects release of the plasmid DNA and the CPP, leading to (6) enhanced gene expression due to the increased nuclear concentration of the therapeutic gene. Inside the nucleus the plasmid DNA may need to be decondensed before it is transcribed.
Recently, one PTD was shown to specifically transduce synovial fibroblasts and was able to cause specific cell death by delivering apoptotic agents exclusively to these cells [135], demonstrating that cell specificity can occur for some CPPs, although the mechanism behind this remains a mystery. As always, when dealing with non-viral gene therapy, tissue specific promoters, such as the transthyretin promoter for expression in hepatocytes [136], and in situ administration of the compound through direct intratumoural or intramuscular injections [104] to the target site can be explored [137].
118 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Wagstaff and Jans
4.3. Delivery of Proteins Many varied therapeutic techniques require the delivery of proteins into cells. Traditionally this has been a difficult task to accomplish, especially in vivo [1]; the use of CPPs greatly facilitates this process. Perhaps the best example of CPP-mediated transduction of a biologically active protein is that of a Tatp--gal fusion protein [59]. Intraperitoneal (i.p.) injection of this protein induced -gal activity in all samples assayed, including blood cells, liver, kidney, lung, heart muscle, spleen and even the brain. Protein delivery across the blood brain barrier is usually restricted to small (< 6 amino acids) highly lipophilic peptides, whereas the -gal fusion protein is over 480 kDa in size, indicating that Tatp was not only able to pass through the blood brain barrier, but was capable of taking large molecules across with it. The blood-brain barrier was confirmed to be intact in these animals, in stark contrast to control mice [59], which were injected with protamine, a protein usually found in sperm that is well known to break down the blood-brain barrier [138]. In another example, the Tat PTD was fused to apoptin, a protein that reportedly induces apoptosis specifically in cancer cells, but not in normal cells [139]. Tat-apoptin protein was efficient at transducing both normal and tumour cells, but remained in the cytoplasm in normal cell lines and did not mediate apoptotic killing of these cell types. In cancer cell lines however, it migrated into the nucleus, resulting in apoptosis after 24 hours. This demonstrates how the fusion of tissue specific functional proteins to CPPs may result in celltype specificity of the induced effect, if not of the delivery vector itself (see also Section 4.2.5.3) and that, clearly, Tat CPP can transport protein into cells in active form. Tat CPP significantly enhances intracellular protein delivery to a wide variety of cell types including all blood cells, bone marrow stem cells, fibroblasts, osteoclasts, osteosarcoma cells and keratinocytes [1, 72, 93, 140]. Other examples of protein delivery using Tatp include delivery of horseradish peroxidase, RNaseA and domain III of Pseudomonas exotoxin A into a wide variety of cell types in vitro [18] and enhancement of intestinal absorption of insulin in an in vitro model system [141]. Tatp has also been used to deliver Bcl-xL, a well-characterised death-suppressing molecule of the Bcl-2 family, in vivo [142]. Bcl-xL is expressed in embryonic and adult neurons of the CNS and may play a critical role in preventing neuronal apoptosis that occurs during brain development or results from diverse pathologic stimuli, including cerebral ischemia [143]. i.p. injection of Tat-Bcl-xl fusion proteins into murine models of stroke transduced brain cells within 1-2 hours and decreased cerebral infarction in a dose-dependent manner. In addition, it attenuated ischemia-induced caspase-3 activation in ischemic neurons [142], demonstrating its ability as a neuroprotectant. Protein delivery by CPP has not been restricted to Tatp. VP22 has been used to deliver the human papilloma virus (HPV) E2 protein to target cells [144]. E2 overexpression in cervical cancer cells can induce growth arrest and/or apoptosis and therefore has applications in cervical cancer therapy [1]. When VP22-E2 expressing Cos-7 cells were seeded into cultures of HPV-transformed cervical carcinoma cells, VP22-E2 was delivered to the nonproducing cells and induced apoptosis, implying that local delivery of VP22-E2 cells may be useful in the treatment of cervical cancer and other HPV-associated diseases [144]. The feasibility of this in vivo in a clinical setting remains to be tested. Tat-mediated protein delivery has also shown potential as a prophylactic vaccine and therapeutic. Proteins cannot usually enter the cytosol to access the MHC class I processing pathway, making it difficult to induce class-I restricted cytotoxic T-lymphocyte (CTL) re-
Protein Transduction
Frontiers in Medicinal Chemistry, 2010, Vol. 5
119
sponses [1, 145]. Tat conjugated antigenic compounds, such as Tat-ovalbumin conjugates, however, have been reported to be taken up by antigen-presenting cells, processed and displayed on the cell surface, resulting in effective killing of the target cells by antigen specific CTLs [145, 146]. CPP-mediated delivery of proteins has potential uses in the treatment of many other diseases/disorders such as in the treatment of tumours or inflammatory conditions, many of which are currently under study [1, 143, 147]. 4.4. Delivery of Other Cargo by CPP Apart from DNA and protein delivery, CPPs are being investigated as potential delivery vectors for a whole host of other therapeutics, only some of which can be mentioned here. For instance, Tatp has been utilised for the delivery of anti-tumour antibodies (Ab), where it significantly enhanced Ab-cell surface interaction and cellular uptake [148]. Similar or slightly enhanced results were seen with other CPPs in an analogous study [91]. Tatp (37-72) tethered to anti-tetanus toxin Ab was efficiently taken up by cells, where it showed a moderate ability to neutralise the tetanus toxin [149]. This has therapeutic applications, as tetanus toxin is known for its very slow degradation rate, especially once inside cells of the nervous system [1, 149]. Unfortunately, a biodistribution study on Tat (44-57)-Ab conjugates showed that, despite efficient cellular uptake, these had greatly a reduced tumour targeting performance, compared to unmodified antibody [150]. This reinforces the need for careful consideration of CPP-cargo conjugation techniques. Tat has also been used to deliver inhibitory peptides to cells, such as peptide inhibitors of the c-Jun N-terminal Kinase (JNK), which have been shown to potently protect against cerebral ischaemia [151]. Delivery of a short, 11aa peptide inhibitor of JNK by Tatp resulted in significant protection of the cells from cell death by necrosis [152]. In a similar vein the Tat PTD has also been used to deliver the C3 exoenzyme, a bacterial toxin that is a highly specific inhibitor of the Rho family of G proteins, to cardiac myocytes, resulting in abnormal cellular projections, and indicating a role for Rho in the maintenance of cellular morphology [153]. These studies indicate the potential use for CPPs to deliver inhibitory compounds to cells with numerous therapeutic applications. Liposomes have been used to decrease the toxicity of drugs and to enhance their half-life and solubility. However, they have display very slow cell penetration, which hampers their therapeutic use [143]. Conjugation of Tatp or Antp onto the surface of liposomes appears to enhance their cellular delivery dramatically, such that they display fast and efficient translocation into the cell cytoplasm [154-156]. Fluorescent microscopic observation of markers trapped inside the liposomes and incorporated into the liposomal membrane demonstrated that the liposomes remain intact in the cytoplasm for the first few hours and migrate slowly towards the nucleus [154]. Eventually they release their contents into the cytoplasm [154], but it is clear that this intracellular release step needs to be significantly improved in order for CPP-liposome complexes to be a viable delivery approach to achieve levels of pharmaceuticals sufficient for a clinical setting [156]. Tatp-liposomes have also been used as gene delivery vectors, resulting in a relatively high transfection efficiency in vitro, with low cytotoxicity, and robust ectopic gene expression [154]. CPPs have also been used to deliver peptide-based imaging agents such as Oxotechnetium V and Oxorhenium V into cellular compartments, achieving intracellular concentrations sufficiently high to carry out imaging and radiotherapy [157]. Tatp can also significantly improve the intracellular uptake of paramagnetic nanoparticles and labels, that can
120 Frontiers in Medicinal Chemistry, 2010, Vol. 5
Wagstaff and Jans
easily be detected by magnetic resonance imaging (MRI) [73, 158]. This technique was so sensitive as to enable single cells to be detected in tissue samples [73]. Clearly, CPPs have a vast array of possible applications in clinical settings. Although optimisation of these therapeutic techniques is required, the results already obtained in in vitro and in vivo settings promises much for the future in this regard. CONCLUSION CPPs are already being utilised with great success. They have shown extraordinary potential in a range of therapeutic applications, both in vitro and in vivo. This is in large part due to the ease with which they can be coupled to numerous classes of cargoes, as well as their reasonable efficiency in cargo delivery and relatively low cytotoxicity. The field of gene therapy in particular, stands to profit most from CPP technology, in that the applications for its use in this setting are the most varied. The application of CPPs in drug and DNA delivery, already underway, does not require precise definition of the mechanism by which CPPs mediate cell entry, but it is becoming increasingly clear that there is more than one mechanism for CPP uptake at work. Endocytosis, endosomolytic activity, macropinocytosis and true protein transduction all seem to contribute to the uptake of different members of the CPP family. Whatever the mechanism, CPPs are clearly likely to be invaluable tools in the not too distant future for the therapeutic delivery of macromolecules. REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]
[12] [13] [14] [15]
Gupta, B.; Levchenko, T. S.; Torchilin, V. P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev., 2005, 57 (4), 637-651. Morris, M. C.; Chaloin, L.; Heitz, F.; Divita, G. Translocating peptides and proteins and their use for gene delivery. Curr. Opin. Biotechnol., 2000, 11 (5), 461-466. Snyder, E. L.; Dowdy, S. F. Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Curr. Opin. Mol. Ther., 2001, 3 (2), 147-152. Frankel, A. D.; Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988, 55 (6), 1189-1193. Green, M.; Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell, 1988, 55 (6), 1179-1188. Derossi, D.; Joliot, A. H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem., 1994, 269 (14), 10444-10450. Joliot, A.; Pernelle, C.; Deagostini-Bazin, H.; Prochiantz, A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. USA, 1991, 88 (5), 1864-1868. Elliott, G.; O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell, 1997, 88 (2), 223-233. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem., 2001, 276 (8), 5836-5840. Rosenbluh, J.; Hariton-Gazal, E.; Dagan, A.; Rottem, S.; Graessmann, A.; Loyter, A. Translocation of histone proteins across lipid bilayers and Mycoplasma membranes. J. Mol. Biol., 2005, 345 (2), 387-400. Rosenbluh, J.; Singh, S. K.; Gafni, Y.; Graessmann, A.; Loyter, A. Non-endocytic penetration of core histones into petunia protoplasts and cultured cells: a novel mechanism for the introduction of macromolecules into plant cells. Biochim. Biophys. Acta, 2004, 1664 (2), 230-240. Pooga, M.; Hallbrink, M.; Zorko, M.; Langel, U. Cell penetration by transportan. FASEB J., 1998, 12 (1), 67-77. Lundberg, P.; Langel, U. A brief introduction to cell-penetrating peptides. J. Mol. Recognit., 2003, 16 (5), 227-233. Lundberg, P.; Magzoub, M.; Lindberg, M.; Hallbrink, M.; Jarvet, J.; Eriksson, L. E.; Langel, U.; Graslund, A. Cell membrane translocation of the N-terminal (1-28) part of the prion protein. Biochem. Biophys. Res. Commun., 2002, 299 (1), 85-90. Takeshima, K.; Chikushi, A.; Lee, K. K.; Yonehara, S.; Matsuzaki, K. Translocation of analogues of the antimicrobial peptides magainin and buforin across human cell membranes. J. Biol. Chem., 2003, 278 (2), 1310-1315.
Protein Transduction [16]
[17] [18] [19] [20] [21]
[22] [23] [24] [25] [26] [27] [28] [29] [30]
[31]
[32] [33] [34] [35] [36] [37] [38] [39]
[40]
Frontiers in Medicinal Chemistry, 2010, Vol. 5
121
Suzuki, K.; Murtuza, B.; Brand, N. J.; Varela-Carver, A.; Fukushima, S.; Yacoub, M. H. Enhanced effect of myocardial gene transfection by VP22-mediated intercellular protein transport. J. Mol. Cell. Cardiol., 2004, 36 (4), 603-606. Siomi, H.; Shida, H.; Maki, M.; Hatanaka, M. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J. Virol., 1990, 64 (4), 1803-1807. Fawell, S.; Seery, J.; Daikh, Y.; Moore, C.; Chen, L. L.; Pepinsky, B.; Barsoum, J. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA, 1994, 91 (2), 664-668. Loret, E. P.; Vives, E.; Ho, P. S.; Rochat, H.; Van Rietschoten, J.; Johnson, W. C., Jr. Activating region of HIV-1 Tat protein: vacuum UV circular dichroism and energy minimization. Biochemistry (Mosc.) 1991, 30 (24), 6013-6023. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem., 1997, 272 (25), 16010-16017. Park, J.; Ryu, J.; Kim, K. A.; Lee, H. J.; Bahn, J. H.; Han, K.; Choi, E. Y.; Lee, K. S.; Kwon, H. Y.; Choi, S. Y. Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells. J. Gen. Virol., 2002, 83 (Pt 5), 1173-1181. Schwarze, S. R.; Hruska, K. A.; Dowdy, S. F. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol., 2000, 10 (7), 290-295. Vives, E.; Granier, C.; Prevot, P.; Lebleu, B. Lett. Pept. Sci., 1997, 4 (4-6), 429. Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard, J. B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. USA, 2000, 97 (24), 13003-13008. Gehring, W. J.; Affolter, M.; Burglin, T. Homeodomain proteins. Annu. Rev. Biochem., 1994, 63, 487-526. Derossi, D.; Chassaing, G.; Prochiantz, A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol., 1998, 8 (2), 84-87. Elliott, G.; O'Hare, P. Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules. J. Virol., 1998, 72 (8), 6448-55. Aints, A.; Guven, H.; Gahrton, G.; Smith, C. I.; Dilber, M. S. Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting. Gene Ther., 2001, 8 (14), 1051-1056. Pooga, M.; Soomets, U.; Hallbrink, M.; Valkna, A.; Saar, K.; Rezaei, K.; Kahl, U.; Hao, J. X.; Xu, X. J.; Wiesenfeld-Hallin, Z.; Hokfelt, T.; Bartfai, T.; Langel, U. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol., 1998, 16 (9), 857-861. Soomets, U.; Lindgren, M.; Gallet, X.; Hallbrink, M.; Elmquist, A.; Balaspiri, L.; Zorko, M.; Pooga, M.; Brasseur, R.; Langel, U. Deletion analogues of transportan. Biochim. Biophys. Acta., 2000, 1467 (1), 165176. Oehlke,